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Abstract 
 
Cardio-embolic stroke accounts for nearly a third of all ischaemic strokes.  The most 
clinically important cardio-embolic sources are non-valvular atrial fibrillation (AF) and 
chronic heart failure.  Strokes due to these conditions are associated with greater disability 
and more mortality, as compared to stroke of other aetiology.  This thesis is aimed at 
addressing some of the challenges faced by clinicians when dealing with stroke in patients 
with AF or heart failure, using an extensive range of historical data.   
Chapter 1 provides an introduction to stroke, AF and heart failure, including current 
prevalences, aetiology, and their complex intertwine relationship.  The current acute stroke 
management in patients with AF or heart failure is also outlined within the chapter.   
In chapter 2, the data sources and statistical methods that were common to the studies in 
the thesis are outlined.  The justifications of using historical data in the absence of evidence 
from robust clinical trials are also detailed. 
Chapter 3 explores the relevance of antithrombotic treatment on patterns and outcomes 
of acute stroke patients with AF.  A non-randomised cohort analysis was conducted using 
data from the Virtual International Stroke Trials Archive (VISTA).  The associations of 
antithrombotic treatment with the modified Rankin scale (mRS) outcome, and the 
occurrence of recurrent stroke and symptomatic intracerebral haemorrhage, at 90 days 
after stroke were described.  Combined sequential antithrombotic therapy (i.e. oral 
anticoagulant and antiplatelet treatment), was associated with favourable outcome on 
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ordinal mRS and significantly lower risk of recurrent stroke, symptomatic intracerebral 
haemorrhage and mortality by day 90, compared to the patients who did not receive any 
antithrombotic treatment.  The relative-risk of recurrent stroke and symptomatic 
intracerebral haemorrhage appeared highest in the first 2 days after stroke before 
attenuating to become constant over time.  Thus, early introduction of oral anticoagulant 
treatment (2-3 days after stroke), and to a lesser extent antiplatelet agents, was associated 
with substantially fewer recurrent stroke events over the following weeks but with no 
excess risk of symptomatic intracerebral haemorrhage. 
Chapter 4 seeks to describe the current prescribing patterns in stroke survivors with AF, 
with particular emphasis on socio-demographic associations.  A cross-sectional analysis of 
city-wide Glasgow primary care data for the year 2010, was conducted.  This chapter 
highlights that oral anticoagulant treatment was under-used in this high risk population, 
especially those of older age and affected by deprivation.  Strategies need to be developed 
to improve prescription of oral anticoagulant treatment.   
Chapter 5 investigates the incidence of stroke within the available heart failure trials 
spanning a 30 year period, according to AF status at baseline. Individual patient data were 
pooled from 11 trials conducted in patients with heart failure and reduced ejection fraction 
(HF-REF); and, 3 trials performed in patients with heart failure and preserved ejection 
fraction (HF-PEF).  Stroke incidence has not significantly declined over time in patients with 
HF-REF enrolled to trials, despite greater use of evidence-based heart failure and oral 
anticoagulant therapies.  However, anticoagulation proportions remain under 70% among 
HF-REF patients with documented AF.  Similar trends of stroke incidence were observed for 
patients enrolled in HF-PEF trials.   
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Some patients with heart failure but without atrial fibrillation may be at high risk of stroke 
and may potentially benefit from oral anticoagulant treatment.  Chapter 6 provides a 
comprehensive description of the current incidence of and risk factors for stroke in patients 
with HF-REF but without AF.  Data from two large and contemporary heart failure trials, 
the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo 
Italiano per lo Studio della Sopravvivenza nell'Insufficienza cardiac- Heart Failure trial 
(GISSI-HF), were pooled to enable the analysis.  The new simple clinical predictive model 
for stroke showed that about one-third of patients without AF have a risk of stroke similar 
to patients with AF.  The predictive model was also validated in an independent large data 
set.  The high risk of stroke in patients without AF might be reduced by individualised and 
safer oral anticoagulant treatment.  
Correspondingly, Chapter 7 explores the risk-model for stroke in a contemporary cohort of 
patients with HF-PEF but without AF.  Data were pooled from the Candesartan in Heart 
failure Assessment of Reduction in Mortality and Morbidity- Preserved trial (CHARM-
Preserved) and the Irbesartan in Heart Failure with Preserved Systolic Function trial (I-
Preserve), for patients with ejection fraction ≥45% only.  The analysis showed that the 
simple clinical model developed in Chapter 6, for patients with HF-REF, is also applicable to 
patients with HF-PEF.  
There are concerns that systemic thrombolysis might not achieve clinically-important 
outcome among chronic heart failure patients with acute ischaemic stroke.  Chapter 8 
evaluates the relevance of chronic heart failure on the outcome of acute stroke patients 
who received thrombolysis.  A non-randomised cohort analysis was conducted using data 
obtained from the Virtual International Stroke Trials Archive (VISTA).  The associations of 
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outcome among chronic heart failure patients with thrombolysis treatment using the mRS 
distribution at day 90, stratified by presence of AF, were evaluated.  Chronic heart failure 
was associated with a worse outcome with or without thrombolysis.  However, acute stroke 
patients who received thrombolysis had more favourable outcome regardless of heart 
failure status, compared to their untreated peers.  The findings should reassure clinicians 
considering systemic thrombolysis treatment in hyper-acute ischaemic stroke patients with 
chronic heart failure. 
 This thesis has summarised and extended our knowledge of the complex relationship 
between stroke and the heart, focusing on atrial fibrillation and heart failure.  It has 
answered many questions and generated many more.  The reported studies may assist 
clinicians who are dealing with stroke in patients with atrial fibrillation or heart failure.  
These conditions are common and each carry poor prognosis.  Thus, even small advances 
in their treatment may have a useful societal impact.  
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Chapter 1  
Introduction and background 
1.1. Stroke 
The current World Health Organization, WHO, definition of stroke (introduced in 1970 and 
still used) is “rapidly developing clinical signs of focal (or global) disturbance of cerebral 
function, lasting more than 24 hours or leading to death, with no apparent cause other 
than that of vascular origin.”1  The majority of strokes are ischaemic, secondary to arterial 
occlusion, with the remainder being due to intracerebral or subarachnoid haemorrhage.2  
A recent Consensus Document from the American Heart Association and American Stroke 
Association (AHA/ ASA) recommends an updated definition, by specifying central nervous 
system infarction (which includes brain, spinal cord and retinal cells attributable to 
ischaemia), based on objective evidence of focal ischaemic injury in a defined vascular 
distribution or clinical evidence of the former with other aetiologies excluded.3  
 
1.1.1. Epidemiology  
In 2010, the global prevalence of stroke was 33 million, with 16 million people experienced 
a first stroke.4  A third of those who had first stroke (approximately 5.2 million people) were 
in <65 years of age.4  Over the past 4 decades, stroke incidence rates have fallen by 42% in 
high-income countries, but increased by >100% in low and middle income countries.5  
 25 
Stroke is one of the leading causes of death and morbidity.6  In 2013, there were 6.5 million 
deaths due to stroke worldwide (≈12% of total death), making stroke the second-leading 
global cause of death after ischaemic heart disease.7  The striking morbidity of stroke is a 
result of the interplay between resulting physical and cognitive impairments, the emotional 
and social implications to those impairments and the high risk for recurrence.  A major 
stroke is perceived by more than half of those at risk of as being worse than death.8 
There were approximately 240,000 inpatient episodes due to a stroke in the National 
Health Service (NHS) hospitals in the UK for the year 2013/14.9  Of these, almost 20,000 
stroke episodes were in Scotland.9  During this period, around 39,000 deaths resulted from 
stroke in the UK, with 6% and 8% of death from stroke in men and women, respectively.9  
Although the age-standardised death rate for stroke in the UK has fallen (by 78% for all 
ages and 85% for those under 75 years of age) between 1968 and 2013, Scotland still has 
the highest death rates from stroke; for men of all ages, and for men and women under the 
age of 75.9  In 2014, the recent Scottish prevalences of stroke for men and women were 
3.3% and 3.1%, respectively.9  For both sexes, this represents an increase from the 
prevalence of stroke in 2003, with only 2.4% for men and 2.1% for female.9  The future 
prevalence of stroke in Scotland is predicted to rise in parallel with the greater increase of 
the elderly proportion (over 80 years) within the Scottish population.10 
 
1.1.2. Pathophysiology and aetiology 
The brain is exquisitely sensitive and susceptible to even brief episodes of ischaemia.11 
Brain ischaemia can be focal, often caused by occlusion of a blood vessel, or global, usually 
as a consequence of hypoperfusion to the whole brain.  The latter typically resulted from 
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profound hypotension or hypoxia, e.g. following a period of cardiac arrest.  Following focal 
vascular occlusion, the extent of blood flow reduction is dependent on the collateral 
vasculature, site of occlusion and the duration of brain ischaemia.  As the brain has a very 
high energy requirement,11-13 any decrease of blood flow leads to potentially reversible 
functional disturbance and, if the shortage is more severe and persists, to irreversible 
morphological damage.14-16  The tissue perfused in the range between functional and 
morphological injury is called the ischaemic penumbra,14-16 an important concept for 
therapeutic target in hyper-acute stroke management.  The ischaemia-induced energy 
failure triggers a complex cascade of electrophysiological disturbance, biochemical 
alteration and molecular dysfunction, which lead to progressive cell death and infarct 
growth.17, 18  The disastrous effect of brain ischaemic injury is exacerbated by the 
accompanied inflammatory responses19, 20 and subsequently the development of early 
cytotoxic and later vasogenic brain oedema.21    
The aetiology of stroke does not influence the hyper-acute management of an ischaemic 
stroke.  However, establishing the cause of stroke is crucial to reduce or prevent 
recurrence.  The most widely used classification system for ischaemic stroke based on 
underlying aetiology is the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria.22  
The original purpose of the TOAST was to categorise stroke patients who would benefit 
from danaparoid in the treatment of ischaemic stroke.22  The system is composed of five 
major stroke subtypes: large artery atherosclerosis, cardio-embolic, small-vessel disease, 
stroke of other determined cause and stroke of undetermined cause.22  The TOAST 
classification system is simple, logical and has been used in many epidemiological studies.  
More recently, the Causative Classification of Stroke (CCS) and the A-S-C-O [A for 
atherosclerosis, S for small vessel disease, C for cardiac source, O for other cause] 
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classification schemes have been developed to incorporate multiple aspects of stroke 
diagnostic evaluation.23, 24  However, these classification systems only offers a crude guide 
to stroke causality.  The causes of stroke may be multifactorial and most strokes do not fall 
perfectly into one specific category. 
   
1.1.3. Cardio-embolic stroke 
Cardio-embolic stroke accounts for 25-35% of all ischaemic strokes,25-27 with the proportion 
depending on the extensiveness of cardiac workup, e.g. electrocardiograph (ECG) 
monitoring or transthoracic/ transoesophageal echocardiography.  There are several 
cardiac disorders that may constitute a source of embolus, but not all sources pose equal 
stroke risks.2  The clinically most important cardio-embolic sources are non-valvular atrial 
fibrillation (AF) and chronic heart failure (HF).28-30  These two conditions are explained in 
Sections 1.2 and 1.3 of the thesis.  Other cardio-embolic causes include rheumatic heart 
disease, prosthetic heart valve, endocarditis, left atrial/ ventricular myxoma or thrombus, 
and patent foramen ovale.2  Alternatively, patients with acute stroke may have embolic 
stroke of undetermined source (ESUS).  ESUS is a new term proposed to define those 
patients with a probable embolic stroke but no definite proof after the initial work-up.31  
A thrombus originating from the heart most frequently travels to the middle cerebral artery 
(MCA) territory, resulting in territorial and cortical infarctions.32  However, cardiac-
embolism may affect any part of the brain including the subcortical and brainstem 
regions.33, 34  Infarction due with cardio-embolic stroke is generally larger in size and 
severity than those associated with other aetiologies.  This is probably due to the larger 
clot size that tends to occlude the proximal vessel and the insufficiently developed 
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collateral circulation in the absence of chronic atherosclerosis.35  Certain clinical features 
are suggestive of cardio-embolic stroke, including sudden onset to maximal deficit, 
decreased level of consciousness at onset, global aphasia without hemiparesis and Valsalva 
manoeuvre at symptom onset.36-38  Neuroimaging data that support cardio-embolic stroke 
include simultaneous or sequential strokes in different arterial territories, predominantly 
in the carotid and middle cerebral artery distribution territories.39  The risk of recurrence 
and mortality are also high following a cardio-embolic stroke.26, 40, 41  
Approximately 20-40% of all patients with stroke experience haemorrhagic transformation 
of an infarct within the first 7 days of stroke onset.42  Meanwhile, haemorrhagic 
transformation occurs in up to a third of patients with cardio-embolic stroke, especially 
within the first few days after stroke.43, 44  There are two types of haemorrhagic 
transformation: petechial or multifocal, which is normally asymptomatic; and secondary 
hematoma, which has mass effects and clinical deterioration.45  A common nomenclature 
utilised in the European Cooperative Acute Stroke Study 2 (ECASS-2), divides haemorrhagic 
transformation lesions into HT1, HT2, PH1, PH2 and remote PH.45, 46  HT has been defined as 
a petechial infarction without space-occupying effect and PH was defined as a haematoma 
with mass effect. HTs are of two subtypes: HT1 (small petechiae) and HT2 (more confluent 
petechiae).  Correspondingly, there are three subtypes of PH: PH1 (≤ 30% of the infarcted 
area with some mild space-occupying effect), PH2 (>30% of the infarcted area with 
significant space-occupying effect) and remote PH (clot remote from infarcted area).45, 46   
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1.2. Atrial fibrillation 
Non-valvular atrial fibrillation (AF) is a supraventricular tachyarrhythmia with 
uncoordinated atrial activation and consequently ineffective atrial contraction.47, 48  It is 
electrographically characterised by irregular R-R intervals (if atrioventricular [AV] 
conduction is present), absence of distinct P waves and irregular atrio-ventricular activity.47, 
48  
 
1.2.1. Epidemiology 
AF is the most common sustained cardiac arrhythmia, affecting 1-2% of the population.47  
In 2010, the worldwide prevalence of AF was estimated at 33.5 million with two-thirds of 
these being men.49  The lifetime risk of developing AF is one in four after the age of 40.50 
For comparison, the lifetime risk of breast cancer in woman of the same age group is one 
in eight.51  Approximately 70% of individuals with AF are aged 65-85 years, and the risk of 
AF increases with age.52  
There are about 1.1 million people in the UK are living with AF.9  The figure may be an 
underestimate as there are many more people living with undiagnosed AF.53  Up to 1.2 
million inpatient episodes related to AF in the UK for the year 2013/2014.9   In Scotland, 
the inpatient episodes related to AF were approximately 90,000 for the same period 
analysed.9  Both UK-wide and Scottish inpatient episodes related to AF represent 3-6% of 
acute medical admissions and accounts for a third of admissions due to cardiac 
arrhythmias.9, 54  There was a modest increase in the Scottish prevalence of AF from 1.3% 
in 2008/09 to 1.6% in 2013/14.9  The apparent increase in prevalence might be related to 
the introduction of the Quality and Outcomes Framework (QOF) into the Scottish general 
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practitioners’ contract since 2004.  The new contract rewards general practitioners for 
keeping good records of their patients who have been diagnosed with the certain medical 
conditions, including AF and stroke.   
AF confers a 5-fold risk of stroke.28  One in five strokes is due to AF, and this figure rises to 
one in three after the age of 80.28, 55  AF-related strokes are associated with higher 
mortality, more disability and more recurrences than non AF-related strokes.56-58  
Paroxysmal AF conveys the same risk of stroke as permanent and persistent AF.59  
Moreover, AF is also associated with a 3-fold risk of heart failure, and 2-fold increased risk 
of dementia and death.60-63 
In general, the prevalence of AF is expected to have at least doubled by 2050 due to the 
ageing population and improved survival from cardiac co-morbidities.64  As a result, the 
number and burden of AF-related strokes will also increase,4 unless effective prevention 
measures are implemented.   
 
1.2.2. Pathophysiology and aetiology 
Any myocardial injury may trigger a slow but progressive structural remodelling process in 
the ventricles and the atria.47, 48  This process involves proliferation and differentiation of 
fibroblasts into myofibroblasts, subsequently promoting connective tissue deposition and 
fibrosis within the structures.47, 48  The structural remodelling in the atria results in electrical 
dissociation between the muscle bundles and local conduction system, which predisposes 
to and perpetuates AF.47, 48 These abnormalities can also be induced by various 
pathophysiological mechanisms, such that AF represents a final common phenotype for 
multiple disease pathways and mechanisms that are not completely understood.47, 48, 65, 66    
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Haemodynamic consequences of AF occur from the suboptimal ventricular rate control, 
uncoordinated atrial contraction, beat-to-beat variability in ventricular filling and 
sympathetic-neurohumoral activation.67-69  Consequences for individual patients with AF 
vary, ranging from no symptoms to fatigue, palpitation, breathlessness, hypotension,   (pre-
) syncope or heart failure.70  However, one of the most serious consequences is the stasis 
of blood that predisposes to more clotting and subsequent risk of embolism to the brain 
circulation. 
There are multiple clinical risk factors that are associated with increased risk of AF.  
Common risk factors include increasing age, hypertension, ischaemic heart disease, 
hyperthyroidism, acute/ chronic alcohol excess and systemic infection.47, 48  
 
1.2.3. Treatment options 
The aims of treatment in chronic ambulatory patients with AF are to improve symptoms 
and prevent severe complications associated with AF.47, 48  Prevention of AF-related 
complications dependent on effective antithrombotic therapy, optimal control of 
ventricular rate and adequate therapy of concomitant heart diseases.47, 48, 65, 71  
Antithrombotic therapy for patients with AF is discussed in Section 1.4.2.  
Rate control vs. rhythm control  
The decision for rate- or rhythm- control strategy requires an individual decision and 
discussion at the beginning of AF management.47, 48  The Atrial Fibrillation Follow-up 
Investigation of Rhythm Management trial (AFFIRM) observed no difference in all-cause 
death or stroke between patients randomised to one strategy or the other.72  The Rate 
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Control versus Electrical Cardioversion for Persistent Atrial Fibrillation trial (RACE) showed 
that rate control was non-inferior to rhythm control for the cardiovascular composite 
endpoint of death and morbidity.73  The Atrial Fibrillation and Congestive Heart Failure trial 
(AF-CHF) that randomised symptomatic heart failure patients with left ventricular ejection 
fraction ≤35% and history of AF, found no difference in the primary outcome of 
cardiovascular death, and the composite outcome of all-death and worsening of heart 
failure.74  
Management of underlying heart disease 
The appearance of AF is frequently associated with exacerbation of concomitant heart 
disease, since AF can either cause, contribute to or be a consequence of deterioration.75, 76  
Thus, adequate therapy of the underlying disease(s), e.g. hypertension, ischaemic heart 
disease or heart failure, is important.47, 48, 65  
   
1.2.4. Mechanisms of stroke 
Although there is a strong association between AF and stroke,28, 55 the pathogenesis of 
stroke in AF is complicated.  There are three possible explanations of stroke mechanism in 
AF: 1) AF causes stroke, 2) stroke causes AF, and 3) AF is associated with other co-
morbidities that causes stroke. 
AF as a cause of stroke 
AF classically fulfils the Virchow’s triad for thrombogenesis.54, 77  First, the impaired atrial 
contraction causes stasis of blood flow (blood flow abnormalities).77  Second, the atrial 
remodelling results in endocardial and endothelial dysfunction (vessel wall 
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abnormalities).77  Third, the sympathethic-neurohumoral activation in patients with AF 
produces a hypercoagulable state (abnormal blood constituents).77  Although there is a 
strong relationship between AF burden and stroke,78-80 it is not consistent across all 
studies.81  A brief subclinical episode of AF in older patients with vascular risk factors is 
associated with a 2-fold increased risk of stroke.82  Meanwhile, clinically apparent AF in 
young and healthy patients does not pose a significantly higher risk of stroke.83  
Furthermore, the link between AF and non-cardioembolic stroke indicates that AF-related 
stroke may not entirely be cardio-embolic.  Ten percent of patients with lacunar strokes 
have AF.84  Large artery atherosclerosis is also more common in patients with AF than those 
without.85  
Stroke as cause of AF 
Stroke may affect the autonomic nervous system which triggers cardiac arrhythmia, most 
commonly, AF.86  However, there is paucity of data to explain the clinically-important 
difference between the brief new-onset AF following a stroke and the long-standing AF, in 
terms of future stroke recurrence.28, 87 
AF associated co-morbidities as causes of stroke 
AF is associated with common risk factors of stroke, such as increasing age, male sex, 
hypertension, ischaemic heart disease, diabetes, heart failure, systemic inflammatory 
response and sleep apnoea.47, 48  These co-morbidities could lead to pathological 
remodelling of the atria which later predisposes to AF. 47, 48  Rather than being the sole 
cause of stroke, AF may be a marker of left atrial abnormalities resulting from the 
cardiovascular burden that are themselves the actual cause of stroke.88   
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1.3. Heart failure 
Heart failure (HF) is a complex clinical syndrome of symptoms (e.g. breathlessness, ankle 
swelling and fatigue) and signs (e.g. tachycardia, tachypnoea, raised jugular venous 
pressure, pulmonary crackles and laterally displaced apical impulse) resulting from an 
abnormality of heart structure and function.89-91  
 Approximately 1 to 2% of all adults in developed countries have HF, with prevalence rising 
to 10% or more among persons 70 years of age or older.92  Over half a million people in the 
UK are living with HF.9  There were almost 160,000 inpatient episodes due to HF in NHS 
hospitals in the UK for the year 2013/14.9  Of these, approximately 13,000 inpatient 
episodes due to HF were in Scotland.9  In 2013, the prevalences of HF in men and women 
of all ages for the UK were 1.2% and 0.8%, respectively.  The comparable figures for men 
and women in Scotland were 1.4% and 0.8%, respectively.  The Scottish prevalence of HF 
for men aged over 75 years was 8.7%; and 6.0% for their female counterparts.9  Overall, 
the prevalence of HF is expected to rise in future as a result of an ageing population, 
improved survival from ischaemic heart disease and the availability more effective 
treatments for HF.93  
The general terminology used to describe HF is historical and is based on the measurement 
of left ventricular ejection fraction (EF).  EF is a mathematical description of the stroke 
volume (which is the end-diastolic volume minus the end-systolic volume) divided by the 
end-diastolic volume.94  In patients with left ventricular systolic dysfunction, the stroke 
volume can be maintained by an increase in end-diastolic volume (because the left ventricle 
dilates) i.e. the heart ejects a smaller fraction of a larger volume.  As the heart further 
dilates, the EF is also reduced but with greater end-diastolic and end-systolic volumes.  The 
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EF is usually measured using an echocardiography, radionuclide technique or cardiac 
magnetic resonance imaging.89-91  
Patients with HF may have a reduced ejection fraction, 40% or less (HF-REF); or normal to 
near-normal (i.e. preserved) ejection fraction, greater than 45% (HF-PEF).89-91  Traditionally, 
HF-REF was commonly known as ‘systolic heart failure’.  Patients with an EF in the range 
40-45% thus represent a ‘grey area’ and most probably have mild systolic dysfunction.89  
Patients with HF-PEF should have evidence of relevant structural heart disease, raised 
natriuretic peptides or evidence of left ventricular diastolic dysfunction.89-91  HF-PEF has 
been previously known as ‘diastolic heart failure’.89  These definitions are crucial as the 
aetiology, management and prognosis of HF-REF and HF-PEF are different.  The diagnosis 
of HF-PEF is more challenging than the diagnosis of HF-REF because it is predominantly a 
diagnosis of exclusion of other potential non-cardiac causes of symptoms suggestive of HF. 
 
1.3.1. Heart failure with reduced ejection fraction 
1.3.1.1. Epidemiology, aetiology and prognosis 
At least half of the patients with HF have low ejection fraction (40% or less).95  Coronary 
artery disease is the cause of approximately two-thirds of cases of HF-REF, although 
hypertension and diabetes are likely to be contributory factors in many cases.  Other causes 
of HF-REF include previous viral infection (recognised or unrecognised), alcohol excess, side 
effects from chemotherapy drugs (e.g. doxorubicin or trastuzumab) and ‘idiopathic’ dilated 
cardiomyopathy (although the cause is thought to be unknown, some cases may have a 
genetic basis).89, 96  In the UK, the most common cause of HF-REF is coronary artery disease, 
and majority of those with HF have had myocardial infarction in the past.90 
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Before the year 1990, as many as two-thirds of patients died within 5 years after the initial 
diagnosis of HF-REF, and hospitalisation due to the exacerbation of symptoms was frequent 
and recurrent.97-99  Effective HF treatment has improved both outcomes in recent years, 
with a relative reduction in mortality up to 20-30%, and in HF hospitalisation up to 30-
50%.97-99  In the UK, there is a trend of improved prognosis for patients with HF over the 
past decades.  The 6-month mortality rate decreased from 26% in 1996 to 14% in 2005.100  
 
1.3.1.2. Pathophysiology 
In patients with HF-REF, the maladaptive changes that occur in the surviving myocytes and 
extracelullar matrix after myocardial injury (e.g. myocardial infarction) lead to pathological 
modelling of the left ventricle with dilatation and impaired contractility.101, 102  These 
changes progress over time, exacerbated by additional injury (e.g. recurrent myocardial 
infarctions) and by systemic responses to the left ventricular systolic dysfunction, notably 
activation of the neurohumoral system.101, 103  These systemic responses have detrimental 
effects on other organs including blood vessels, kidneys, muscles, bone marrows, lungs and 
liver.103  Cumulatively, the detrimental systemic effects account for the clinical 
manifestations of the syndrome of heart failure; including development and worsening of 
symptoms, declining functional capacity with diminished quality of life, episodes of overt 
decompensation leading to hospitalisation, myocardial electrical instability causing 
arrhythmia, and premature death.  Premature death in patients with HF is usually due to 
pump-failure or a ventricular arrhythmia.101  Moreover, the limited cardiac reserve in 
patients with HF-REF is dependent on atrial contraction and synchronised contraction of 
the left ventricle.  Any concomitant events that affect these contractility functions (e.g. 
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development of atrial fibrillation or left bundle-brunch block) or that impose extra 
haemodynamic demand on the failing heart (e.g. anaemia) can lead to acute 
deterioration.101  The interruption of pathological left ventricular remodelling and 
associated systemic responses form the basis of much of the treatment for HF.101, 103  
 
1.3.1.3. Treatment options 
The goals of treatment in patients with HF-REF are to relieve symptoms, prevent 
hospitalisation and improve survival.89-91  The mainstay treatment for ambulatory patients 
with HF-REF is pharmacologic therapy, which will be discussed here.  Other available 
treatment options include lifestyle modification (e.g. exercise training),104 implantable 
devices,105, 106 and in selected cases, cardiac transplantation.107 
Diuretics for Symptomatic Relief 
Diuretics provide rapid symptomatic relief for breathlessness and fluid retention.89-91  The 
commonest diuretic group used for this purpose is the loop diuretic.  The effects of diuretics 
on mortality and morbidity have not been studied in patients with HF-REF, presumably 
because the effects were clinically compelling.  Other agents are required to reduce the 
progression of the disease. 
Treatments that Alter the Disease Progression 
i. Angiotensin Converting Enzyme (ACE) Inhibitors 
ACE inhibitors are the first line therapy for patients with HF-REF to alter the disease 
progression.  An agent in this class is usually started promptly following the diagnosis and 
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continued indefinitely.89-91  ACE inhibitors have a significant effect on left ventricular (LV) 
modelling and improve symptoms.108  Two large trials showed that patients with HF-REF, 
who were treated with enalapril, compared to placebo, had lower rates of hospitalisation 
and death.108, 109  These benefits were additional to those gained with conventional 
treatment at the time (i.e. diuretics and digoxin).  
ii. Angiotensin Receptor Blockers (ARBs) 
The efficacy of ARBs is similar to that of ACE inhibitors.110, 111  They are routinely used as an 
alternative to ACE inhibitors, primarily in patients who experienced cough as a result of the 
ACE inhibitor therapy. 
iii. Beta-Blockers  
In addition to ACE inhibitors, beta-blockers are also first line therapy in patients with HF-
REF regardless of the aetiology and symptom severity.89-91  Beta-blocker therapy improves 
symptoms and leads to a substantial improvement in ejection fraction (approximately 5-
10%).112, 113  In the three key placebo-controlled trials, treatment with a beta-blocker 
(bisoprolol,114 carvedilol115 or metoprolol CR/XL116) was shown to reduce mortality and HF 
hospitalisation (with relative risk reduction [RRR] of approximately 30% for each outcome), 
within 1 year of starting treatment.  In these trials, more than 90% of patients were on an 
ACE inhibitor or ARB.114-116 
 iii. Mineralocorticoid/ Aldosterone Receptor Antagonists (MRAs) 
The body of evidence that supports the efficacy of MRAs in patients with HF-REF was 
derived from The Randomised Aldactone Evaluation Study (RALES) and the Eplerenone in 
Mild Patients Hospitalisation and Survival Study in Heart Failure (EMPHASIS-HF) trials.117, 
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118  The RALES trial, which was undertaken with spironolactone in patients with severe HF, 
showed relative risk reduction in death and HF hospitalisation of 30% and 35%, 
respectively, within an average of 2 years of starting treatment, compared with the  
placebo.117  Furthermore, the EMPHASIS-HF trial showed that treatment with eplerenone 
led to reduction in the risk of all-cause death by 24% and hospitalisation for any reason by 
23%, within approximately 2 years of starting treatment, compared to placebo.118  These 
benefits were additional to those gained with conventional treatment, i.e. ACE inhibitor in 
RALES; and, ACE inhibitor and beta-blocker in EMPHASIS-HF.26, 27      
 iv. Angiotensin Receptor Neprilysin Inhibitor (ARNI) 
The latest entry to the timeline of clinically-important HF-REF trials is the Prospective 
comparison of angiotensin receptor neprilysin inhibitor (ARNI) with angiotensin converting 
enzyme inhibitor to Determine Impact on Global Mortality and morbidity in Heart Failure 
trial (PARADIGM-HF).119  The study showed a novel approach to HF therapy, ARNI with 
LCZ696, a combination of sacubitril and valsartan, reduced overall mortality by 16% and 
cardiovascular mortality by 20%, as compared with enalapril.  The inhibition of angiotensin 
receptor and neprilysin resulted in higher levels of peptide (e.g. natriuretic peptides), which 
have vasodilatory properties, facilitate sodium excretion, and probably have effects on LV 
remodelling.119 
 v. Other recommended treatments 
There are several other pharmacologic agents that are valuable in the management of 
patients with HF-REF.  However, they have not been clearly shown to reduce all-cause 
mortality22, 23 (or in the case for isosorbide mononitrate and hydralazine, this has only been 
shown in African-Americans).120  Most of these treatment agents have demonstrated 
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benefits for symptom improvement, HF hospitalisation or both.121, 122  Thus, they are useful 
alternative or additional treatment in patients with HF-REF.  For example, treatment with 
digoxin has been shown to reduce HF hospitalisation by 28% within an average of 3 years 
starting treatment, but without any meaningful impact on all-cause mortality.121  Similarly, 
ivabradine therapy has been shown to have an RRR in HF hospitalisation of 26% within 
approximately 2 years starting treatment, but without significant reduction in 
cardiovascular death (or all-cause death).122      
 
1.3.2. Heart failure with preserved ejection fraction 
1.3.2.1. Epidemiology, aetiology and prognosis 
Up to half of patients with HF have a preserved ejection fraction (HF-PEF).93, 123, 124  These 
patients have a different epidemiological and aetiological profile from patients with HF-
REF.123, 125  Patients with HF-PEF are generally older, often female, obese and more likely 
to have hypertension and atrial fibrillation, compared to patients with HF-REF.  They are 
also less likely to have coronary artery disease.  The prevalence of HF-PEF has increased 
over the last decade,93 the highest in patients over the age of 75 years.126-129  This disease 
may occur as a consequent of left ventricular diastolic dysfunction, valvular heart disease, 
pericardial disease or circulatory congestive states.130  Examples of the latter include rapid 
fluid administration, severe anaemia and thyrotoxicosis.130   
The mortality rate attributable to HF-PEF remains unchanged.93  Although the mortality 
rates may not be as high as patients with HF-REF,131 the prognosis of patients with HF-PEF 
is substantially worse than that of patients with hypertension and other conditions that 
increase cardiovascular risk.132  
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1.3.2.2. Pathophysiology  
The predominant abnormality in patients with HF-PEF is diastolic dysfunction.130, 133  The 
abnormal passive elastic properties of the left ventricle are thought to be caused by the 
increased myocardial mass and remodelling of the extramyocardial collagen network.130, 
133  As a result, the LV compliance or distensibility is reduced, time course of LV filling is 
altered and the diastolic pressure is elevated. 130, 134  Under these circumstances, a 
relatively small increase of   intravascular volume or an increase in venous tone/ arterial 
stiffness, or both can lead to a substantial increase in the left atrial and pulmonary venous 
pressures and may produce frank decompensation.133, 134  
The differences and similarities between HF-PEF and HF-REF are shown in Table 1-1.  
Despite a normal ejection fraction, a considerable number of patients with HF-PEF also 
have low stroke volume, and limited capacity to augment cardiac output during physical 
activity.135, 136  The elevated LV diastolic and pulmonary venous pressures cause a reduction 
in lung compliance, which increases the effort of breathing and triggers the symptom of 
breathlessness.38, 39  The reduced cardiac output during physical activity also leads to 
immediate muscle fatigue.137, 138      
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Table 1-1. Differences and similarities between heart failure with preserved 
ejection fraction (HF-PEF) and heart failure with reduced ejection fraction (HF-
REF). Adapted from Gaash et al (2004)130  
Characteristic HF-PEF HF-REF 
Clinical features   
Symptoms Yes Yes 
Congestive state Yes Yes 
   
Physical activity   
Exercise capacity ↓ ↓ 
Cardiac output augmentation ↓ ↓ 
   
Left ventricular structure    
Myocardial mass ↑  
(usually concentric) 
↑  
(usually eccentric) 
Relative wall thickness ↑↑ ↓ 
Cardiac myocyte ↑ diameter ↑ length 
Extracellular matrix (collagen) ↑↑ ↓ 
   
Left ventricular function   
Ejection fraction Normal/ ↑ ↓ 
Stroke volume Normal/ ↓ Normal/ ↓ 
Myocardial contractility ↓ ↓↓ 
End-systolic volume ↓ ↑↑ 
End-diastolic volume Normal ↑↑ 
End-diastolic pressure ↑ ↑ 
Preload reserve Limited Exhausted 
   
Left atrial size ↑ ↑ 
   
Morbidity ↑↑ ↑↑ 
Survival ↓ ↓↓ 
                        ↓ indicates decreased; ↑ indicates increased. 
 
1.3.2.3. Treatment options 
There is no treatment that has been shown to reduce morbidity and mortality in patients 
with HF-PEF.139-141  Diuretics are commonly used to relieve breathlessness and oedema, as 
in patients with HF-REF.89-91  Adequate treatment of hypertension, coronary artery disease 
and rate control in patients with AF are considered to be beneficial.89-91 
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1.3.3. Stroke related to heart failure (with or without atrial fibrillation) 
1.3.3.1. Epidemiology 
A historical meta-analysis based on heart failure trials and cohort studies reported that the 
incidence of stroke in patients with HF is 47.4 per 1000 persons over 5 years.142  The 
incidence of stroke is particularly high over the early phase after diagnosis of HF, estimated 
to be as much as 17-fold higher within the first month of diagnosis.  The risk attenuates 
over time although it is still higher than in the general population.143-145  The annual risk of 
stroke in patients with mild-moderately symptomatic HF is approximately 1.5%,146, 147 
compared to a risk of 4% in patients with severe HF109 and a risk of <0.5% in the general 
population.148  
The prevalence of AF in heart failure is common and increases with abnormal findings on 
echocardiogram and New York Heart Association (NYHA) functional class, reaching to 
almost 50% in those with NYHA class IV.149  This is relevant, because AF is associated with 
2- to 3-fold higher risk of stroke and death in patients with heart failure, compared to those 
in sinus rhythm.150, 151 
However, many of the older studies did not distinguish between HF-REF and HF-PEF. 
Importantly, most did not differentiate the presence or absence of concomitant AF, or 
account for the potential benefit of oral anticoagulant treatment in patients with or 
without AF.  The number of stroke events in any individual studies was often small, partly 
due to the relatively modest size and short duration of the HF trials.  Furthermore, the 
treatment options for patients with HF have changed over the last 3 decades, which may 
affect the present risk of stroke.  As a consequence, the risk of stroke in contemporary 
heart failure population, especially those without AF, is unknown.      
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1.3.3.2. Mechanism of stroke 
Given that heart failure is commonly associated with AF, the elevated risk of stroke in 
patients with HF in sinus rhythm may be partly due to undiagnosed subclinical AF.  
Nonetheless, HF itself (i.e. in the absence of AF), particularly HF-REF, may predispose to 
stroke through fulfilment of the Virchow’s triad of thrombogenesis.152  First, patients with 
HF have stasis of blood flow related to LV dysfunction and dyskinesia (blood flow 
abnormalities).153, 154  Second, patients with HF have endocardial and endothelial 
dysfunction from pathological LV remodelling (vessel wall abnormalities).153, 154  Third, 
patients with HF have hypercoagulable state and platelet dysfunction resulting from 
neurohumoral activation and chronic diuretic use (abnormal blood constituents).153, 154  In 
addition to cardio-embolism, some strokes in patients with HF may be directly related to 
pump-failure causing hypoperfusion which may lead to watershed infarction.155 
           
1.3.3.3. Heart failure following a stroke 
Evidence suggests that myocardial ischaemia and even infarction are common following a 
stroke, particularly after subarachnoid haemorrhage.156, 157  Segmental hypokinesia of the 
left ventricle and acute HF have been described in right hemispheric infarction.158  The rapid 
appearance and disappearance of the ECG changes or pulmonary oedema in younger 
stroke patients without underlying heart disease argue against macrovascular factors and 
in favour of neurogenic factors.147, 148  
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The brain structures that are critical to the development of HF following a stroke are 
known.  There is an accumulation of data that suggest stroke involving the insular cortex 
may be associated with neurogenic HF, arrhythmias and sudden death.159-161  Other 
important brain structures that are associated with HF are medulla oblongata and 
hypothalamus.162, 163  However, the mechanisms by which lesions in these structures lead 
to HF are not completely understood.  
Neurogenic HF commonly presents within few minutes to hours of severe central nervous 
system insult such as stroke in critical structure, subarachnoid haemorrhage or traumatic 
brain injury.164  Resolution usually occurs within several days.164  Although many episodes 
of neurogenic HF are well tolerated with conservative management,164 its development is 
associated with higher 1-year mortality, but not a poorer 1-year functional outcome, 
compared to those without neurogenic HF.165    
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1.4. Treatment of stroke in patients with atrial fibrillation or heart failure 
1.4.1. Acute stroke 
1.4.1.1. Intravenous thrombolytic treatment 
Rapid administration of intravenous thrombolytic treatment (recombinant tissue-type 
plasminogen activator [rtPA]) to eligible patients remains the mainstay of early therapy for 
hyper-acute ischaemic stroke.166, 167  Timely restoration of blood flow in patients with acute 
stroke is effective in minimizing long-term morbidity.  Various national and international 
guidelines recommend the administration of intravenous (IV) rtPA within 4.5 hours of 
ischaemic stroke onset for appropriate patients. 166-169  The number needed to treat (NNT) 
to achieve good outcome (and to avoid a single case of death or dependency) following IV 
rtPA treatment is 7.170 The NNT to achieve reduction in disability is 3.171  Meanwhile, the 
number needed to harm following treatment is 30.  These figures compare favourably to 
other thrombolytic treatment such as in acute myocardial infarction.  Every effort should 
be made to minimize onset-to-treatment times, which is a key driver of efficacy for rtPA 
treatment in patients with acute stroke.172, 173 
Nonetheless, IV rtPA treatment is one of the very limited medical therapies available for 
patients with acute ischaemic stroke.  Only a third of patients achieve evident benefit from 
the treatment,171 and the treatment itself carries a small but important risk of intracerebral 
haemorrhage.  This raises a conundrum whether certain baseline co-morbidities would 
identify subgroup of patients in whom treatment does not lead to a measurable advantage.  
Age, diabetes, AF and previous stroke appear unlikely to influence treatment response.174-
177  However, the impact of heart failure on outcome in patients with acute stroke who 
received IV rtPA is unknown. 
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1.4.1.2. Endovascular thrombectomy treatment 
Endovascular thrombectomy treatment for acute ischaemic stroke has evolved 
substantially over the last few years. The clinical trials published from 2015 onwards 
showed that thrombectomy, when performed with modern neurothrombectomy devices 
(mainly stent retrievers), more rigorous imaging selection criteria and more efficient 
workflow for patient treatment, significantly improves outcomes after acute ischaemic 
stroke caused by proximal large vessel occlusion in the anterior circulation.178-182  The 
clinical benefit extends across a wide range of age, initial stroke severity and for patients 
eligible and ineligible for IV rtPA.183  However, it is worth noting that up to 90% of patients 
enrolled in the trials received IV rtPA, and approximately 70% of these patients received 
the thrombolytic treatment within 180 minutes of symptom onset.183  Following this, the 
European Stroke Organisation and the American Heart Association/ American Stroke 
Association recommend that mechanical thrombectomy, in addition to IV rtPA when 
eligible, is provided to patients with large artery occlusion in the anterior circulation up to 
6 hours after symptom onset.184, 185  The recommendations also specify that stringent 
imaging selection criteria should applied, and old age alone is not a reason to withhold such 
treatment.175, 176   
At the time of writing, no trial or subgroup analysis of existing studies had examined the 
effect of endovascular thrombectomy treatment in acute stroke patients with either atrial 
fibrillation or heart failure. 
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1.4.2. Stroke thrombo-prophylaxis  
1.4.2.1. Patients with atrial fibrillation 
The presence of AF increases the risk of first and recurrent strokes.  The risk is exacerbated 
with advancing age, diabetes, hypertension, previous stroke and any other previous 
cardiovascular events.  Two scores are now routinely employed to predict stroke risk and 
guide stroke thrombo-prophylaxis treatment.186-188  The most common is the CHA2DS2-
VASc score (Congestive heart disease, Hypertension, Age ≥75 [doubled], Diabetes, Stroke 
[doubled]- Vascular disease, Age [65-74], and Sex category [female]).48, 71, 188  The annual 
risk of stroke according to each integer score of the CHA2DS2-VASc is shown in Table 1-2.  
There is accumulating evidence that the CHA2DS2-VASc score is better than others (such as 
CHADS2), at identifying patients with AF who are ‘truly low-risk’ for stroke, and who thus 
do not need any antithrombotic treatment.189-191  The European Society of Cardiology (ESC) 
guidelines advocate that patients with AF who have a CHA2DS2-VASc score of ≥1 should 
receive effective stroke thrombo-prophylaxis, either vitamin K oral anticoagulant e.g. 
warfarin (with ≥70% time in therapeutic range), or one of the non-vitamin K oral 
anticoagulants (NOACs).71  Meanwhile, the American Heart Association (AHA) guidelines 
recommend oral anticoagulant treatment for patients with score CHA2DS2-VASc  ≥2.48  
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Table 1-2. Adjusted stroke rate according to CHA2DS2-VASc score. Adapted 
from Camm et al (2010)47  
CHA2DS2-VASc score Adjusted stroke rate 
(%/ year) 
0 0% 
1 1.3% 
2 2.2% 
3 3.2% 
4 4.0% 
5 6.7% 
6 9.8% 
7 9.6% 
8 6.7% 
9 15.2% 
 
Antiplatelet agent 
The evidence to support the use of antiplatelet agent (commonly aspirin) for stroke 
prevention in patients with AF is weak, with a potential for harm.192-194  Risk of major 
gastrointestinal or intracranial haemorrhage with aspirin is not significantly different 
compared to oral anticoagulant, especially in the elderly.192-194  Combination of dual-
antiplatelet therapy, e.g. aspirin plus clopidogrel, has additional efficacy for stroke 
prevention over aspirin monotherapy, but with notable risk of major haemorrhage.195  
Current guidelines do not recommend the use of antiplatelet agent for stroke prevention 
in patients with AF.71 48 
Vitamin K antagonist oral anticoagulant  
The most widely used and studied oral anticoagulant for stroke prevention in patients with 
AF is the vitamin K antagonist, warfarin.  In a meta-analysis, dose-adjusted warfarin 
reduced the risk of stroke by 64% compared to placebo, and by approximately 40% 
compared to antiplatelet treatment.196  The net clinical benefit for warfarin treatment in 
patients with AF also increased with age.197, 198  
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Non-vitamin K oral anticoagulants  
Large randomised clinical trials have compared five non-vitamin K oral anticoagulants 
(NOACs) with warfarin for prevention of stroke and systemic embolism in patients with AF.  
Dabigatran was evaluated in the ‘Randomised Evaluation of Long-term Anticoagulant 
therapy (RE-LY)’ trial;199 Rivaroxaban in the ‘Rivaroxaban Once Daily Oral Direct Factor Xa 
Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism 
Trial in Atrial Fibrillation  (ROCKET-AF)’ study;200 Apixaban in the ‘Apixaban for Reduction in 
Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)’ trial;201 and 
Edoxaban in the ‘Effective Anticoagulation with Factor Xa Next Generation in Atrial 
Fibrillation–Thrombolysis in Myocardial Infarction 48’ (ENGAGE AF-TIMI 48) trial.202  The 
first NOAC class agent to be studied, ximelagatran, has been withdrawn from the market 
due to hepatic toxicity.203-205  All four of the currently available NOACs have shown non-
inferiority for efficacy compared with warfarin, with better safety and consistently lower 
numbers of intracranial haemorrhages.  In a meta-analysis that compared the treatment 
effects of warfarin vs. NOACs, the latter significantly reduced stroke or systemic embolic 
events by 19% compared with warfarin, mainly driven by a reduction in haemorrhagic 
stroke.206  Death was 10% lower in patients randomised to NOAC therapy and intracranial 
haemorrhage was halved, while major bleeding events were more frequent.206  However, 
there is currently no direct head-to-head comparison among the NOACs.  An indirect 
comparison between dabigatran, apixaban and rivaroxaban, showed no significant 
differences in efficacy endpoints (including stroke), but major bleeding was less with 
apixaban and low dose dabigatran.207  Apixaban has been shown to be superior to aspirin 
in patients with AF who were unable or unwilling to take warfarin.208  
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The NOACs offer the benefits of effective oral anticoagulant treatment, better safety and 
more convenience for patients.  They have predictable pharmacological profiles, a rapid 
onset of action, and fewer practical constraints compared to warfarin (e.g. no requirement 
for regular monitoring, fewer interactions with other drugs and no food interactions).    
 
1.4.2.2. Patients with heart failure but without atrial fibrillation 
Many patients with HF have cardiovascular co-morbidities such as angina, myocardial 
infarction, diabetes and AF; which may require antithrombotic therapy for stroke thrombo-
prophylaxis.  Antiplatelet treatment may be indicated in patients with HF but without AF 
for stroke prevention (if at increased cardiovascular risk).  There is currently no clear 
evidence to support the use of an oral anticoagulant for stroke prevention in patients with 
HF but without AF. 
Four trials that examined warfarin in patients with heart failure but without AF consistently 
failed to show superiority for primary outcomes that included death and stroke, when 
compared to aspirin.209-212  Moreover, warfarin treatment in the trials was associated with 
a higher incidence of major haemorrhage, though the risk of intracranial haemorrhage 
remained very low and not-significantly different compared to aspirin.  However, when 
stroke outcome is considered itself, meta-analyses of the trials showed that warfarin could 
effectively reduce ischaemic stroke by 28-51%.213-216  The overall mortality was similar 
between aspirin and warfarin. 213-216   
The above findings highlight the need to better understand risks and predictors of stroke 
in HF population.  Given the favourable risk-benefit profile of the NOACs, identification of 
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those at the highest risk of stroke may allow individualised and safer stroke prevention 
strategies in patients with HF but without AF. 
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1.5. Aims 
The overall aim of this thesis was to address some of the challenges faced by clinicians 
when dealing with stroke in patients with atrial fibrillation or heart failure, using the vast 
range of historical data.  
Chapter 2 discusses the key aspects of the methods used throughout the thesis.  Patients 
with acute ischaemic stroke and concomitant AF are at risk of early recurrent stroke but 
also haemorrhagic transformation of the infarct.  Chapter 3 aims to explore the relevance 
of antithrombotic treatment on the patterns and outcome of acute stroke patients with AF.  
With accumulating evidence that supports the use of oral anticoagulant treatment for 
stroke prevention in patients with AF, Chapter 4 describes the current prescribing patterns 
in stroke survivors with AF, with particular emphasis on socio-demographic associations.  
Since the incidence of stroke in patients with HF may be reducing due to increasing use of 
disease-modifying and oral anticoagulant therapies, Chapter 5 aims to investigate the 
incidence of stroke within the available HF-REF and HF-PEF trials spanning a 30 year period, 
according to AF status at baseline.  Chapter 6 aims to develop and validate novel risk-
models for stroke in a contemporary cohort of patients with HF-REF but without AF.  
Correspondingly, Chapter 7 explores the novel risk-model for stroke in a contemporary 
cohort of patients with HF-PEF but without AF.  Finally, Chapter 8 aims to investigate the 
impact of chronic HF on the outcome of acute stroke patients who received systemic 
thrombolysis.  
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Chapter 2  
Data and Methods 
2.1. Preamble 
In this chapter, I will describe the data sources and statistical methods used that were 
common to the studies in this thesis.  Detailed study specific methods are described within 
the relevant chapters. 
 
2.2. Richness of data in completed clinical trials and registries 
Randomised clinical trials (RCTs) are the gold standard design for rigorous evaluation of a 
single variable (e.g. effect of a drug treatment versus placebo) in a precisely defined patient 
group.  RCTs are a reliable measure of efficacy with minimal bias and allow meta-analysis 
at a later date.  However, practical and financial constraints limit the development of robust 
clinical trials.  Consequently, many clinically important questions will remain unanswered. 
An alternative approach, though less robust than RCTs, is the prospective cohort studies. 
Cohort studies have the advantage of being tailored to collect specific exposure data to 
investigate rare events, such as intracerebral haemorrhage.217  The disadvantages of a 
prospective cohort study may be the long follow-up period while waiting for the events to 
occur and highly susceptible to selection bias.217  Thus, a compromise is desirable to allow 
clinical action pending or in absence of definitive clinical trial/ cohort study approaches.   
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There have been many clinical trials and registries in the fields of cardiovascular and 
cerebrovascular medicine over the past decades.  The datasets from these trials often 
reside in industry and academic archives long after publication.  Irrespective of the trials’ 
outcomes, patient data collected during the course of the trials can still have scientific 
value.  The completed trials contain rich data on patient demography, laboratory 
measurements, cardiac/ brain imaging, outcome measures, adverse events and timing of 
these events in relation to the start of the treatment.  Disregarding the treatment groups, 
the data are rich in patient natural history and can be used for secondary analyses.  For 
example, data from completed heart failure (HF) trials could be used to investigate the 
incidence of stroke in patients with HF, in the presence or absence of atrial fibrillation (AF); 
or to facilitate the development of prognostic models for stroke in patients with HF.  
Retrospective analyses of existing data can also contribute to proof-of-concept studies, 
end-point optimisation, pilot studies and the planning of future trials. 
While there are many benefits in the use of existing data, there are some caveats that need 
to be considered.  Each trial has distinct inclusion and exclusion criteria.  Any analysis using 
existing data may be subject to selection bias.  For instance, some existing HF trials included 
patients with just a narrow ejection fraction range or symptom profile; and some stroke 
trials only randomised patients with a particular stroke severity.  Thus, the results from 
such analyses may not be generalised to the wider population. 
In addition, existing data from completed trials and registries may not contain variables on 
the important confounders and outcomes relevant to the new analysis.  However, the 
impact of missing data can be minimised by the use of appropriate statistical strategies, for 
example matching and bootstrapping techniques.  Surrogate or alternative variables can 
also be generated to lessen the impact of missing data.  Caution must also be taken when 
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making recommendations based on secondary analysis of existing data, in relation to the 
development of new treatments over time.  These caveats must be taken into 
consideration when drawing conclusions from the analysis.  Of course, any retrospective 
analysis of existing data is not a substitute for a well-designed clinical trial. 
 
2.3. Data sources 
2.3.1.1. Heart failure trials 
The Institute of Cardiovascular and Medical Sciences of the University of Glasgow, UK, is in 
a unique position to have access to anonymised heart failure trials datasets at individual 
patient data level as listed in Table 2.1.  The data access was obtained through one of the 
following three routes: 1) local investigator, Professor John J.V McMurray (Professor of 
Medical Cardiology, University of Glasgow) in collaboration with the original trials’ 
investigators; 2) open access National Institutes of Health (NIH) data repository (Biologic 
Specimen and Data Repository Information Coordinating Center, BioLINCC); and 3) the 
Virtual International Cardiovascular and Cognitive Trials Archive (VICCTA).   
 
2.3.1.2. VISTA database 
The Virtual International Stroke Trials Archive (VISTA) is a collaborative venture that 
collates data from completed acute stroke trials (from year 1998) and provides access to 
anonymised data for exploratory analyses.218  Across the entire archive, data are available 
on more than 82,000 individual patients and are stored anonymously.219  All patients with 
stroke were treated as per institutional practice and stroke guidelines acceptable at the 
 57 
point of trial conduct.  Access to VISTA database is controlled by a steering committee that 
consists of principal investigators from all contributed trials.218  
 
Table 2-1. Heart failure trials datasets that are accessible for this thesis project 
HF Category HF Trials Patients 
 
 
Heart failure with 
reduced ejection 
fraction        
(HF-REF) 
Studies of Left Ventricular Dysfunction- Treatment (SOLVD-T) Trial108 2569 
Studies of Left Ventricular Dysfunction- Prevention (SOLVD-P) Trial220 4228 
Digitalis Intervention Group Trial (DIG)121 6800 
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-2)114  2647 
The Beta-Blocker Evaluation of Survival Trial  (BEST)116  2707 
The Randomised Aldactone Evaluation Study (RALES)117 1663 
The Sudden Cardiac Death in Heart Failure (SCD-HeFT) trial221 2521 
Candesartan in Heart Failure Assessment of Reduction in Mortality 
and Morbidity Trial (CHARM-Alternative)110 
2028 
Candesartan in Heart Failure Assessment of Reduction in Mortality 
and Morbidity Trial (CHARM-Added)222  
2548 
Eplerenone in Mild Patients Hospitalization and Survival Study in 
Heart Failure (EMPHASIS-HF)118 
2737 
Controlled Rosuvastatin Multinational Study in Heart Failure Trial 
(CORONA)223 
5011 
Effect of Rosuvastatin in Patients with Chronic Heart Failure Trial 
(GISSI-HF)224 
4574 
Heart failure with 
preserved ejection 
fraction   
(HF-PEF) 
The ancillary Digitalis Investigation Group (DIG-PEF) Trial225 988 
Candesartan in Heart Failure Assessment of Reduction in Mortality 
and Morbidity Trial (CHARM-Preserved)141 
3023 
Irbesartan in Heart Failure with Preserved Ejection Fraction   
(I-Preserve) Study139 
4128 
 The Treatment of Preserved Cardiac Function Heart Failure with an 
Aldosterone Antagonist (TOPCAT) Trial140 
3445 
 
2.3.1.3. VICCTA database 
The Virtual International Cardiovascular and Cognitive Trials Archive (VICCTA) is the 
extension of its successful sister collaboration, VISTA.226  VICCTA is a collaborative venture 
that brings existing anonymised datasets from a series of completed trials and registries in 
the wider cardiovascular areas including diabetes, ischaemic heart disease, heart failure, 
atrial fibrillation, thrombo-embolism and cognition, for secondary analyses. Similar to 
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VISTA, access to VICCTA data is governed by a steering committee that comprises 
contributing trialists.226 
 
2.3.1.4. LES registry 
Local Enhanced Service (LES) is a contractual arrangement with the primary care services 
designed to augment the basic patient-level data collection required through the General 
Medical Services (GMS) Quality and Outcome Framework (QoF) specification.227  LES 
facilitates effective monitoring and clinical audit.227  There are currently several active LES 
covering key disease areas, including coronary heart disease, chronic obstructive 
pulmonary disease (COPD), stroke and AF.227  LES offers financial incentives to encourage 
proactive case finding, annual nurse-led reviews and centralised data storage.227  To ensure 
data quality, the LES initiative provides annual practice nurse training to ensure consistency 
of data collection and central data analysis and quality control.227  Thus, the LES registry is 
rich with valuable data on specific disease management in the community.    
 
 
2.4. Descriptive and inferential statistics 
Descriptive statistics were generated to compare groups of patients relevant to the aim(s) 
of individual chapters in the thesis.  Depending on their distribution, data are presented as 
means (standard deviation) and medians (inter-quartile range) for continuous variables and 
frequency (percent) for categorical variables.     
Unadjusted baseline comparisons between groups were conducted using two sample t-
test, the Mann-Whitney U-test, or the chi-square test depending on the distribution and 
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nature of the data.  A p-value of <0.05 was used to define a statistically significant 
difference for all analyses.   
 
2.5. Analysis of outcome measures 
2.5.1. Analysing binary and ordinal outcome measures: logistic regression 
The outcome measure in the analyses contained in this thesis can either be a binary or an 
ordinal measure.  For example, the modified-Rankin Scale (mRS) can be analysed as both a 
binary and an ordinal measure.228  The mRS is a commonly used scale to assess global 
outcome after stroke, and the most widely used clinical outcome measure in stroke 
trials.228  The scale ranges from 0-6, running from perfect health without symptoms to 
death.228  The mRS is transformed into a binary measure when it is dichotomised into good 
outcome (e.g. mRS 0-2) versus poor outcome (e.g. mRS>2).  The binary response can be 
analysed using the binary logistic regression model.229  
  
The mRS can also be considered as a full ordinal measure (mRS 0-6), rather than just cut at 
a specific point, so the results reflect all health state transitions in the analysis.  When the 
mRS is treated as an ordinal scale, it can be analysed using ordinal logistic regression with 
the proportional odds model.230  Ordinal analysis accounts for the full distribution of the 
mRS and is generally expected to offer greater statistical power as compared to 
dichotomised analysis.  Although there are criticisms that the nature of the mRS does not 
always meet the ordinality assumption, this method has gained popularity in recent 
years.230, 231  The significance of the ordinal analysis is assessed using the Cochran-Mantel-
Haenszel (CMH) test or the Mann-Whitney effect size measure.232, 233  
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The logistic regression techniques quantify the predictive value of an explanatory variable 
on a response variable.  The analysis can be adjusted to account for significant differences 
between the groups of any defined variables, and variables that are considered clinically-
important.  The binary or ordinal logistic regression techniques were used in the studies 
contained in Chapters 3, 4 and 8.   
 
2.5.2. Survival analysis 
Survival analysis is used to calculate survival (time-to-event) probabilities.217  Originally, 
such analyses were performed to give information on time-to-death in fatal conditions, 
thus the term “survival”.217  However, the analysis can also be applied to many other 
defined outcomes, for example, first stroke, recurrent stroke and symptomatic 
intracerebral haemorrhage.  This method is used to compare treatment groups and to 
provide prognostic information.217  Survival analysis was used in the majority of studies 
included in this thesis. 
 
2.5.2.1. Kaplan-Meier curves 
The Kaplan-Meier curve is commonly used to estimate the survivor function from censored 
life time data, assuming all censors are independent of the event of interest.234  It 
determines the probabilities and proportions of individuals without the event (“surviving”), 
enabling the estimation of a cumulative survival probability.  These probabilities can be 
depicted graphically in a Kaplan-Meier curve.  The x-axis shows the length of survival time, 
and the y-axis shows the cumulative probabilities of remaining event-free (“survival”).   
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2.5.2.2. Log-rank test 
Long-rank test is used to compare the survival experiences of two or more studied groups, 
taking into account the entire follow-up period.217  It is a significance test that evaluates 
the null hypothesis that there is no difference in the probability of survival in the different 
groups.217  It does not depict the size of the differences between the groups.217 
    
2.5.2.3. Cox proportional hazard regression 
The Cox-proportional hazard regression is the multivariable extension of the log-rank 
test.235, 236  It allows assessment of the effects of several variables on time-to-event 
outcome either to test hypotheses about predictive factors or to produce a predictive 
model.236  The predictor variables can be any mixture of continuous, binary or categorical 
data.236  This method yields a set of regression coefficients that represent the relationship 
between each predictor variable and the time-to-event outcome, after adjusting for all the 
other variables in the model.235, 236 
 
2.5.2.4. Cumulative incidence function 
The cumulative incidence function is used to describe survival data with competing risks.237   
For example, in a study that evaluates the incidence of first stroke in patients with or 
without AF, the variables of interest are the first stroke event and the time-to-first stroke.  
However, some patients who are at risk of stroke may die prematurely because of other 
causes.  To estimate the rate of stroke across time, death and time-to-death should be 
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treated as its competing risk meaning the event of death (for individual without prior 
stroke) precludes the possibility of the same individual getting a stroke.  
 
2.6. Modelling and performance of the model 
2.6.1. Development of stroke models 
Chapters 6 and 7 of the thesis focused on the development of novel risk models for stroke 
in cohorts of contemporary patients with heart failure.  The modelling was primarily 
performed using a Cox proportional hazard regression multivariable analysis.  The 
candidate variables for the model were selected from ‘univariable screening’ and 
supplemented by variables which are considered clinically-important.238  Univariable 
screening was performed by looking at all univariable relationships with the dependent 
variable (i.e. stroke event).  Any statistically significant variable is included in a main 
model.238  Automated variable selection procedures e.g. forward, backward, or stepwise 
selection, were then applied and compared to obtain the final model with the smallest set 
of predictor variables.238  The variables included in the final model were assessed for 
missing data.   
  
2.6.2. Performance: discrimination and calibration  
2.6.2.1. Discrimination: overall C-index 
Discrimination is part of the model validation process that evaluates the predictive model’s 
ability to separate those who developed the event from those who did not.  The most 
popular discrimination measure is the Receiver Operating Characteristic (ROC) curves.217 
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However, the measurement of predictive accuracy is more complex for survival analysis in 
the presence of censoring.  To overcome this, Harrell’s C statistic was introduced as a 
natural extension of the ROC curves.239  Overall C-index was then developed as a parameter 
to describe the performance of a given model applied to the population under 
consideration and discuss the statistics used as its sample estimate.240  Thus, the overall C-
index is a more attractive technique to describe the performance of a Cox model, rather 
than the traditional Harrell’s C statistic. 
The discrimination of the risk models for stroke in Chapters 6 and 7 were evaluated using 
the overall C-index.  The C-indices were calculated based on the analysis codes published 
in a validated, commonly cited and publically available SAS proceeding paper, Liu et al.241 
 
2.6.2.2. Calibration: Hosmer-Lemeshow test 
The Hosmer-Lemeshow test is a statistical test for goodness of fit for regression models, 
i.e. how well the model agrees with the data.242  The test evaluates the null hypothesis that 
there is no difference between the observed and predicted values of the response variable.  
Thus, if the test is non-significant (p≥0.05), the null hypothesis cannot be rejected, and 
implies that the model fits the data satisfactorily.  
  
 64 
2.6.3. External validation 
There are growing numbers of prognostic models related to stroke.243-250  Although many 
of the models have favourable properties, few have been incorporated into clinical 
practice.  One of the common limitations is the lack of external validation of the prognostic 
model(s) in independent cohorts.251  
In order to develop robust risk models for stroke that are applicable to clinical practice, the 
final models identified in Chapters 6 and 7 were externally validated using independent 
datasets appropriate for the target population.    
 
2.7. Statistical software 
All analyses were undertaken using SAS versions 9.2/ 9.3/ 9.4 (SAS Institute, Inc., Cary, 
NC, USA). 
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Chapter 3  
The outcome of acute 
ischaemic stroke patients 
with atrial fibrillation who 
received early anti-
thrombotic therapy: analysis 
from VISTA 
3.1. Background 
Atrial fibrillation (AF) is a common cause for cardio-embolic stroke.28  Patients with AF are 
at risk of early recurrent ischaemic stroke even after thrombolytic therapy.252  Among the 
AF cohort, there is excellent evidence to support the use of oral anticoagulant treatment 
for recurrent stroke prevention.253, 254 
Nevertheless, there is considerable uncertainty on the optimal latency after acute stroke 
at which oral anticoagulant treatment should commence, in order to prevent recurrent 
stroke without resulting in a symptomatic intracerebral haemorrhage.  The European 
Stroke Organisation and The American Stroke Association do not recommend the use of 
anticoagulation in the hyper-acute period after stroke but neither do they recommend an 
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acceptable delay after stroke to start anticoagulation.166, 167  Meanwhile, the National 
Institute for Health and Care Excellence (NICE) and the Royal College of Physicians UK 
recommend an arbitrary 2 weeks period of delay after stroke to start anticoagulation.169, 
255  The NICE guideline also specifies that the delay is for patients with disabling ischaemic 
stroke, though the degree of disability is not defined.169  Clinically, it seems reasonable to 
begin oral anticoagulant treatment as soon as the patient is both medically and 
neurologically stable.  This is often 2 or 3 days after stroke.  This likely achieves therapeutic 
anticoagulation level by days 5 to 7 when a traditional vitamin K antagonist (VKA) is used.  
However, cardio-embolic stroke is associated with an increased risk of haemorrhagic 
transformation in the first few days after stroke.43, 44  
Two meta-analyses suggested that immediate anticoagulation post–stroke is inadvisable 
because it offers no net benefit.256, 257  Nonetheless, there is no evidence to dispute the 
value of later or prolonged oral anticoagulant treatment.  It appears that there may be a 
threshold delay after stroke at which the value of anticoagulation switches from neutral to 
beneficial, at least among patients with AF.   
We sought to describe the associations of antithrombotic therapy commenced (i.e. oral 
anticoagulant or antiplatelet agent) on the patterns and outcomes of modified-Rankin 
Scale (mRS), recurrent stroke and symptomatic intracerebral haemorrhage in a cohort of 
patients with recent stroke and AF.  We also considered dichotomised outcomes as a 
secondary endpoint (i.e. mortality and good outcome measure at 90 days). 
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3.2. Methods 
3.2.1. Data source 
We conducted a non-randomised cohort analysis using data obtained from the Virtual 
International Stroke Trials Archive (VISTA, http://www.vistacollaboration.org/), specifically 
from ‘VISTA Acute’ sub-section.218  VISTA is a collaborative registry that collates and 
provides access to completed acute stroke trials’ data (from year 1998), anonymised in 
relation to patients and trials’ identity, for novel exploratory analyses.  The cohort data that 
were released to us did not contain trials that investigated thrombolysis therapy in hyper-
acute stroke.  However, the data contained trials in which thrombolysis was commonly 
used as standard therapy.  Conduct and reporting of the analysis is in accordance with the 
STROBE guidelines for cohort studies.258 
 
3.2.2. Participants and variables 
We selected patients who had been randomised to receive placebo or any drug now known 
to possess no confirmed action on stroke outcome.  We excluded patients who lacked the 
relevant baseline or outcome information: baseline National Institutes of Health stroke 
scale (NIHSS), age, medical history, concomitant medication, occurrence of adverse and 
serious adverse events and mRS at day 90.  We included only patients who were known to 
have medical history of AF or found to have AF on baseline ECG.  Data on anticoagulant 
treatment were based on warfarin or other VKA treatment started after stroke.  Data on 
antiplatelet treatment were based on platelet aggregation inhibitor (which includes 
derivatives of salicylic acid, thienopyridine and dipyridamole) started after stroke.  
Non-vitamin K oral anticoagulants (NOACs) were not available during the original acute 
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stroke trials that were the data source for this analysis.  Thus, NOACs were not considered 
in the analysis.  Our follow-up period was 90 days after stroke.    
 
3.2.3. Definition of outcome events 
Symptomatic recurrent stroke was defined as any stroke with neurological deterioration, 
as indicated by NIHSS that was higher by ≥4 points than the value at baseline, or any stroke 
leading to death.  Similarly, symptomatic intracerebral haemorrhage was defined as any 
intracerebral haemorrhage with neurological deterioration, with worsening of NIHSS by ≥4 
points from baseline, or any intracerebral haemorrhage leading to death. Thus, recurrent 
stroke and symptomatic intracerebral haemorrhage are each a combined endpoint of fatal 
and non-fatal events. 
 
3.2.4. Statistical methods 
Descriptive statistics were recorded for recent stroke patients with AF, assessing the 
complete cohort and comparing those who were treated with versus without antiplatelet 
agent after stroke, and with versus without oral anticoagulant after stroke.   We described 
mean (standard deviation [SD]) or median (inter-quartile range [IQR]) for continuous 
variables and count (percentage) for categorical variables.   
Our primary outcome measures were the ordinal shift of the mRS at day 90 using the full 
scale and the occurrence of recurrent stroke and symptomatic intracerebral haemorrhage 
by 90 days after stroke.  For comparison with prior trials, dichotomised outcomes at day 90 
(mortality, mRS 0-1, mRS 0-2 and NIHSS 0-1) were reported.  We calculated the odds ratio 
(OR) of achieving the studied outcome(s) against the comparator, and corresponding 95 
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percent confidence intervals (95%CI) using proportional odds logistic regression (i.e. 
ordinal regression for mRS distribution and binary regression for dichotomised outcome).  
Adjustment were made for age, baseline NIHSS and thrombolysis treatment.259 
We plotted the spread of recurrent stroke and symptomatic intracerebral haemorrhage 
over the 90 days period, for patients who received oral anticoagulant treatment versus 
patients who had antiplatelet treatment.  
Within the cohort who sustained recurrent stroke, we grouped the patients into:  i) those 
who had recurrent stroke in absence of anticoagulation; ii) patients who had recurrent 
stroke within 10 days of commencing anticoagulation; and iii) patients who had recurrent 
stroke beyond 10 days of commencing anticoagulation.  The cumulative percentage of 
recurrent stroke and symptomatic intracerebral haemorrhage on each day post-initial 
stroke by these groupings was plotted.  Similar groupings were made for patients treated 
with antiplatelet agent and their cumulative percentage of recurrent stroke and 
symptomatic intracerebral haemorrhage were plotted.  
All analyses were undertaken using SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA). 
 
3.3. Results 
3.3.1. Baseline characteristics 
Of the 10,304 ischaemic stroke patients available from VISTA, 8,060 were excluded as they 
were in sinus rhythm.  We obtained individual patient data for the remaining 1,644 stroke 
patients with AF, which formed our cohort. (Figure 3-1)  From this post-stroke cohort, 518 
(31%) were given oral anticoagulant treatment alone, 162 (10%) were given antiplatelet 
 70 
alone and 782 (48%) received a combination of the two. 182 (11%) did not receive any 
antithrombotic therapy.  The median start time for oral anticoagulant treatment was at day 
2 (IQR: 1-3) after stroke, whilst the median start time for antiplatelet treatment was at day 
1 (IQR: 1-3) after stroke.  Patients who received oral anticoagulant treatment were 
commonly younger and had less severe baseline NIHSS. Patients who received no 
antithrombotic therapy tended to have more severe baseline NIHSS.  
Baseline characteristics are given in the Table 3-1. The proportions of patients who were 
on antithrombotic treatment prior to the initial stroke (i.e. at baseline) are as follows; oral 
anticoagulant agent only; 286 (17%); antiplatelet agent only, 488 (30%); and combination 
of the two, 78 (5%).    
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Figure 3-1. Flow chart for selection of ischaemic stroke patients with atrial 
fibrillation from VISTA. 
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Table 3-1. Baseline characteristics of the cohort according to antithrombotic 
treatment received following stroke. 
Variables Antithrombotic treatment received after stroke 
No Antithrombotic 
(No anticoagulation, 
no antiplatelet), 
n=182 
Antiplatelet only, 
n=162 
Anticoagulation 
treatment only, 
n=518 
Anticoagulation 
treatment and 
antiplatelet,  
n=782 
Male; n (%) 85 (46.7%) 85 (52.5%) 243 (46.9%) 359 (45.9%) 
Age, years;  
   mean (SD) 
77.1 (9.0) 75.8 (10.0) 73.4 (10.1) 74.2 (9.8) 
Baseline NIHSS;  
   median (IQR), 
16 (11-21) 15 (11-19) 14 (10-18) 14 (9-18) 
Received 
thrombolysis 
treatment; n (%) 
71 (39.0%) 51 (31.5%) 203 (39.2%) 293 (37.5%) 
SBP at baseline 
(mmHg)  
154.3 (26.5) 155.8 (27.3) 153.3 (25.3) 155.6 (25.5) 
Heart rate at baseline 
(beats/min) 
80.38 (16.7) 81.8 (18.7) 83.9 (21.5) 83.8 (21.8) 
BMI at baseline 
(kg/m2) 
26.7 (4.7) 25.8 (4.8) 27.0 (5.0) 26.8 (4.4) 
Glucose at baseline 
(mmol/L) 
8.1 (3.0) 7.4 (2.7) 7.7 (3.1) 7.5 (2.5) 
INR at baseline 1.5 (1.1) 1.3 (0.9) 1.4 (1.0) 1.4 (0.9) 
 
Medical History,  
n (%) 
    
Previous stroke  46 (25.3%) 54 (33.3%) 108 (20.9%) 150 (19.2%) 
Transient ischaemic 
attack 
11 (6.7%) 10 (6.8%) 45 (9.1%) 70 (9.3%) 
Diabetes  50 (27.5%) 36 (22.2%) 122 (23.6%) 147 (18.8%) 
Hypertension 151 (83.0%) 127 (78.4%) 393 (75.9%) 616 (78.8%) 
Ischaemic heart 
disease 
78 (42.9%) 58 (35.8%) 199 (38.4%) 273 (24.9%) 
Chronic heart 
failure 
36 (19.8%) 33 (20.7%) 84 (16.2%) 132 (16.9%) 
Myocardial 
infarction 
23 (12.6%) 22 (13.6%) 74 (14.3%) 107 (13.7%) 
All continuous variables are described in ‘mean (standard deviation)’ unless stated otherwise. n: number of observations; 
SD: standard deviation; IQR: inter-quartile range; NIHSS: National Institutes of Health stroke scale;SBP: systolic blood 
pressure; BMI: body mass index; INR: International Normalized Ratio.  
 
3.3.2. Outcome 
In this cohort, 157 (10%) patients had recurrent stroke, 50 (3%) patients sustained 
symptomatic intracerebral haemorrhage and 390 (24%) patients died from any cause, by 
day 90. (Table 3-2)  Combined antithrombotic therapy with oral anticoagulant and 
antiplatelet agents was associated with more favourable functional outcome across the full 
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scale mRS at 90 day after adjustment for age, baseline NIHSS and thrombolysis treatment, 
OR=1.79 (95%CI: 1.32-2.42), as compared to no antithrombotic therapy received. The 
treatment effect of combined antithrombotic therapy lost statistical significance when 
outcome was dichotomised as mRS 0 to 1, mRS 0 to 2 and NIHSS 0 to 1.  
Combined antithrombotic therapy was associated with significantly lower risk of recurrent 
stroke, symptomatic intracerebral haemorrhage and mortality, by day 90, as compared to 
no antithrombotic therapy received [recurrent stroke, OR=0.33 (95%CI: 0.21-0.53); 
symptomatic intracerebral haemorrhage, OR=0.18 (95%CI: 0.09-0.37); and mortality, 
OR=0.34 (95%CI: 0.24-0.50)].  Similar results were obtained for respective antiplatelet or 
oral anticoagulant only therapy, as shown in Table 3-2.  Neither oral anticoagulant nor 
antiplatelet therapy alone was associated with a difference in functional outcome at day 
90 across all outcome measures after adjustment for age, baseline NIHSS and thrombolysis 
treatment.  The distribution of mRS at day 90 for each antithrombotic group versus control 
is shown in Figure 3-2. 
Among patients who suffered recurrent stroke, approximately 80% of patients had this 
event within 2 days post-initial stroke. (Figure 3-3 [panel a])  This pattern was the same for 
patients who had their recurrent stroke event within 10 days of commencing oral 
anticoagulant versus those who were not treated with oral anticoagulant, i.e. it mostly 
happened early.  Among patients who suffered symptomatic intracerebral haemorrhage, 
80% of patients who received no oral anticoagulant suffered symptomatic intracerebral 
haemorrhage by day 2 post-initial stroke and among patients who had symptomatic 
intracerebral haemorrhage within 10 days of commencing oral anticoagulant, 
approximately 80% of the symptomatic intracerebral haemorrhage cases occurred by day 
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3. (Figure 3-4 [panels a and c]) Similar patterns were seen in patients treated with 
antiplatelet agent. (Figure 3-3 [panel b], Figure 3-4 [panels b and d]). 
 
 
Figure 3-2. Distribution of mRS outcome at day 90 by antithrombotic therapy. 
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Table 3-2. Clinical outcomes at 90 days (adjusted for age, baseline NIHSS and 
thrombolysis treatment). 
 No anticoagulant Anticoagulant OR (95% CI) P-
value 
All 
 
 
Symptomatic intracerebral haemorrhage; n/N (%) 
 
Antiplatelet 3/162 (1.9%) 15/782 (1.9%) 0.92 (0.25-3.37) 0.904 18/944 (1.9%) 
No Antiplatelet 17/182 (9.3%) 15/518 (2.9%) 0.43 (0.20-0.94) 0.034 32/700 (4.6%) 
OR (95%CI) 0.24 (0.07-0.88) 0.59 (0.28-1.24)   0.42 (0.22-0.78) 
P-value 0.032 0.164   0.006 
All 20/344 (5.8%) 30/1300 (2.3%) 0.49 (0.26-0.92) 0.027  
 
 
Recurrent stroke; n/N (%) 
 
Antiplatelet 14/162 (8.6%) 52/782 (6.7%) 0.78(0.41-1.47) 0.439 66/944 (7.0%) 
No Antiplatelet 36/182 (19.8%) 55/518 (10.6%) 0.61(0.37-1.01) 0.056 91/700 (13.0%) 
OR (95%CI) 0.43 (0.22-0.86) 0.60 (0.40-0.91)   0.53 (0.37-0.74) 
P-value 0.016 0.015   <0.001 
All 50/334 (14.5%) 107/1300 (8.2%) 0.62 (0.42-0.91) 0.013  
 
Mortality; n/N (%) 
 
Antiplatelet 45/162 (27.8%) 139/782 (17.8%) 0.69 (0.45-1.06) 0.093 184/944 (19.5%) 
No Antiplatelet 74/182 (40.7%) 132/518 (25.5%) 0.70 (0.46-1.05) 0.083 206/700 (29.4%) 
OR (95%CI) 0.60 (0.35-1.02) 0.58 (0.43-0.78)   0.56 (0.44-0.73) 
P-value 0.061 <0.001   <0.001 
All 119/334 (34.6%) 271/1300 (20.9%) 0.65 (0.48-0.87) 0.004  
 
mRS 0-1; n/N (%) 
 
    
Antiplatelet 33/160 (20.6%) 164/779 (21.2%) 0.70 (0.43-1.14) 0.153 197/939 (21.0%) 
No Antiplatelet 37/174 (21.3%) 122/516 (23.6%) 0.81 (0.49-1.35) 0.413 159/690 (23.0%) 
OR (95% CI) 1.19 (0.63-2.25) 0.94 (0.69-1.28)   0.96 (0.72-1.26) 
P-value 0.602 0.689   0.743 
All 70/334 (21.0%) 286/1295 (22.1%) 0.77 (0.54-1.09) 0.142  
 
mRS 0-2; n/N (%) 
 
    
Antiplatelet 46/160 (28.7%) 239/779 (30.7%) 0.78 (0.50-1.21) 0.268 285/939 (30.4%) 
No Antiplatelet 46/174 (26.4%) 179/516 (34.7%) 1.13 (0.71-1.81) 0.609 225/690 (32.6%) 
OR (95% CI) 1.36 (0.75-2.45) 0.90 (0.68-1.19)   0.96 (0.75-1.24) 
P-value 0.308 0.438   0.752 
All 92/334 (27.5%) 418/1295 (32.3%) 0.95 (0.69-1.31) 0.795  
 
NIHSS 0-1; n/N (%) 
 
    
Antiplatelet 28/159 (17.6%) 182/745 (24.4%) 1.18 (0.72-1.94) 0.512 210/904 (23.2%)  
No Antiplatelet 34/172 (19.8%) 136/508 (26.8%) 1.18 (0.72-1.93) 0.508 170/680 (25.0%) 
OR (95% CI) 0.94 (0.49-1.81) 0.94 (0.70-1.26)   0.94 (0.72-1.23) 
P-value 0.852 0.694   0.669 
All 62/331 (18.7%) 318/1253 (25.4%) 1.19 (0.84-1.67) 0.336 62/331 (18.7%) 
OR, odds ratio; CI, confidence interval; n: number of observations; National Institutes of Health stroke scale; mRS: 
modified Rankin Scale. OR given are odds of achieving a 1 on the specified outcome. OR values given across are 
anticoagulant versus no anticoagulant split by antiplatelet regimen. OR values given downward are antiplatelet versus no 
antiplatelet split by anticoagulation regimen. Significant results are highlighted in bold. Values in italics indicate odd ratios 
or P-values.  
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Figure 3-3. The percentage of recurrent stroke (RS) and symptomatic 
intracerebral haemorrhage (SICH) during follow-up according to 
antithrombotic treatment received, a) anticoagulation; and b) antiplatelet. 
The percentage of events for RS displayed below zero on the x-axis and SICH displayed above zero on the x-axis. Days 
after stroke on the x-axis. RS: recurrent stroke; SICH: symptomatic intracerebral haemorrhage. Note: a) in the no 
anticoagulant group there are no SICH past day 6 and no RS past day 53; b) in the no antiplatelet group there are no SICH 
past day 28 and no RS past day 53.  
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Figure 3-4. Cumulative percentage of events on each day split by treatment 
received, a) recurrent stroke (RS) and anticoagulation; b) RS and antiplatelet 
agent; c) symptomatic intracerebral haemorrhage (SICH) and anticoagulation; 
and d) SICH and antiplatelet agent. 
RS: recurrent stroke; SICH: symptomatic intracerebral haemorrhage. 
 
3.4. Discussion 
We describe the pattern of outcomes for recent stroke patients with AF who were treated 
with oral anticoagulant or antiplatelet treatment, in relation to recurrent stroke and 
symptomatic intracerebral haemorrhage.  Early introduction of oral anticoagulant (after 2-
3 days post-stroke), and to a lesser extent antiplatelet agent, was associated with 
substantially fewer recurrent stroke events over the following weeks but with no excess 
risk of symptomatic intracerebral haemorrhage.  However, we have not been able to define 
an optimal time in patients with AF after acute stroke at which point oral anticoagulant 
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treatment should commence, to prevent recurrent stroke without resulting in symptomatic 
intracerebral haemorrhage. 
The conundrum around antithrombotic therapy, especially oral anticoagulant treatment, is 
that patients with AF and recent stroke, who are at highest risk of recurrent stroke, are also 
at high risk of intracerebral haemorrhage.  This was evidenced in our cohort who 
demonstrated simultaneously high recurrent stroke and symptomatic intracerebral 
haemorrhage occurrence during the early period after stroke.  The risks of haemorrhagic 
transformation and recurrent stroke are especially high after stroke due to the natural 
progression,44, 196 and many of the recurrent stroke and symptomatic intracerebral 
haemorrhage that were recorded in very early period after stroke likely occurred before 
the start of oral anticoagulant or were spontaneous, i.e. incidental to anticoagulation, 
rather than attributable to treatment.  This effect was shown in our cumulative percentage 
of recurrent stroke and symptomatic intracerebral haemorrhage graphs plotted for 
patients who were on oral anticoagulant and antiplatelet agent and those who were not 
on any treatment.   
We found that patients who were not treated with antithrombotic treatment had higher 
incidences of recurrent stroke (20%, 36/182) and symptomatic intracerebral haemorrhage 
(9%, 17/182) and mortality (41%, 74/182) by 90 days, compared to the patients who 
received any antithrombotic treatment.  Patients who were not offered treatment tended 
to have greater stroke severity.  We speculate that the severe stroke may lead to 
haemorrhagic transformation subsequently becoming symptomatic.  Patients with greater 
stroke severity may also not be treated with antithrombotic treatment if prognosis was 
thought to be poor enough that palliative care was deemed to be more appropriate. 
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Our data came from trials that were conducted before the introduction of NOACs.   These 
agents represent an alternative treatment for stroke patients with AF that may circumvent 
much of the known inconvenience of VKA.207, 260, 261  However, NOACs have an almost 
immediate anticoagulant effect compared to VKA agent.  NOACs have generated high 
interest for use in prevention of AF-related stroke, have not yet been tested in the 
immediate period following an acute stroke.199-202  Two modest-size cohort studies have 
shown that early initiation of NOAC, with median delay of 4-5 days after stroke onset, 
seemed safe.262, 263 
Current guidelines do not recommend the use of antiplatelet agent for stroke prevention 
in patients with AF,47, 48, 71, 166-168 but antiplatelet was frequently used in our cohort. This 
may indicate the underutilisation of oral anticoagulant drugs.  Each of our patients already 
scored at least 2 points on the CHA2DS2-VASc score.188  This score translates into ‘moderate 
to high’ risk of future stroke, in which anticoagulation treatment is generally warranted.  
We also found that combined antithrombotic therapies with both oral anticoagulant and 
antiplatelet was associated with more favourable functional outcome across full scale mRS. 
However, this combination is not routinely recommended for long-term stroke prophylaxis 
as there is increased risk of bleeding; and this risk rises with the duration of treatment.264, 
265  The finding should be interpreted with caution.  It may reflect selection bias and 
confounding factors, i.e. aggressive treatment was started for patients who had a less 
severe stroke, hence these patients had fewer complications.  Such patients, in general, 
were presumably not of advanced age and without multiple co-morbidities that might 
interfere with chronic anticoagulant use.  Taking this into account, there is a subgroup of 
patients with stroke who did better with early introduction of antithrombotic therapy.  This 
would suggest synergistic benefit of oral anticoagulant therapy in protecting against 
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recurrent stroke risk in AF, with antiplatelet therapy improving outcome as reported in the 
International Stroke Trial (IST) and the Chinese Acute Stroke Trial (CAST).266, 267  We can 
only speculate that the combination of oral anticoagulant and antiplatelet treatment in the 
cohort might not reflect intended long-term prescription of both agents, but instead may 
signify early short-term concomitant antiplatelet agent while waiting the long-term oral 
anticoagulant drug (usually VKA) to achieve its therapeutic state. 
This study has several limitations.  Although our analysis was performed using data derived 
from rigorous clinical trials, the non-randomised nature of registry data inevitably 
incorporates selection bias for antithrombotic treatment and other confounders.  The non-
random allocation of oral anticoagulant or antiplatelet treatment is a weakness.  We could 
not determine the rationale for treatment decisions for patients from our database, which 
entirely depends on individual clinicians’ perceptions of risks and benefits.  
Our outcome events (recurrent stroke and symptomatic intracerebral haemorrhage) data 
were based on Serious Adverse Events (SAE) reports that fit with the definition of the events 
described in the Methods section (Section 3.2), rather than relying upon systematic brain 
imaging to identify the events.  Therefore, it is likely that our estimates of recurrent stroke 
or symptomatic intracerebral haemorrhage are less exact in terms of time.  
We also recognise that the current and increasing availability of thrombolysis treatment 
(rtPA) could certainly have influenced the results.  First, rtPA can be regarded as a ‘stress 
test’ whereby patients who tolerated the treatment (without any ill-effect) would routinely 
able to tolerate long-term oral anticoagulant treatment.  Second, rtPA is usually given in a 
selected group of patients without predisposition of bleeding or contra-indication to the 
treatment.  Allocation for rtPA would highlight the possible safety for long-term oral 
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anticoagulant, as the contra-indications for thrombolysis and anticoagulation treatments 
are near similar.   Third, rtPA is generally associated with good outcome after stroke.  Thus, 
more patients with better outcome following stroke may receive oral anticoagulant 
treatment.  Fourth, patients who received rtPA routinely have repeat brain imaging, 24-
hour post-treatment, which provides a ‘safety measure’ prior to starting long-term oral 
anticoagulant treatment. 
While we understand the attraction of subgroup analysis into mono-, dual- or triple- 
antiplatelet therapy, the numbers of each subgroup will become too small, thus difficult to 
make any useful inference.  We speculate that clinicians would be as cautious as to start 
dual- or triple- antiplatelet treatment compared to start oral anticoagulant treatment 
following stroke, due to the risk of exacerbating any haemorrhagic transformation.  
In conclusion, because the risks and benefits appear to track together, it seems justified to 
begin oral anticoagulant treatment once the patient is medically and neurologically stable, 
taking into account the potential of haemorrhagic transformation as part of the natural 
progression after stroke and the increasing risk of recurrent stroke with time if left 
untreated.  Although we appreciate that the analysis cannot be generalised, the patterns 
do suggest that early introduction of oral anticoagulant, and to a lesser extent antiplatelet 
agent, was associated with substantially fewer recurrent stroke events over the following 
weeks but with no excess risk of symptomatic intracerebral haemorrhage.  Early 
antiplatelet followed by oral anticoagulant treatment seems reasonable.  This issue 
deserves further attention. 
  
 82 
Chapter 4  
Oral anticoagulant treatment 
in stroke survivors with atrial 
fibrillation: a cross-sectional 
registry-based analysis  
4.1. Background 
Atrial fibrillation (AF) is a common and treatable cause of ischaemic stroke.28  With an aging 
population and better survival of patients with chronic cardiac diseases, prevalence of AF 
is expected to increase substantially.268 
We have effective treatments to prevent AF-related stroke.  Oral anticoagulant drugs, 
traditionally vitamin K antagonists (VKA) such as warfarin, reduce the annual risk of 
recurrent AF with a typical annual absolute risk reduction of 2.7%, higher in the context of 
secondary prevention after stroke.196  International guidelines and local prescribing 
protocols advocate consideration of oral anticoagulant treatment for subjects with AF 
informed by stroke and bleeding risk-stratification tools.71, 168, 169  Examples include the 
CHADS2   and CHA2DS2-VASC stroke risk scores and the HAS-BLED bleeding risk score.187, 188, 
269  The most important risk factor for future AF-related stroke is history of a previous stroke 
event and so all scoring systems recommend oral anticoagulant treatment in ischaemic 
stroke survivors with AF.   
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Glasgow data suggest potential underutilisation of evidence-based secondary prevention 
for cardiovascular diseases,227 although rates of oral anticoagulant treatment in stroke 
survivors have not previously been described at city level.  Prescribing data in cohorts of 
stroke survivors can help describe patterns of anticoagulation, which may in turn be used 
to explain and target potential areas of prescribing inequality.  While there have been 
several studies describing patterns of prescribing in cardiovascular disease, there are 
limited numbers of studies looking at clinical and socio-demographic predictors or 
associations with prescribing.  Highly cited studies of VKA prescribing inequality are now 
over a decade old.270, 271  Recognising the recent emphasis on treatment of AF in primary 
care, a contemporary analysis of prescribing in primary care was warranted. 
The “substrate” for such analyses should be a representative sample of community 
dwelling stroke survivors, well-phenotyped for socio-demographic, clinical and prescribing 
data.  In Glasgow UK, we have a city wide database that is suited to analyses of prescribing 
patterns, offering central data storage of annual comprehensive, individual patient level 
assessment of stroke survivors – the NHS Greater Glasgow and Clyde: Local Enhanced 
Service (stroke) registry. 
We sought to describe primary care oral anticoagulant prescribing in stroke survivors using 
LES data.  Primary outcomes of interest were: association between oral anticoagulant 
prescribing and clinical or demographic factors, in particular the association between oral 
anticoagulant prescribing and common AF/ bleeding risk stratification tools and 
associations with socio-economic deprivation. 
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4.2. Methods 
We conducted a cross-sectional analysis of a city-wide primary care data resource.   
Conduct and reporting of our analysis is in accordance with the STROBE guidelines for cross-
sectional studies.258 
 
4.2.1. Setting 
Greater Glasgow and Clyde Health board provides services for a population of around 1.2 
million people in the Glasgow city area.  Annual hospital admissions for stroke are around 
3,000,227 with 15,312 people registered by primary care practices (all GP practices) as 
having previously had a TIA or stroke, for the year 2010.  Glasgow is broadly typical of 
urban, UK settings albeit with high level of cardiovascular disease burden and socio-
economic deprivation.227 
 
4.2.2. Data source 
We used the Glasgow LES registry, limited to the last available year with full data input 
(2010).227  The LES is a contractual arrangement with primary care services, designed to 
augment the basic patient-level data collection required through the General Medical 
Services (GMS) Quality and Outcome Framework (QoF) specification.  In total, 209 out of 
213 GP practices in Glasgow participated in the LES initiative.  There are currently several 
active LES covering key disease-areas including atrial fibrillation and stroke.  By linking LES 
to practice level prescribing and diagnostic/referral registers, the system offers robust data 
on medication and co-morbidity.  
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4.2.3. Participants 
We identified all stroke survivor patients from the LES Stroke Database.  We excluded care-
home residents or housebound subjects and limited data by ischaemic aetiology and 
presence of AF using LES specific Read-codes.  We limited our search to the most recent 
year of LES with a full dataset available and collated clinical, demographic and prescribing 
data by predefined variables described below. 
 
4.2.4. Variables  
Presence of AF is assessed at annual LES review using medical record review and manual 
pulse check, supplemented if required by a 12 lead electrocardiograph.  This process of AF 
case-finding has been shown to be sensitive and has been employed in clinical trials.272, 273 
Under the rubric “AF” we included both persistent and paroxysmal AF and also atrial flutter.  
Data on anticoagulant treatment were taken from patient level prescribing data and 
treatment was defined as at least one prescription for warfarin or other VKA within the one 
year period of interest.  Using the same method we also collated data on any antiplatelet 
agents prescribed.  The non-vitamin K oral anticoagulants (NOAC) were not prescribed in 
primary care for stroke prevention during the period of data collection (2010) and so were 
not considered. 
We collated data on: age; sex; race; systolic blood pressure (using standard 
sphygmomanometer, mmHg); glycosolated haemoglobin (HbA1c, %); total cholesterol 
(mmol/l) and body mass index (kg/m2).  We described rates of excessive alcohol intake 
(defined at practice level); smoking (defined as any current use of cigarettes or other 
related products); any major bleeding episode in last year (defined as requiring 
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hospitalisation); AF duration of greater than 10 years and substantial disability (defined as 
requiring external assistance with mobility and transfers). 
Socio-economic status was described using the Scottish Index of Multiple Deprivation 
(SIMD).274  The SIMD is assigned on the basis of the datazone (using postcode data) of 
residence and contains various domains, which carry different weighting; income (28%), 
employment (28%), health (14%), education (14%), geographic access to services (9%), 
crime (5%), and housing (2%).274  The data from each domain were combined into an overall 
index to rank relative multiple deprivation.  We used postcode data within the LES to assign 
SIMD and then described data as quintiles with quintile 1 representing the most deprived 
area.274 
Risk of AF-related stroke was described using CHADS2 (input co-variables: heart [“cardiac”] 
failure; hypertension; age; diabetes; previous stroke) and CHA2DS2-VASC (input co-variables 
as before with additional scoring by age and presence of vascular disease) scores,187, 188 
both scored using conventional criteria.  As all included patients had history of ischaemic 
stroke, minimum possible score was 2 for both tools.  We did not have access to all variables 
that comprise HAS-BLED269 and so we used a modified HAS-BLED (mHAS-BLED) (input co-
variables; hypertension, age, excessive alcohol, previous stroke or bleeding episode [total 
possible 5 points]).  To complement this analysis, we also described bleeding risk using 
criteria derived from National Institute Clinical Excellence (NICE) Guideline 36,275 assigning 
one point each for age (≥75 years); concomitant antiplatelet use; bleeding history; co-
morbidity (≥3 other active medical conditions), suboptimal diabetes control (HbA1c ≥7.5%) 
and suboptimal blood pressure control (BP ≥160mmHg systolic). 
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The LES data input defaults to “not present” unless data are entered, thus we do not have 
specific data on missing variables for categories included in LES database.  Clinical 
diagnoses recorded in LES are linked to hospital discharge records and primary care 
registers and so should be robust.  Mechanisms for practice level and central data quality 
control are routinely employed for LES.  Prescribing data; postcode (SIMD) and co-
morbidity were all linked for patient level practice records.  As further internal validity 
checks our local stroke Managed Clinical Network (MCN) clinical lead reviewed our collated 
data to “sense check” the face validity. 
 
4.2.5. Statistical methods 
Descriptive statistics were recorded for stroke survivors with AF, assessing the complete 
cohort and comparing those who were VKA-treated and VKA-untreated.  We described 
mean (standard deviation [SD]) or median (inter-quartile range [IQR]) for continuous 
variables and count (percentage) for categorical variables.  Patients were categorised by 
stroke risk using CHADS2 and CHA2DS2-VASC; and by bleeding risk using mHAS-BLED score 
and NICE criteria. 
Unadjusted comparisons of VKA treated and untreated groups were conducted using 2-
sample t-test, Mann-Whitney U-test, 2 proportions test, or the chi square test depending 
on the distribution and nature of the data.  As an internal quality control measure we 
recorded “significance” on univariable at the conventional level (p<0.05) and using 
sequentially rejective Bonferroni method analyses to correct for multiple analysis.276  
Under this correction, “significance” was defined as p<0.002 (significant level/number of 
variables, 0.05/25=0.002).  Factors to include in the multivariable analysis were chosen on 
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the basis of clinical and scientific validity as well as (unadjusted) significance.  Input 
covariables were: age, socio-economic deprivation (SIMD), systolic BP, body mass index, 
smoking, history of bleeding, duration of AF >10 years, depression, obesity, diabetes, 
disability, heart failure, use of antiplatelet, a combined co-morbidity score and the risk 
scores of CHADS2, CHA2DS2-VASC, mHASBLED and NICE criteria. 
We calculated odds ratios (ORs) and corresponding 95 per cent confidence intervals 
(95%CI) to express the odds of VKA treatment, in univariable analysis.  Our multivariable 
analysis adjusted for clinically important or specific covariables using a binary logistic 
regression against a dichotomised outcome measure of VKA treated/ VKA untreated.  All 
analyses were undertaken using SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA).  
 
4.3. Results 
The LES Stroke Database for 2010 contained data on 19,952 stroke survivors collected from 
209 primary care practices (out of 213 practices in Glasgow [98%]).227  Of the 19,952 
patients, 4,653 were excluded as care-home residents, housebound status or non-
ischaemic stroke.  The remaining 15,299 stroke survivors were median age 72 years (IQR: 
68-76); 7,557 were male (49%). (Figure 4-1) 
Of this community dwelling ischaemic stroke survivor population, 3,439 patients (22%) had 
a diagnosis of AF, their median age was 78 years (IQR: 72-84), and 1,699 were male (49%).  
There was a high prevalence of socio-economic deprivation with 1,280 patients (37%) in 
the most deprived quintile.  The population was almost exclusively Caucasian, 3,387 
patients (99%).   The cohort were at high risk of AF-related stroke with median CHADS2 
score 3 (IQR: 2-4); median CHA2DS2-VASC score 5 (IQR: 4-6).  One third of the cohort i.e. 
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1,165 patients (34%), were treated with VKA.  Antiplatelets were prescribed in 668 patients 
(19%), with 149 patients (6%) on concomitant antiplatelet agent while prescribed VKA. 
(Table 4-1)  
 
 
 
Figure 4-1. Flow chart for selection of ischaemic stroke survivor patients from 
the Local Enhanced Service (Stroke) registry. 
GP: General Practitioners; VKA: vitamin K antagonist. 
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Table 4-1. Baseline characteristics of ischaemic stroke survivors with atrial 
fibrillation. 
  VKA Prescription  
 
 
All patients, n (%) 
(N=3,439) 
VKA Treated 
(n=1,165) 
VKA Untreated 
(n= 2,274) 
p 
 
Male 1699 (49) 598 (51) 1101 (48) 0.106 
Age; median (IQR) 78 (72-84) 77 (70-82) 79 (73-85) <0.001 
Caucasian 3387 (99) 1153 (99) 2234 (98) 0.250 
Socio-economic  
deprivation 
      <0.001 
  SIMD* most 
deprived 
1280 (37) 416 (36) 864 (38)  
  SIMD* least deprived 590 (17) 260 (22) 330 (15)  
        
BP,mmHg;  
   median (IQR) 
133 (125-142) 132 (123-140) 134 (126-143) 0.627 
HbA1c, %;  
   median (IQR) 
7.0 (6.0-8.0) 6.7 (6.1-7.5) 7.0 (6.0-8.0) 0.760 
Chol, mmol/l; 
   median (IQR) 
4.0 (4.0-5.0) 4.2 (3.6-4.7) 4.0 (4.0-5.0) 0.954 
BMI; median (IQR) 27 (24-31) 27 (24-32) 26 (23-31) 0.009 
Alcohol intake 
excessive 
31 (1) 12 (1) 19 (1) 0.568 
Smoker 919 (27) 372 (32) 547 (24) <0.001 
History of bleeding 72 (2) 16 (1) 56 (3) 0.035 
AF duration >10 yrs 1283 (37) 460 (40) 823 (36) 0.059 
Disability 566 (17) 130 (11) 436 (19) <0.001 
        
Co-morbidities        
Hypertension 502 (15) 178 (15) 324 (14) 0.418 
Diabetes Mellitus 786 (23) 241 (21) 545 (24) 0.030 
Obesity 286 (8) 141 (12) 145 (6) <0.001 
Depression 602 (18) 261 (22) 341 (15) <0.001 
Coronary heart 
disease 
1116 (33) 379 (33) 737 (32) 0.942 
Heart failure 711 (21) 265 (23) 446 (20) 0.032 
COPD 329 (10) 106 (9) 223 (10) 0.504 
 
Risk stratification score;  
   median (IQR) 
      
CHADS2   3 (2-4) 3 (2-4) 3 (2-4) 0.012 
CHA2DS2-VASC   5 (4-6) 5 (4-6) 5 (4-6) 0.004 
mHAS-BLED  2 (2-2) 2 (2-2) 2 (2-2) 0.025 
NICE  1 (1-1) 1 (0-2) 1 (1-2) <0.001 
        
Concomitant antiplatelet prescription      
Any antiplatelet agent 668  (19) 142  (6)  526  (23)  <0.001 
Aspirin 367  (11)  78  (3)  289  (13)   
Clopidogrel 200  (6)  34  (1)  166  (7)   
Dipyridamole 173  (5)  38  (2)  135  (6)   
Significant values after Bonferroni correction (P<0.002) in bold.  
AF:atrial fibrillation,  VKA:vitamin K antagonist, SIMD: Scottish Index of Multiple Deprivation, described as quintiles, BP: 
Systolic blood pressure.  
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Median CHA2DS2-VASC scores were similar comparing those prescribed VKA and not 
prescribed VKA (median: 5, IQR: 4-6).  Univariable analyses at our corrected level of 
significance suggested that younger age, history of depression, smoking cigarettes and 
obesity were associated with VKA prescription.  Those with increasing disability, and higher 
levels of socio-economic deprivation, were less likely to be prescribed VKA.  Higher CHADS2 
and CHA2DS2VASC scores were associated with lower proportion VKA prescriptions (OR: 
0.87, 95%CI: 0.80-0.95, and OR: 0.90, 95%CI: 0.49-0.95, respectively).  Anticoagulant 
related bleeding risk, mHAS-BLED, was inversely associated with VKA prescription on first 
analysis but not after correction for multiplicity; NICE criteria for bleeding risk and 
antiplatelet treatment were associated with lower VKA prescription. (Figures 4-2 & 4-3) 
In multivariable analysis, older age (OR: 0.97, 95%CI: 0.96-0.98) and higher deprivation 
scores (OR: 0.59, 95%CI: 0.57-0.76) were independently associated with no VKA 
prescription.  An active diagnosis of depression was associated with a higher rate of VKA 
prescriptions in stroke survivors (OR: 1.47, 95%CI: 1.18-1.83). (Table 4-2) 
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Figure 4-2. Proportions of patients treated with VKA, antiplatelet, 
combination and no treatment at various levels of stroke risk. 
Data are proportion of patients (expressed as percentage of total patients) at each level of  CHA2DS2VASC 
score from 2 to 9. VKA: vitamin K antagonist. 
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Figure 4-3. Forrest plot for unadjusted univariable associations of VKA 
prescription. 
BMI: body mass index; AF: atrial fibrillation; VKA: vitamin K antagonist. 
 
 
Table 4-2. Multivariable analysis of associations of VKA prescription. 
Covariables 
 
P-value OR (95%CI) 
Age (years) 
 
<0.001 
0.97 (0.96-0.98) 
Socio-economic deprivation (SIMD, quintiles) 
 
<0.001 
0.59 (0.57-0.76) 
Depression (present/absent) 
 
<0.001 
1.47 (1.18-1.83) 
SIMD: Scottish Index of Multiple Deprivation, described as quintiles; VKA: vitamin K antagonist.  
Input covariables detailed in the Methods section above (Section 4.2.5). 
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4.4. Discussion 
Our findings suggest a major evidence-practice gap in oral anticoagulant utilisation in a 
cohort of stroke survivors at high risk of future AF-related stroke.  On univariable analysis, 
there appears to be an inverse care association, with those at greatest risk being least likely 
to be prescribed oral anticoagulant treatment. 
Our finding of low VKA prescription among stroke survivors with advanced age represents 
non-concordance with prescribing guidelines and failure to use evidence based treatment.  
The low VKA prescribing rate described is consistent with previous UK primary care 
analyses.277, 278  For example, a 1996 study found that only 22% of those aged over 70 with 
AF who were potential candidates for oral anticoagulant were treated.278  It is disappointing 
that 14 years later our study describes a similarly poor use of oral anticoagulant treatment. 
Our finding of low VKA prescription in stroke survivors from areas of socio-economic 
deprivation is in keeping with other analyses of stroke secondary prevention in the UK.   
This potential inequality of treatment is a major concern as higher deprivation is 
independently associated with poorer cardiovascular outcomes.279  Our data do not allow 
us to definitively describe reasons for lower prescribing rates.  However, previous studies 
have suggested that areas of socio-economic deprivation are less likely to engage with 
primary care.280, 281  Our findings reinforce the need for health service planners to improve 
cardiovascular risk management in socio-economically deprived areas. 
The finding that patients with depression were more likely to be prescribed VKA was 
unexpected.  Higher VKA prescription in this group may reflect more frequent encounters 
between patients and physicians, which may subsequently lead to better identification of 
stroke risk factors and review of preventative treatments.  
 95 
Factors associated with VKA prescribing are of interest, but equally those factors associated 
with not prescribing merit attention.  Clinical and demographic features we may intuitively 
think would influence anticoagulant decisions, for example, alcohol excess was not 
associated with VKA prescription, albeit numbers included were modest for certain 
categories.  Other factors such as previous bleeding and the HASBLED bleeding risk score, 
showed modest association on univariable analysis, albeit not when correct for multiplicity 
of analysis and no association in the multivariable model.  
Single antiplatelet use is not routinely recommended for stroke prevention in AF.197, 282 but 
was reasonably frequent particularly in those not prescribed VKA.  The concomitant use of 
an antiplatelet agent alongside VKA was also seen in this cohort.  This combination is not 
routinely recommended for long-term stroke prophylaxis as there is increased risk of 
bleeding.  Although there may be sound reasons to prefer a single antiplatelet or combined 
antiplatelet-VKA strategy for the individual patient, the high rate of antiplatelet usage in 
our dataset again suggests that prescribing decisions are not made according to local 
guidelines or contemporary evidence based recommendations.62, 160, 161  During the time 
period we analysed, the NOACs were not approved for use in primary care and so are not 
represented in our data.  These agents represent an alternative treatment for stroke 
survivors with AF that may circumvent much of the inconvenience of VKA.  We can only 
speculate as to whether availability of these agents will impact on future anticoagulation 
rates.  Our analysis of ‘recent pre-NOAC prescribing’ provides an ideal baseline to assess 
the impact of NOAC availability on the overall prescribing of anticoagulant agents in this 
high risk group of patients. 
LES data lack any measure of why treatment decisions were made, with no facility to record 
clinical decision or patient preference.  Reasons for not prescribing VKA may be entirely 
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appropriate but the rationale is not captured.  The conundrum around oral anticoagulant 
treatment is that patients at highest risk of AF-related stroke are also at high risk of VKA 
related bleeding complications.  This was evidenced in our cohort who demonstrated 
simultaneous high stroke and bleeding risk profiles.  In this sample, the median CHADS2 
score of 3 and the median CHA2DS2-VASC of 5 roughly translate into the adjusted stroke 
rates of 5.9% and 3.9% per year, respectively.187, 188  The median mHASBLED score of 2 
would indicate a group at high risk of bleeding. 
We suspect the low rates of VKA prescription described are not unique to Glasgow or 
indeed to the UK.  Various international analyses have shown that VKA are under 
prescribed in stroke survivors;271, 283 that VKA treatment is often discontinued in the 
community284 and that rates of discontinuation of VKA are higher than for other secondary 
preventative medications.285 
A particular strength of our study was the availability of the LES data.  This resource gave 
us comprehensive data on stroke survivors.  We deliberately excluded stroke survivors 
resident in care-homes or housebound as we recognise that this group are likely to be 
poorly represented in a primary care based assessment scheme and that decisions on 
anticoagulation in this group are complex.  Although we feel that our cohort is broadly 
representative of an urban UK setting, we recognise that many stroke survivors with AF 
may live in more rural settings and our data may not be applicable to this group.  However, 
given the challenges of providing and monitoring anticoagulation in a rural setting, we 
wonder if the rates of treatment may be comparable or lower that what we have 
demonstrated.   
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Like all retrospective registry based studies, we were reliant on the quality of coding in the 
Glasgow LES database.  Coding errors can be source of potential bias or imprecision.  We 
hope that the effect of any misreporting of key variables will be modest given our large 
dataset; the internal and external quality control employed and the requirement for annual 
training by practice nurses collecting LES data.  Many of the covariables included in the 
analysis were defined at individual practice level, which could also be potential sources of 
bias from underreporting and selection.  Although the infrastructural support to ensure 
data quality seems robust, we are aware that there has been no formal validation of the 
LES data.  We acknowledge that our cohort consisted of 99% caucasians, which is an over-
representation compared to the contemporary Glasgow population.  Our analysis was 
necessarily limited to those with confirmed AF and the AF detection relied on single episode 
screening.  Undetected paroxysmal AF has the same elevated risk of stroke as sustained AF 
and conventional assessment may miss a large proportion with occult AF.286, 287  It is 
possible that rates of AF in our cohort are substantially larger than we report.  The LES data 
only captured drug prescriptions that were authorised by general practitioners.  The use of 
additional over the counter medicines (including over the counter antiplatelet agent) may 
be under reported.  Our data present only a snapshot across a single year.  As LES data 
collection continues this should allow a time-trend analyses of anticoagulant treatment and 
the impact this has on stroke incidence.  The current latency between the LES data 
collection and availability for analysis is approximately 1.5- 2 years. 
In conclusion we have demonstrated that the majority of urban community dwelling stroke 
survivors with atrial fibrillation are not prescribed oral anticoagulant treatment and that 
patients with highest risk may be the least likely to be prescribed VKA.  Further work should 
aim to describe why anticoagulation decisions are made, thus identifying potential barriers 
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to effective anticoagulation. Ultimately we must improve anticoagulation rates for stroke 
survivors.  
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Chapter 5  
Incidence of stroke in 
patients enrolled in heart 
failure trials  
5.1. Heart failure with reduced ejection fraction 
5.1.1. Background 
Heart failure (HF) is considered a leading cause of cardio-embolic stroke.29  Whether heart 
failure per se, rather than atrial fibrillation (AF) associated with HF, accounts for the risk of 
stroke is uncertain as most analyses of stroke in HF did not disaggregate patients with and 
without AF.  Nonetheless, HF, particularly heart failure with reduced ejection fraction (HF-
REF), predisposes to stroke through fulfilment of Virchow’s triad for thrombogenesis;152 
stasis of blood flow related to ventricular dysfunction, endocardial-endothelial dysfunction, 
and a hypercoagulable state associated with neurohumoral imbalance.153, 154 
The stepwise introduction of disease-modifying drugs for HF-REF, including angiotensin 
converting enzyme inhibitors (ACE-I),108, 220 angiotensin receptor blockers (ARB),110, 222 
beta-blockers116, 288 and mineralocorticoid receptor antagonists (MRA),117, 118 has been 
shown to improve survival and left ventricular function over time.  The latest guidelines 
recommend combination treatment in most patients.89  More recently, sacubitril-valsartan 
has reduced the risk of death and cardiovascular outcomes compared with enalapril.289 
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Guidelines also advocate the use of oral anticoagulants in patients with heart failure and 
AF, for stroke prevention.48, 71 
Understanding whether the risk of stroke has changed over time, in parallel with the 
sequential introduction of disease-modifying medications and oral anticoagulants, may 
inform improvements in drug use.  We examined the incidences of stroke during follow-up 
from eleven randomised controlled trials among patients with HF-REF, conducted during 
the period 1986 to 2014, according to AF status at baseline. 
 
5.1.2. Methods 
5.1.2.1. Data source 
We sought individual patient data from major HF-REF trials that were accessible to us. 
(Table 2-1)  These trials have contributed to the guidelines-recommended therapy and 
were broadly representative of patients with chronic ambulatory HF-REF, within the last 30 
years.  We included only trials that have recorded both atrial fibrillation status and the 
outcome of stroke.  We performed a pooled analysis of patient level data from eleven 
randomised controlled trials, namely, the Treatment and the Prevention trials of the 
Studies of Left Ventricular Dysfunction (SOLVD),108, 220 the Digitalis Investigation Group 
(DIG) Trial,121 the Beta-blocker Evaluation of Survival Trial (BEST),288 the Alternative and the 
Added trials of Candesartan in Heart failure: Assessment of Reduction in Mortality and 
morbidity (CHARM) programme,110, 222  the Sudden Cardiac Death in Heart Failure (SCD-
HeFT) trial,221 the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart 
Failure (EMPHASIS-HF) trial,118 the Gruppo Italiano per lo studio della sopravvivenza 
nell’Insufficienza cardiaca Heart failure (GISSI-HF) trial,224 the Controlled Rosuvastatin 
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Multinational Trial in Heart Failure (CORONA) trial,223 and the Prospective comparison of 
ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure 
(PARADIGM-HF) trial.289  The design and results of these trials have been published 
elsewhere and their main characteristics are summarised in Table 5-1. 
 
5.1.2.2. Statistical methods 
We defined patients with AF as those with either AF on their baseline ECG or a history of 
AF. The remaining patients were defined as those “without AF”.  We described the full 
cohort and compared these 2 sub-groups, using means (standard deviation [SD]) or 
medians (inter-quartile range [IQR]) for continuous variables and count (percentage) for 
categorical variables.  We also compared the baseline characteristics of patients who 
developed stroke during the trials’ follow-up with those who did not.  
The outcome of interest was stroke.  The majority of the trials had included stroke as a 
component of their cardiovascular endpoints, adjudicated by an independent committee 
in a blinded fashion using pre-specified criteria. Reasonably comparable criteria were used 
in most trials. (Table 5-2)  
We estimated the incidence rates of stroke (per 1000 patient-years) for each trial’s follow-
up period, according to AF status.  A Joinpoint regression was used to fit the trends in 
annual rates of stroke across the trials and to calculate the overall change, expressed as a 
percentage (Joinpoint software, version 4.2).  Cumulative incidence functions of stroke 
occurrences were estimated, accounting for the competing risk of death.290, 291  To satisfy 
the assumption of the independence of stroke events, we only included the first stroke 
event post-enrolment.  We calculated the hazard ratio (HR) and corresponding 95 percent 
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confidence intervals (95%CI) to express the hazard rate of stroke in each arm of the trials 
using Cox proportional hazard models adjusting for previously established predictors of 
ischaemic stroke292 and other confounding variables.   
All analyses, apart from the Joinpoint regression, were undertaken using SAS version 9.3 
(SAS Institute, Inc., Cary, NC, USA).  
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Table 5-1. Design of the clinical trials in heart failure patients with reduced ejection fraction (HF-REF) included in the analysis. 
 
SOLVD-T SOLVD-P DIG BEST CHARM-Alternative CHARM-Added SCD-HeFT 
 
(N=2569) (N=4228) (N=6800) (N=2707) (N=2028) (N=2548) (N=2521) 
Inclusion criteria 
       
Age, years 21-80 21-80 21-75 ≥18 ≥18 ≥18 ≥18 
NYHA class - - - III-IV II-IV II-IV II-III 
LVEF requirement ≤35% ≤35% ≤45% ≤35% ≤40% ≤40% ≤35% 
HF hospitalization - - -  Hospitalization for a 
cardiac reason 
within  6 months if 
NYHA class II 
Hospitalization for a 
cardiac reason 
within  6 months if 
NYHA class II 
- 
Creatinine, µmol/L - - <265 <265 <265 <265 - 
eGFR –
mL/min/1.73m2 
- - - - - - - 
SBP, mmHg - - - - - - - 
Potassium, mmol/L - - >3.2, <5·5 - <5·5 <5·5 - 
Others Symptomatic 
patients only 
Asymptomatic 
patients only 
Sinus rhythm only - intolerance to ACEI  - No history of prior 
sustained ventricular 
tachycardia/ 
ventricular 
fibrillation 
Comparison Enalapril vs. Placebo Enalapril vs. Placebo Digoxin vs. Placebo Bucindolol vs. 
Placebo 
Candesartan vs. 
Placebo 
Candesartan vs. 
Placebo 
ICD therapy vs. 
(Amiodarone or 
Placebo) 
Study period 1986-1989 1986-1990 1990-1995 1995-1998 1999-2003 1999-2003 1997-2003 
Site distribution 83 hospitals linked 
to 23 centres in the 
United States, 
Canada and Belgium 
83 hospitals linked 
to 23 centres in the 
United States, 
Canada and Belgium 
302 centres in the 
United States and 
Canada 
90 centres in the 
United States and 
Canada 
618 centres in 26 
countries 
618 centres in 26 
countries 
148 centres in the 
United States, 
Canada and New 
Zealand 
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EMPHASIS-HF 
(N=2737) 
GISSI-HF 
(N=4574) 
CORONA 
(N=5011) 
PARADIGM-HF 
(N=8399) 
Inclusion criteria 
    
Age, years ≥55 ≥18 ≥60 ≥18 
NYHA class II II-IV II-IV II-IV 
LVEF, % ≤30 
(30-35 if QRS duration 
>130msec) 
≤40 ≤40 (≤35 if NYHA class 
II) 
≤40/≤35 (since 
December 15th 2012) 
HF hospitalization Cardiovascular 
hospitalization within 6 
months; if not, BNP 
≥250pg/ml or NT pro-
BNP ≥500pg/ml in men 
and 750pg/ml in 
women 
If LVEF >40%, patient 
had to have at least 
one heart failure 
hospitalisation in the 
preceding year.  
No if heart failure 
hospitalization within 
12 months, BNP 
≥100pg/ml or NT pro-
BNP ≥400pg/ml; if not, 
BNP ≥150pg/ml or NT 
pro-BNP ≥600pg/ml 
Creatinine, µmol/L - ≤220 ≤220 - 
eGFR –
mL/min/1.73m2 
≥30 - - ≥30 
SBP, mmHg >85 - - ≥95 
Potassium, mmol/L ≤5.0 - - ≤5.4 
others - - Ischaemic aetiology - 
Comparison Eplerenone vs. 
Placebo 
Rosuvastatin  vs. 
Placebo 
Rosuvastatin  vs. 
Placebo 
LCZ696 vs. 
Enalapril  
Study period 2006-2010 2002-2008 2003-2007 2009-2014 
Site distribution 278 centres in 29 
countries 
357 centres in Italy 371 sites in 19 
European countries, 
Russia, and South 
Africa 
1043 centres in 47 
countries 
 
NYHA: New York Heart Association; LVEF: Left 
ventricular ejection fraction; SBP: systolic blood 
pressure; HF: Heart failure; ICD: implantable 
cardioverter defibrillator; ACEI: angiotensin converting 
enzyme inhibitor; NT-proBNP: N-terminal-pro-brain 
natriuretic peptide. 
 
 
SOLVD-T:   Studies of Left ventricular dysfunction- 
Treatment;  
SOLVD-P:  Studies of Left ventricular dysfunction-
Prevention;  
DIG:  Digitalis Investigation Group;  
BEST:  Beta-blocker Evaluation of Survival Trial;  
CHARM-Alternative: Candesartan in Heart failure 
Assessment of Reduction in Mortality and 
morbidity-Alternative;  
CHARM-Added: Candesartan in Heart failure 
Assessment of Reduction in Mortality and 
morbidity-Added;  
SCD-HeFT:  Sudden Cardiac Death in Heart Failure;  
EMPHASIS-HF: Eplerenone in Mild Patients 
Hospitalization and Survival Study in Heart 
Failure;  
GISSI-HF:  Gruppo Italiano per lo Studio della 
Sopravvivenza nell’Insuffi cienza cardiaca 
Heart Failure trial;  
CORONA:  Controlled Rosuvastatin Multinational Trial 
in Heart Failure;  
PARADIGM–HF: Prospective Comparison of ARNI with 
ACEI to Determine Impact on Global 
Mortality and Morbidity in Heart Failure 
Trial. 
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Table 5-2. Definitions of ‘stroke’ used in the trials. 
 
 
SOLVD-T:  Studies of Left ventricular dysfunction- Treatment;  SOLVD-P: Studies of Left ventricular dysfunction-
Prevention;  DIG: Digitalis Investigation Group;  BEST: Beta-blocker Evaluation of Survival Trial;  CHARM-Alternative: 
Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Alternative;  CHARM-Added: 
Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Added;  SCD-HeFT: Sudden Cardiac 
Death in Heart Failure;  EMPHASIS-HF: Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure;   
GISSI-HF:  Gruppo Italiano per lo Studio della Sopravvivenza nell’Insuffi cienza cardiaca Heart Failure trial;  CORONA: 
Controlled Rosuvastatin Multinational Trial in Heart Failure;  PARADIGM–HF: Prospective Comparison of ARNI with ACEI 
to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. 
 
 
5.1.3. Results 
We obtained individual patient data for 44,122 patients enrolled across eleven randomised 
controlled trials conducted in patients with HF-REF, spanning a 30-year period (1986-2014). 
Of these, 10,724 had AF and 33,398 did not have AF at baseline.  Stroke occurred in 406 
patients (3.8%) with AF and in 974 patients (2.9%) without AF. 
Trial  Definition of Stroke 
SOLVD-T Focal neurological signs or symptoms lasting more than 24 hours.  
SOLVD-P 
DIG Investigator reported cases stroke  
(following a letter sent to DIG investigators by the DIG Steering Committee). 
BEST Fatal or non-fatal stroke, derived from Adverse Events recording.  
CHARM-Alternative Focal neurological signs or symptoms with a duration of at least 24 hours. 
CHARM-Added 
SCD-HeFT Investigator reported cases of stroke. 
EMPHASIS-HF Focal neurological signs or symptoms lasting more than 24 hours.  
GISSI-HF Sudden focal neurologic deficit lasting more than 24 hours.  
CORONA Unequivocal signs of focal or global neurological deficit with sudden onset, with a 
duration longer than 24 hours, and judged to be of vascular origin.  
PARADIGM-HF A focal neurological deficit of central origin lasting more than 24 hours, with or 
without imaging confirmation of cerebral infarction or intracerebral haemorrhage.   
OR 
A focal neurological deficit of central origin lasting less than 24 hours with 
corresponding imaging evidence of cerebral infarction or intracerebral 
haemorrhage.  
OR 
A focal neurological deficit of central origin lasting less than 24 hours that was 
treated with thrombolytic therapy or directed percutaneous intervention. 
OR 
A non-focal encephalopathy lasting more than 24 hours with imaging evidence of 
cerebral infarction or haemorrhage adequate to account for the clinical state. 
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5.1.3.1. Baseline characteristics of study population 
Patient characteristics for each trial are summarised in Table 5-3.  CORONA and EMPHASIS-
HF had minimum age thresholds for enrolment of 60 and 55 years respectively, and each 
reported a higher mean age than other included trials.  Females contributed approximately 
a fifth of the cohort in each trial.  The pooled data included patients from the whole 
spectrum of New York Heart Association (NYHA) class symptom severity.  The majority of 
patients across the trials also had an ischaemic aetiology, except for GISSI-HF. AF was 
present in approximately a third of patients in the more contemporary trials.  Hypertension 
was also more common in recent trials.  There was a substantially greater use of ACE-I/ 
ARB, beta-blockers and MRAs in the more recent trials. 
 
5.1.3.2. Baseline characteristics of patients with versus without AF 
The characteristics of patients with and without AF according to stroke outcome in each 
trial are shown in Tables 5-4 and 5-5.  Irrespective of AF status, patients who experienced 
stroke were generally older and had history of hypertension, diabetes and previous stroke. 
There was no obvious difference in LVEF, between those who had a stroke and those who 
did not.  Among patients without AF, more strokes were observed in those with higher 
NYHA class, or who had insulin treated diabetes.  
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Table 5-3. Baseline characteristics of patients within the included heart failure with reduced ejection fraction trials. 
 SOLVD-T 
(n=2569) 
SOLVD-P 
(n=4228) 
DIG  
(n=6800) 
BEST 
(n=2707) 
CHARM-
ALTERNATIVE 
(n=2028) 
CHARM-
ADDED 
(n=2548) 
SCD-HeFT 
(n=2521) 
EMPHASIS-
HF (n=2737) 
GISSI-HF 
(n=4574) 
CORONA 
(n=5011) 
PARADIGM- 
HF 
(n=8399) 
Demographics, %            
Age, years 60±10 59±10  64±11 60±12 66±11 64±11 59±12 69±8 68±11 73±7 64±11 
Female  20 11 22 22 32 22 23 22 23 24 22 
LVEF ,% 25±7  28±6 29±9 23±7 30±7 28±7 24±7 26±5 33±9 31±6 29±6 
Caucasian 80 87 85 70 89 91 77 83 100 99 66 
NYHA            
I 11 67 13 0 0 0 0 . 0 0 5 
II 57 33 54 0 48 24 70 100 63 37 70 
III 30 0.1 31 92 49 73 30 . 35 61 24 
IV 2 0 2 8 4 3 0 . 3 2 1 
Duration of heart 
failure, years 
. . 3±3 0.1±0.1 4±4 4±4 4±4 . 2±1 2±1 2±1 
Ischaemic aetiology 71 83 71 59 68 62 52 69 40 100 60 
SBP, mmHg 125±18 125±16 126±20 118±19 130±19 125 ±19 120 ±19 124±17 127±18 129±16 121±15 
DBP, mmHg 77±10 78±10 75±11 72±12 77±11 75 ±11 71±11 75±10 77 ±10 76±9 74±10 
Heart rate, bpm 80±13 75±12 79±13 82±13 74±14 74±13 75±14 72±12 73 ±14 72±11 72±12 
Body mass index, 
kg/m2 
. . 27±5 28±6 27±5 28 ±5 . 28±5 27 ±5 27±5 28±6 
Current smoker 22 24 . 18 14 17 16 45 14 11 14 
            
AF status, %             
AF on baseline ECG 10 4 0 12 13 16 7 31 19 24 25 
History of AF 5 10 0 24 25 27 15 31 12 18 37 
AF (baseline ECG or 
medical history) 
13 12 0 25 26 28 16 34 31 42 37 
            
Laboratory tests            
Creatinine, µmol/L 109±27  102±23 113±33 110±36 114±40  103±35 107±58 102±27 102±30 115±28 99±26 
NT-proBNP, pg/ml 
(median) 
. . . . . . . . 
839  
(367-1865) 
1465  
(617-3114) 
1615  
(888-3231) 
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 SOLVD-T 
(n=2569) 
SOLVD-P 
(n=4228) 
DIG  
(n=6800) 
BEST 
(n=2707) 
CHARM-
ALTERNATIVE 
(n=2028) 
CHARM-
ADDED 
(n=2548) 
SCD-HeFT 
(n=2521) 
EMPHASIS-
HF (n=2737) 
GISSI-HF 
(n=4574) 
CORONA 
(n=5011) 
PARADIGM- 
HF 
(n=8399) 
            
Medical History, %            
Angina  28 27 27 52 42 47 34 56 12 73 27 
MI 66 80 65 42 61 56 44 50 33 60 43 
Revascularisation          
(PCI or CABG) 
21 37 . 36 35 34 37 34 20 26 31 
Peripheral vascular 
disease 
. . . 16 . . . . 8 13 6 
Hypertension 42 37 45 59 50 48 56 66 54 63 71 
Previous Stroke  8 6 . . 9 9 7 10 5 12 9 
Diabetes 26 15 28 36 27 30 30 31 26 29 35 
Insulin treated 
diabetes 
. . . 15 9 9 11 . 6 8 9 
            
Concomitant 
treatment, % 
           
Digoxin 67 12 . 92 46 58 70 27 40 33 30 
Diuretics               
(Thiazide or 
Loop) 
85 17 78 94 85 90 84 85 90 88 80 
ACE inhibitor . . 94 91 0.2 100 85 78 78 80 78* 
ARB . . . 6 . . 14 19 18 92† 23* 
β-blocker 8 24 . . 55 55 69 87 62 75 93 
Aldosterone 
antagonist 
9 4 8 4 0.2 0.5 20 . 40 39 56 
Pacemaker 5 3 . 9 9 9 . 14 12 11 13 
Device (ICD, CRT) . . . 3 3 4 . 17 7 3 16 
Anti-arrhythmic 22 15 . 3 13 13 . 14 20 12 . 
Antiplatelet 34 24 . . 58 51 56 66 52 59 56 
Anticoagulant  16 12 . . 31 38 34 32 30 35 32 
Any 
antithrombotic 
47 64 . . 84 84 82 88 81 90 81 
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 SOLVD-T 
(n=2569) 
SOLVD-P 
(n=4228) 
DIG  
(n=6800) 
BEST 
(n=2707) 
CHARM-
ALTERNATIVE 
(n=2028) 
CHARM-
ADDED 
(n=2548) 
SCD-HeFT 
(n=2521) 
EMPHASIS-
HF (n=2737) 
GISSI-HF 
(n=4574) 
CORONA 
(n=5011) 
PARADIGM- 
HF 
(n=8399) 
(antiplatelet or 
anticoagulant) 
Nitrate 42 30 43 . 37 33 29 . 33 33 . 
Calcium channel 
blocker 
31 35 . . 16 10 11 . 10 . . 
            
Treatment arm, % 50 50 50 50 50 50 33 50 50 50 50 
All continuous values are given in mean±standard deviation unless stated otherwise. Categorical values are presented in percentage.  
NYHA: New York Heart Association; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; AF: atrial fibrillation; MI: myocardial infraction; CABG: coronary artery bypass 
graft; PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator; CRT: cardiac resyncronisation therapy; ACE: angiotensin converting enzyme; ARB: angiotensin receptor 
blocker. 
Full name of the trials are described in the footnote for Table 5-1.   
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Table 5-4. Baseline characteristics of patients without atrial fibrillation according to outcome of stroke in each trials. 
 SOLVD-T 
(n=2235) 
SOLVD-P 
(n=3703) 
DIG  
(n=6800) 
BEST 
(n=2044) 
CHARM- 
ALTERNATIVE 
(n=1501) 
CHARM-
ADDED 
(n=1848) 
SCD-HeFT 
(n=2124) 
EMPHASIS 
(n=2737) 
GISSI-HF 
(n=1806) 
CORONA 
(n=2916) 
PARADIGM- 
HF 
(n=5283) 
 Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Demographics, %                       
Age, years 
60 
 ±10 
61  
± 9 
58 
 ±10  
60  
±10 
63  
±11 
66  
±10 
59 
 ±12 
61 
 ±11 
65  
±11   
70 
 ±10  
62 
 ±11 
67  
±10 
58 
 ±12 
60  
±11 
68  
±8 
71  
±8 
66  
±11 
69 
 ±11 
72  
±7 
74 
 ±7 
62 
 ±12 
63 
 ±10 
Female  20 28 11 12 22 20 24 39 32 44 23 23 25 24 25 18 22 16 25 24 23 23 
LVEF ,% 29 ±7 25 ±6 28 ±6 28 ±6 29 ±9 30 ±8 23 ±7 23 ±7 30 ±7 30 ±7 28 ±7 28 ±7 24 ±7 22 ±8 26 ±5 25 ±5 32 ±8  32 ±9 31 ±7 31 ±6 29 ±6 30 ±6 
Caucasian 80 70 87 73 85 90 68 63 87 93 89 83 76 73 78 67 . . 98 98 57 59 
NYHA                       
I 11 8 67 68 13 12 . . . . . . . . . . . . . . 6 8 
II 57 53 32 32 54 57 . . 50 41 25 26 71 65 . . 66 62 41 29 75 71 
III 30 30 0.1 . 31 31 93 86 47 54 73 64 29 35 . . 32 36 58 67 19 20 
IV 2 . . . 2 1 7 14 3 6 2 9 . . . . 2 1 1 4 0.4 1 
Duration of heart 
failure, years 
. . . . . . 
0.1 
±0.1 
0.1 
±0.1 
3 ±4 5 ±5 4 ±4 3 ±3 3 ±4 4 ±5 . . 2 ±1 2 ±1 2 ±1 2 ±1 2 ±1 2 ±1 
Ischaemic aetiology 75 71 85 82 71 72 57 59 41 83 45 79 34 54 55 76 . . . . 62 70 
SBP, mmHg 
125 
±17 
128 
±19 
125 
±16 
130 
±18 
126 
±20 
131 
±21 
119 
±19 
121 
±23 
130 
±19 
135 
±22 
125 
±18 
131 
±19 
120 
±19 
120 
±20 
124 
±17 
130 
±16 
126 
±18 
126 
±18 
130 
±16 
130 
±17 
121 
±15 
125 
±17 
DBP, mmHg 77 ±10 
80  
±11 
78 ±10 
80  
±9 
75 
±11 
76 ±12 72 ±12 72 ±15 
77  
±11 
77 ±12 
75  
±11 
73 ±10 
71  
±11 
71 
 ±11 
74 ±10 77 ±10 77 ±10 
77 
 ±9 
76  
±9 
77  
±8 
73  
±10 
75 ±12 
Heart rate, bpm 80 ±13 83 ±14 75 ±12 78 ±12 79 ±13 78 ±13 83 ±13 84 ±13 74 ±13 73 ±13 74 ±13 
73 
 ±11 
75 ±14 76 ±12 71 ±12 71 ±10 72 ±12 72 ±12 70 ±10 72 ±10 
71  
±11 
74  
±11 
Body mass index, 
kg/m2 
. . . . 27 ±5 27 ±5 28 ±6 26 ±6 28 ±5 27 ±4 28 ±5 26 ±5 . . 27 ±5 25 ±4 27 ±4 26 ±4 27 ±4 27 ±5 27 ±5 28 ±5 
Current smoker 22 33 24 31 . . 18 26 14 15 18 28 17 18 44 39 16 20 12 12 16 20 
                       
Laboratory tests                       
Creatinine, µmol/L 
109 
±27 
111 
±26 
101 
±23 
103 
±24 
113 
±33 
113 
±30 
107 
±35 
106 
±38 
107 
±99 
102 
±45 
100 
±34 
102 
±37 
105 
±61 
116 
±43 
99 ±27 
102 
±27 
100 
±30 
101 
±28 
114 
±28 
118 
±29 
97 ±26 
101 
±29 
NT-proBNP, pg/ml 
(median) 
. . . . . . . . .  . . . . . . 
73  
(35-
169) 
170 
(85-
321) 
133 
(52-
292) 
169 
(66-
348) 
1439 
(812-
2951) 
1673 
(1001-
3375) 
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 SOLVD-T 
(n=2235) 
SOLVD-P 
(n=3703) 
DIG  
(n=6800) 
BEST 
(n=2044) 
CHARM- 
ALTERNATIVE 
(n=1501) 
CHARM-
ADDED 
(n=1848) 
SCD-HeFT 
(n=2124) 
EMPHASIS 
(n=2737) 
GISSI-HF 
(n=1806) 
CORONA 
(n=2916) 
PARADIGM- 
HF 
(n=5283) 
 Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Medical History, % 
Angina  59 71 58 82 26 72 52 59 59 70 55 70 57 64 45 33 11 18 74 70 26 32 
MI 70 59 83 76 65 62 41 40 64 76 58 68 44 53 54 48 35 34 65 68 47 54 
Revascularisation          
(PCI or CABG) 
23 25 36 27 . . 35 33 36 30 35 21 37 42 35 30 22 16 28 26 34 35 
Peripheral vascular 
disease 
. . . . . . 16 33 . . . . . . . . 7 15 13 12 6 4 
Hypertension 42 51 36 46 45 56 59 66 48 57 46 51 54 67 65 72 52 59 62 61 66 83 
Previous Stroke  7 11 5 16 . . . . 7 19 7 13 6 7 8 9 3 6 10 17 7 21 
Diabetes 26 37 15 25 28 37 36 49 27 33 29 45 30 42 34 30 27 32 30 32 34 46 
Insulin treated 
diabetes 
. . . . . . 15 23 9 15 10 9 12 24 . . 7 11 9 12 9 16 
                       
Concomitant 
treatment, % 
                      
Digoxin 64 57 6 10 . . . . 39 33 52 45 69 60 19 18 32 41 20 20 23 16 
Diuretics               
(Thiazide or 
Loop) 
85 89 17 23 78 82   84 89 88 85 83 89 83 79 88 88 85 88 78 75 
ACE inhibitor . . . . 94 96 . . 0.2 . 100 100 85 87 77 82 . . . . . . 
ARB . . . . . . . . . . . . 14 91 20 88 . . . . 22 31 
β-blocker 8 4 25 19 . . . . 57 52 57 58 70 65 87 79 66 62 76 74 93 89 
Aldosterone 
antagonist 
9 12 4 5 8 6 . . 0.2 . 0.5 . 20 9 . . 39 40 35 38 56 54 
Pacemaker 4 4 2 1 . . 6 7 6 9 6 4 . . 11 6 11 15 8 7 11 8 
Device (ICD, CRT) . . . . . . 3 1 3 2 3 2 . . 17 3 7 7 3 2 16 15 
Anti-arrhythmic 21 20 13 10 . . . . 8 13 9 2 . . 10 . 16 12 8 5 . . 
Antiplatelet 34 34 55 37 . . . . 64 67 59 72 59 73 77 79 61 62 74 78 68 75 
Anticoagulant  13 17 10 16 .  .  20 15 26 21 28 15 14 9 14 14 17 17 12 6 
Any antithrombotic 
(antiplatelet or 
anticoagulant) 
46 43 64 50 . . . . 81 81 79 89 80 84 85 88 76 76 88 93 76 80 
Nitrate 43 45 31 29 42 48 . . 38 48 33 47 29 38 . . 32 48 35 38 . . 
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 SOLVD-T 
(n=2235) 
SOLVD-P 
(n=3703) 
DIG  
(n=6800) 
BEST 
(n=2044) 
CHARM- 
ALTERNATIVE 
(n=1501) 
CHARM-
ADDED 
(n=1848) 
SCD-HeFT 
(n=2124) 
EMPHASIS 
(n=2737) 
GISSI-HF 
(n=1806) 
CORONA 
(n=2916) 
PARADIGM- 
HF 
(n=5283) 
 Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Calcium channel 
blocker 
32 29 36 37 . . .  16 33 11 13 11 16 . . 10 8 . . . . 
                       
Treatment arm, % 49 45 51 43 50 52 50 53 50 39 50 55 32 25 51 48 50 59 50 49 50 49 
All continuous values are given in mean±standard deviation unless stated otherwise. Categorical values are presented in percentage.  
NYHA: New York Heart Association; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; AF: atrial fibrillation; MI: myocardial infraction; CABG: coronary artery bypass 
graft; PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation therapy; ACE: angiotensin converting enzyme; ARB: angiotensin receptor 
blocker. 
* Concomitant treatment of ACE inhibitor or ARB. 
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Table 5-5. Baseline characteristics of patients with atrial fibrillation according to outcome of stroke in each trial. 
 SOLVD-T 
(n=334) 
SOLVD-P 
(n=525) 
BEST  
(n=663) 
CHARM- 
ALTERNATIVE 
(n=527) 
CHARM-
ADDED 
(n=700) 
SCD-HeFT 
(n=397) 
EMPHASIS 
(n=931) 
GISSI-HF 
(n=1436) 
CORONA 
(n=2095) 
PARADIGM- 
HF 
(n=3116) 
 Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Demographics, %                     
Age, years 
62  
±10 
61 
±10 
61 
±10 
65  
±13 
65  
±11 
65  
±11 
69  
±10 
70 
 ±10 
67  
±10  
70  
±8 
64  
±11 
66 
 ±8 
70  
±8 
70  
±8 
71  
±9 
76 
 ±7 
74  
±7 
74  
±7 
67 
 ±10 
68 
 ±10 
Female  17 11 12 16 13 . 31 33 16 34 14 33 17 24 23 37 21 20 20 25 
LVEF ,% 
25 
 ±7 
28  
±7 
28  
±6 
30 
 ±5 
23  
±7 
25  
±8 
30  
±7 
30  
±7 
28  
±8 
29  
±7 
24  
±7 
22  
±7 
26  
±5 
28  
±3 
35 ±10 
37  
±11 
31 
 ±6 
32 
 ±7 
31  
±6 
32  
±6 
Caucasian 83 63 89 89 78 72 93 92 95 97 81 87 93 93 . . 99 100 82 81 
NYHA                     
I 9 0 61 63 0 0 0 0 0 0 0 0 . . 0 0 0 0 3 2 
II 59 53 39 37 0 0 44 21 22 17 65 60 . . 56 44 33 26 64 56 
III 29 47 0 0 89 94 51 75 72 80 35 40 . . 40 48 65 74 32 42 
IV 3 0 0 0 11 6 5 4 6 3 0 0 . . 4 8 2 0 1 0 
Duration of heart 
failure, years 
. . . . 
0.2 
±0.1 
0.2 
±0.2 
4 ±5 4 ±5 5 ±5 5 ±5 5 ±5 3 ±2 . . 2 ±1 2 ±1 2 ±1 2 ±1 2 ±1 2 ±1 
Ischaemic aetiology 50 47 68 68 64 72 61 54 55 63 56 73 64 71 . . . . 56 60 
SBP, mmHg 
126 
±18 
123 
±16 
127 
±17 
135 
±21 
117 
±19 
120 
±22 
129 
±19 
134 
±19 
124 
±19 
130 
±21 
121 
±20 
119 
±24 
123 
±17 
132 
±16 
127 
±18 
133 
±20 
128 ± 
17 
132 
±16 
122 
±15 
123 
±16 
DBP, mmHg 
77  
±10 
75  
±12 
77  
±10 
80  
±13 
71  
±11 
72 
 ±10 
76  
±11 
77 
 ±9 
74  
±11 
78 
 ±13 
70 
 ±12 
69 
 ±11 
75 
 ±11 
81  
±11 
77  
±10 
80 
 ±8 
76 
 ±9 
78  
±9 
74 
 ±10 
76  
±9 
Heart rate, bpm 80 ±14 82 ±14 80 ±13 74 ±17 79 ±13 88 ±14 76 ±15 75 ±10 73 ±14 70 ±19 73 ±15 77 ±14 73 ±14 79 ±18 76 ±15 78 ±16 73 ±12 72 ±10 74 ±13 75 ±15 
Body mass index, 
kg/m2 
. . . . 27 ±6 26 ±5 27 ±5 27 ±5 28 ± 5 26 ±5 . . 28 ±5 29 ±5 27 ±5 27 ±4 27 ±5 27 ±4 29 ±6 29 ±6 
Current smoker 16 37 21 16 15 11 12 4 13 6 10 20 46 36 9 8 8 9 11 8 
                     
Laboratory tests                     
Creatinine, µmol/L 
110  
±27 
117 
±29 
103 
±23 
107 
±33 
118 
±37 
125 
±44 
131 
±37 
132 
±81 
111 
±37 
114 
±31 
114 
±40 
124 
±64 
105 
±26 
95 ±23 
105 
±31 
114 
±38 
117 
±28 
118 
±25 
102 
±27 
105 
±26 
NT-proBNP, pg/ml 
(median) 
. . . . . . . . .  .  .  
167 
(87-
330) 
455 
(86-
558) 
234 
(114-
448) 
197 
(108-
492) 
1883 
(1094-
3645) 
2014 
(1181-
4249) 
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 SOLVD-T 
(n=334) 
SOLVD-P 
(n=525) 
BEST  
(n=663) 
CHARM- 
ALTERNATIVE 
(n=527) 
CHARM-
ADDED 
(n=700) 
SCD-HeFT 
(n=397) 
EMPHASIS 
(n=931) 
GISSI-HF 
(n=1436) 
CORONA 
(n=2095) 
PARADIGM- 
HF 
(n=3116) 
 Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Medical History, % 
Angina  45 53 47 47 49 56 55 54 47 46 53 67 41 29 12 11 71 65 30 30 
MI 42 37 64 42 48 33 53 46 48 54 44 67 43 36 27 30 53 58 36 37 
Revascularisation          
(PCI or CABG) 
27 26 46 26 41 33 34 42 32 37 40 60 31 36 16 11 24 22 28 23 
Peripheral vascular 
disease 
. . . . 16 17 . . . . . . . . 9 21 13 17 6 9 
Hypertension 40 47 43 79 59 72 54 71 53 49 61 73 69 93 58 73 65 77 78 85 
Previous Stroke  10 11 10 21 . . 12 29 12 11 9 13 12 14 7 11 14 23 11 15 
Diabetes 22 16 15 26 33 39 26 21 29 34 30 47 27 36 25 27 29 30 35 24 
Insulin treated 
diabetes 
. . . . 13 22 9 4 8 6 10 7 . . 5 10 7 7 8 6 
                     
Concomitant 
treatment, % 
                    
Digoxin 85 95 56 47 . . 64 75 76 89 78 73 42 50 57 62 51 51 43 44 
Diuretics               
(Thiazide or 
Loop) 
86 89 16 32 . . 90 88 95 100 85 93 89 71 94 98 93 94 84 79 
ACE inhibitor . . . . . . . . 100 100 83 73 78 79 . . . . . . 
ARB . . . . . . . . . . 16 13 18 14 . . . . 23 27 
β-blocker 7 5 15 21 . . 48 54 51 60 66 47 87 86 55 60 73 83 93 93 
Aldosterone 
antagonist 
14 5 3 11 . . .  1 . 21 13 . . 43 40 45 40 55 48 
Pacemaker 7 5 5 5 17 11 18 17 17 11 . . 21 29 15 17 15 18 17 8 
Device (ICD, CRT) . . . . 4 6 4 8 6 3 . . 19 . 7 2 3 6 18 9 
Anti-arrhythmic 27 26 33 32 . . 28 25 24 23 . . 23 7 29 22 19 17 . . 
Antiplatelet 26 37 49 63 . . 39 58 30 43 39 40 45 71 31 41 38 49 37 42 
Anticoagulant  37 21 21 11 . . 60 50 72 57 68 47 66 50 64 54 61 51 66 55 
Any antithrombotic 
(antiplatelet or 
anticoagulant) 
58 58 66 74 . . 92 88 94 86 91 87 94 100 93 92 93 92 90 91 
Nitrate 35 32 24 21 . . 33 33 30 17 28 47 . . 31 43 29 28 . . 
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 SOLVD-T 
(n=334) 
SOLVD-P 
(n=525) 
BEST  
(n=663) 
CHARM- 
ALTERNATIVE 
(n=527) 
CHARM-
ADDED 
(n=700) 
SCD-HeFT 
(n=397) 
EMPHASIS 
(n=931) 
GISSI-HF 
(n=1436) 
CORONA 
(n=2095) 
PARADIGM- 
HF 
(n=3116) 
 Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke  
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Calcium channel 
blocker 
25 26 26 21 . . 15 25 10 6 11 . . . 11 17 . . . . 
                     
Treatment arm, % 57 58 46 68 51 44 49 63 51 51 36 67 48 36 48 51 51 45 49 51 
All continuous values are given in mean±standard deviation unless stated otherwise. Categorical values are presented in percentage.  
NYHA: New York Heart Association; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; AF: atrial fibrillation; MI: myocardial infraction; CABG: coronary artery bypass 
graft; PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator; CRT: cardiac resyncronisation therapy; ACE: angiotensin converting enzyme; ARB: angiotensin receptor 
blocker. 
* Concomitant treatment of ACE inhibitor or ARB. 
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5.1.3.3. Strokes rates in patients without AF   
The overall rate of stroke in patients with HF-REF but without AF was 10.8 per 1000 patient-
years (95%CI: 10.1-11.5).  The annual rates of stroke within each trial are shown in Table 5-
6.  There was a non-significant downward trend in the rate of stroke across the trials over 
time, with the incidence rate of 27% lower. (Figure 5-1)  The 1-, 2-, and 3-year cumulative 
incidence function (CIF) of stroke for each trial are shown in Table 5-6.  
Compared to the control arm of the earliest trial- SOLVD-T, the risks of stroke were 43% 
and 24% lower in the treatment arm of CHARM-Added and PARADIGM-HF, respectively, 
after adjustment for the listed covariates [HR 0.57 (95%CI: 0.33-0.97)  and 0.76 (0.53-1.10), 
respectively]. (Figure 5-2)  The groups of patients who received higher proportion of oral 
anticoagulant at baseline were less likely to have a stroke. (Figure 5-2)  
 
5.1.3.4. Strokes rates in patients with AF 
The average annual rate of stroke across the trials for patients with AF was 15.6 per 1000 
patient-years (95%CI: 14.1-17.1).  The annual rate of stroke in each trial was higher among 
patients with AF compared to those without. (Table 5-6)  Although not statistically 
significant, there was a downward trend for the stroke rates across the trials over time, 
with incidence rate of 39% lower. (Figure 5-3)  The 1-, 2-, and 3-year cumulative incidence 
function (CIF) of stroke for each trial were shown in Table 5-6. 
The proportion of patients who were on oral anticoagulant treatment had steadily 
increased across the trials, ranging from 39% in the control arm of SOLVD-T to 65% in the 
treatment arm of PARADIGM-HF.  Approximately two thirds of patients with AF enrolled in 
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the contemporary trials (i.e. CHARM trials and onwards) were on oral anticoagulant. (Figure 
5-4)  The hazard ratios for stroke in most treatment groups were not statistically significant 
when compared to the control arm of the SOLVD-T trial, after adjustment. (Figure 5-4)    
 
 
Figure 5-1. Trends for incidence rate of stroke for patients without atrial 
fibrillation, across the trials, with each treatment arm shown separately. 
Full name of the trials are explained in the footnote for Table 5-1. C indicates control group; T: treatment group. 
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Table 5-6. Stroke outcome, annual adjusted rate of stroke and cumulative incidence of stroke for patients with and without atrial fibrillation. 
 SOLVD-T  SOLVD-P  
DIG  
 
BEST  CHARM-
ALTERNATIVE  
CHARM-
ADDED  
SCD-HeFT  EMPHASIS-HF  GISSI-HF  CORONA  
PARADIGM- 
HF 
 
 
Patients without AF 
Number of patients 
without AF, n 
2235 3703 6800 2044 1501 1848 2124 1806 3138 2916 5283 
Number of stroke,  
n (%) 
76 (3.4) 114 (3.1) 191 (2.8) 70 (3.4) 54 (3.6) 53 (2.9) 55 (2.6) 33 (1.8) 85 (2.7) 121 (4.2) 122 (2.3) 
Annual stroke rate*, 
1000 patient-years 
12.7  
(9.9-15.6) 
10.8  
(8.8-12.8) 
9.9  
(8.5-11.3) 
17.2  
(13.1-21.2) 
14.2  
(10.4-18.0) 
10.0  
(7.3-12.7) 
7.8  
(5.8-9.9) 
10.4  
(6.9-14.0) 
7.8  
(6.1-9.4) 
16.7  
(13.8-19.7) 
10.6  
(8.7-12.5) 
            
Cumulative incidence 
of stroke†, % (95% CI) 
           
1 year 
1.12 
(0.74-1.63) 
0.81 
(0.56-1.14) 
0.94  
(0.73-1.20) 
1.79 
(1.28-2.45) 
1.53  
(1.00-2.26) 
1.14 
(0.73-1.71) 
0.28 
(0.12-0.60) 
1.41 
(0.90-2.08) 
1.09 
(0.77-1.50) 
1.27  
(0.91-1.73) 
1.04 
(0.80-1.35) 
2 years 
1.81  
(2.06-2.71) 
1.92 
(1.51-2.40) 
1.82  
(1.52-2.16) 
3.11  
(2.39-3.98) 
2.47 
(1.77-3.35) 
1.90 
(1.35-2.60) 
0.81 
(0.49-1.27) 
1.79  
(1.21-2.56) 
1.60 
(1.20-2.09) 
2.85 
(2.29-3.50) 
1.96 
(1.60-2.38) 
3 years 
2.94 
(2.28-3.72) 
2.84  
(2.30-3.46) 
2.56 
(2.20-2.97) 
4.10 
(3.19-5.16) 
3.34 
(2.49-4.37) 
2.60 
(1.94-3.40) 
1.24 
(0.83-1.81) 
2.53 
(1.66-3.67) 
2.12 
(1.65-2.67) 
4.25 
(3.53-5.06) 
2.69 
(2.20-3.34) 
 
Patients with AF 
Number of patients 
with AF, n 
334 525 . 663 527 700 397 931 1436 2095 3116 
Number of stroke,        
n (%) 
19 (5.7) 19 (3.6) . 18 (2.7) 24 (4.6) 35 (5.0) 15 (3.8) 14 (1.5) 63 (4.4) 102 (4.9) 97 (3.1) 
Annual stroke rate*, 
1000 patient-years 
22.9  
(12.3-33.6) 
16.0  
(8.8-23.2) 
. 
14.7  
(7.9-21.4) 
19.3  
(11.6-27.1) 
18.6  
(12.4-24.8) 
12.1  
(6.0-18.2) 
8.2  
(3.9-12.5) 
14.0  
(10.5-17.5) 
20.3  
(16.4-24.3) 
14.1  
(11.3-16.9) 
            
Cumulative incidence 
of stroke†, % 
           
1 year 
2.10  
(0.93-4.09) 
1.71 
(0.85-3.12) 
. 
1.74 
(0.93-3.01) 
1.90  
(0.98-3.36) 
2.14 
(1.26-3.43) 
1.26 
(0.48-2.78) 
0.47  
(0.16-1.16) 
1.26 
(0.78-1.95) 
1.96 
(1.43-2.62) 
1.41 
(1.04-1.88) 
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 SOLVD-T  SOLVD-P  
DIG  
 
BEST  CHARM-
ALTERNATIVE  
CHARM-
ADDED  
SCD-HeFT  EMPHASIS-HF  GISSI-HF  CORONA  
PARADIGM- 
HF 
 
2 years 
3.89 
(2.18-6.37) 
3.17 
(1.88-4.98) 
. 
2.48 
(1.45-3.97) 
2.66 
(1.53-4.31) 
3.00 
(1.92-4.47) 
1.77  
(0.79-3.46) 
1.22 
(0.57-2.34) 
2.39 
(1.69-3.28) 
3.10  
(2.42-3.91) 
2.67 
(2.13-3.32) 
3 years 
5.76 
(3.51-8.77) 
4.35 
(2.58-6.79) 
. 
3.30 
(2.00-5.12) 
4.78 
(3.15-6.91) 
4.43 
(3.08-6.14) 
3.45 
(1.93-5.67) 
2.35 
(1.29-3.93) 
3.09 
(2.28-4.09) 
5.06 
(4.14-6.11) 
3.86 
(3.11-4.71) 
* Adjusted annual rate of stroke (per 1000 patient-years). Adjustment made for age and sex. 
† Cumulative incidence function of stroke occurrences were estimated accounting for competing risk of death. Full name of the trials are explained the footnote for Table 1. 
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Figure 5-2. Hazard ratios of stroke for patients without atrial fibrillation in each arm of the trials. 
Annual rate of stroke was adjusted for age and sex. Hazard ratio of stroke was adjusted for age, sex, NYHA class, history of diabetes, previous stroke and ischaemic aetiology.   
OAC: Oral anticoagulant at baseline. Ref: Reference. C: control; T: treatment; HR: hazard ratio; LCI: Lower confidence interval; UCI: Upper confidence interval. 
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Figure 5-3. Trends for incidence rate of stroke for patients with atrial 
fibrillation, across the trials, with each treatment arm shown separately. 
Full name of the trials are explained in the footnote for Table 5-1. C indicates control group; T: treatment group. 
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Figure 5-4. Hazard ratios of stroke for patients with atrial fibrillation in each arm of the trials included. 
Annual rate of stroke was adjusted for age and sex. Hazard ratio of stroke was adjusted for age, sex, NYHA class, history of diabetes, previous stroke and ischaemic aetiology.   
OAC: Oral anticoagulant at baseline. Ref: Reference. C: control; T: treatment; HR: hazard ratio; LCI: Lower confidence interval; UCI: Upper confidence interval. 
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5.1.4.  Discussion  
This analysis of 44,122 patients with HF-REF enrolled in eleven randomised clinical trials 
conducted across the last 30 years shows that the rate of stroke did not significantly decline 
in patients, irrespective of AF status.  The incidence of stroke remains static despite the 
increasing use of evidence-based pharmacotherapies known to reduce cardiovascular at 
least some outcomes, and the growing awareness for oral anticoagulant treatment in 
patients with AF.   
The sequential introduction of disease-modifying heart failure drugs across the trials has 
been shown to improve left ventricular function in terms of LVEF.112, 113, 293-295  However, 
LVEF itself is not a consistent predictor of stroke.296-298   Thus, stroke in HF-REF may also be 
related to the burden of atherosclerotic cerebrovascular disease rather than 
thromboembolism alone.  Perhaps, in these patients, the management of traditional 
vascular risk factors may be as important for stroke prevention.     
Additionally, we observed that the incidence and risk of stroke were lower in the groups 
that had higher exposure to oral anticoagulant treatment at baseline, particularly so for 
patients with AF.  There was a notable increase in the proportion of oral anticoagulant use 
across the trials, consistent with the trends observed in less selected patients with AF over 
a similar time span to that covered in our study.299, 300  Interestingly, lower risks of stroke 
were also observed in patients without AF from groups with higher proportion of oral 
anticoagulant. This is in line with the thrombo-prophylaxis benefit suggested in the 
Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial (WARCEF).211  WARCEF 
suggested that any benefit was offset by an increased risk of major bleeding.211  However, 
non-vitamin K antagonist oral anticoagulants (NOACs) cause less bleeding than warfarin.  
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Identification of patients without AF who are at the highest risk of stroke may lead to 
individualised and safer stroke thrombo-prophylaxis using the newer anticoagulant agents. 
We can only speculate that if the benefits of treatments shown in the trials are fully 
translated into general population, together with effective risk stratification and safer oral 
anticoagulant, we might anticipate that patients with heart failure will be less likely to have 
stroke, as was highly probable in the past.  This hypothesis needs to be tested in clinical 
trials. 
Our study has potential limitations. Our retrospective study was based on a highly selected 
group of patients based on individual trials criteria.  Patients enrolled in trials usually 
receive the best evidence-based treatment of the day.  “Real-world” cohorts will be older, 
have more co-morbidity and will receive fewer, and lower doses of, evidence-based 
drugs.301-303  There may also be potential biases in comparing the trials with different 
interventions and defined endpoints.  
Our study evaluated the incidences and risks of stroke according to AF status at baseline. 
New onset AF occurring during follow-up in the trial was not examined, due to limited data 
availability.  During the period we analysed, the NOACs were not commonly used oral 
anticoagulant.  Thus, the main oral anticoagulant used within the trials was a vitamin K 
antagonist (VKA).  Our data also lack time in therapeutic range that is crucial for effective 
anticoagulation when using VKA agent.  The reasons for deciding not to anticoagulate 
patients with AF may be entirely appropriate, but the rationale was not captured.   
Strengths of our study include the large sample and use of individual patient data recruited 
from rigorously conducted clinical trials.  The trials also usually describe richer baseline 
characterisation of patients and this allows more complete multivariable adjustment.  In 
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this respect, our estimate of the risks of stroke over time may be conservative. The stroke 
outcome was also carefully adjudicated in most of the trials included, and comparable 
definitions for stroke event were used.  This is rarely the case in non-trial cohorts.  
In conclusion, the incidence of stroke has not significantly declined over time in patients 
with HF-REF enrolled to trials, despite greater use of evidence-based heart failure and oral 
anticoagulant therapies.  The anticoagulation rates remain under 70% among HF-REF 
patients with documented AF.  Patients with heart failure and reduced ejection fraction, 
with AF, are at high risk of stroke, and proven measures could still be better implemented. 
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5.2. Heart failure with preserved ejection fraction 
5.2.1. Background 
Many patients with heart failure have a preserved (i.e. normal or near-normal) left 
ventricular ejection fraction (HF-PEF).93, 304  Such patients tend to be older, female and 
more likely to have cardiovascular co-morbidities, including hypertension and atrial 
fibrillation (AF).93, 123, 304  Although patients with HF-PEF are thought to have a considerably 
better outcome than their counterparts with reduced ejection fraction (HF-REF),132 their 
risk profile still predisposes them to a disabling, potentially fatal, stroke.  However, little is 
known about the incidence of stroke in HF-PEF, which may have changed over time, 
especially in the absence of AF.  We therefore examined the incidences of stroke during 
follow-up from three randomised controlled trials among patients with HF-PEF, conducted 
during the period 1990 to 2008, according to AF status at baseline. 
 
5.2.2. Methods 
5.2.2.1. Data source 
We performed analysis of patient level data from three randomised controlled trials in 
patients with chronic ambulatory HF-PEF conducted within the last 20 years, namely, the 
ancillary Digitalis Investigation Group (DIG-PEF) Trial,225 the Candesartan in Heart failure: 
Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved Trial,141 and the 
Irbesartan in Heart Failure with Preserved Ejection Fraction (I-Preserve) trial.139  We 
included only patients with left ventricular ejection fraction (LVEF) ≥45%.  The design and 
results of these trials have been published elsewhere and their main characteristics are 
summarised in Table 5-7. 
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Table 5-7. Design of the clinical trials in heart failure patients with preserved 
ejection fraction (HF-PEF). 
 DIG-PEF 
(N=988) 
CHARM-Preserved 
(N=3023) 
I-Preserve 
(N=4128) 
Inclusion criteria    
Age, years 21-75 ≥18 ≥60 
NYHA class - II-IV II-IV 
LVEF requirement >45% >40% ≥45% 
HF hospitalization - Hospitalization for a 
cardiac reason within 6 
months if NYHA class II. 
HF hospitalization in the 
preceding 6 months or 
NYHA class III/IV 
and abnormal CXR, ECG, 
or echocardiogram. 
Creatinine, µmol/L <265 - <221 
eGFR,mL/min/1.73m2 - - - 
SBP, mmHg - - ≥100, <160 
Potassium, mmol/L >3.2, <5·5 - - 
Others Sinus rhythm only  - 
Comparison Digoxin vs. Placebo Candesartan vs. Placebo Irbesartan vs. Placebo 
Study period 1990-1995 1999-2003 2002-2008 
Site distribution 302 centres in the 
United States and 
Canada 
618 centres in 26 
countries. 
293 centres in 25 
countries. 
NYHA: New York Heart Association; LVEF: Left ventricular ejection fraction; SBP: systolic blood pressure; HF: Heart 
failure; CXR: chest X-Ray; ECG: electrocardiogram. 
 
DIG-PEF:   Digitalis Intervention Group- Preserved Ejection Fraction;  
CHARM-Preserved: Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Preserved;  
I-Preserve:  Irbesartan in Heart Failure with Preserved Ejection Fraction Study. 
 
 
5.2.2.2. Definition of atrial fibrillation and stroke 
We defined AF status as either AF on their baseline ECG or a history of AF.  Our outcome of 
interest was stroke.  CHARM-Preserved and I-Preserve trials had included stroke as a 
component of their cardiovascular endpoints, adjudicated by an independent committee 
in a blinded fashion using pre-specified criteria.  In DIG-PEF, stroke was identified 
retrospectively and was not centrally adjudicated.  Reasonably comparable criteria were 
used in the three trials. (Table 5-8) 
 
 128 
Table 5-8. Definitions of ‘stroke’ in the trials included. 
 
 
DIG-PEF:   Digitalis Intervention Group- Preserved Ejection Fraction;  
CHARM-Preserved: Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Preserved;  
I-Preserve:  Irbesartan in Heart Failure with Preserved Ejection Fraction Study. 
 
 
5.2.2.3. Statistical methods 
We described the full cohort and compared these 2 sub-groups, using means (standard 
deviation [SD]) or medians (inter-quartile range [IQR]) for continuous variables and count 
(percentage) for categorical variables.  We also compared the baseline characteristics of 
patients who developed stroke during the trials’ follow-up versus their stroke-free 
counterparts.  
We estimated the incidence rates of stroke (per 1000 patient-years) for each trial’s follow-
up period, according to AF status, adjusted for age and sex.  A Joinpoint regression was 
used to fit the trends in annual rates of stroke across the trials and to calculate the overall 
change, expressed as a percentage (Joinpoint software, version 4.2).  Cumulative incidence 
functions of stroke occurrences were estimated, accounting for the competing risk of 
death.290, 291   We calculated the hazard ratio (HR) and corresponding 95 percent confidence 
intervals (95%CI) to express the hazard rate of stroke in each arm of the trials using Cox 
proportional hazard models adjusting for previously established predictors of ischemic 
stroke292 and  other confounding variables.   
Trial  Definition of Stroke 
DIG-PEF Investigator reported cases stroke (following a letter sent to DIG investigators by 
the DIG Steering Committee). 
CHARM-Preserved Focal neurological signs or symptoms with a duration of at least 24 hours. 
I-Preserve A persistent (≥ 24 hours) disturbance of focal neurological function resulting in 
symptoms thought to be due to athero/thrombotic cerebral infarction, embolus, 
evidence of haemorrhage or for which there is no certain aetiology.  
 129 
All analyses, apart from the Joinpoint regression, were undertaken using SAS version 9.3 
(SAS Institute, Inc., Cary, NC, USA).  
 
5.2.3. Results 
We analyzed individual patient data for 7,689 patients enrolled in three randomised 
controlled trials conducted in patients with HF-PEF (LVEF  ≥45%) from 1990-2008.  Of these, 
stroke occurred in 124/ 2,025 patients (6.1%) with AF and in 202/ 5,664 patients (3.6%) 
without AF.   
Patient characteristics for each trial are summarised in Table 5-9.  By trial design, DIG-PEF 
trial only contains patients in sinus rhythm.  Patients with AF constitute a third of the cohort 
from the CHARM-Preserved and I-Preserve trials.  Approximately two-thirds of patients in 
each trial had a history of hypertension.  Each trial also contains approximately 30% of 
patients with diabetes.  
The characteristics of patients with and without AF according to stroke outcome in each 
trial are shown in Tables 5-10 and 5-11, respectively.  In patients with AF, those who 
experienced stroke were more likely to have a history of hypertension and previous stroke. 
Approximately half of the patients with AF were on oral anticoagulant at baseline.  In 
patients without AF, those who had stroke tend to have history of hypertension, previous 
stroke and diabetes treated with insulin.  Fewer than 10% of patients without AF had been 
anticoagulated. 
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Table 5-9. Baseline characteristics of patients within the heart failure with 
preserved ejection fraction trials. 
 DIG-PEF 
(n=988) 
CHARM-Preserved 
(n=2573) 
I-Preserve 
(n=4128) 
Demographics, %    
Age, years 67±10 67±11  72±7 
Female  59 1488 (58) 16374 (40) 
LVEF ,% 55±8 56±9 59±9 
Caucasian 86 91 93 
NYHA    
I 20 - 0 
II 58 62 21 
III 21 37 76 
IV 1 2 3 
Duration of heart 
failure, years 
- 3 ±4 3 ±4 
Ischaemic aetiology 56 54 - 
SBP, mmHg 138±21 137±19 136±15 
DBP, mmHg 77±11 78±11 79±9 
Heart rate, bpm 76±11 71±13 71±10 
Body mass index, kg/m2 29 ±6 29 ±6 30 ±5 
Current smoker - 13 18 
    
AF status, %     
AF on baseline ECG 0 17 17 
History of AF 0 30 29 
AF (baseline ECG or 
medical history) 
0 31 30 
    
Laboratory tests    
Creatinine, µmol/L 111±34 99±36 88±28 
    
Medical History, %    
Angina  30 59 43 
MI 49 41 23 
Revascularisation          
(PCI or CABG) 
- 32 13 
Peripheral vascular 
disease 
- - - 
Hypertension 60 66 88 
Previous Stroke  - 9 10 
Diabetes 29 28 27 
Insulin treated 
diabetes 
- 10 8 
    
Concomitant treatment, 
% 
   
Digoxin - 27 14 
Diuretics               
(Thiazide or Loop) 
76 75 80 
ACE inhibitor 86 18 25 
β-blocker - 55 59 
Aldosterone antagonist 8 11 21 
Pacemaker - 7 6 
Device (ICD, CRT) - 1 0.3 
Anti-arrhythmic - 10 - 
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 DIG-PEF 
(n=988) 
CHARM-Preserved 
(n=2573) 
I-Preserve 
(n=4128) 
Antiplatelet - 58 59 
Anticoagulant  - 25 19 
Any antithrombotic 
(antiplatelet or 
anticoagulant) 
- 80 75 
Nitrate 39 33 27 
Calcium channel 
blocker 
- 33 40 
    
Treatment arm, % 50 50 50 
All continuous values are given in mean±standard deviation unless stated otherwise. Categorical values are presented in 
percentage.  
NYHA: New York Heart Association; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; 
AF: atrial fibrillation; MI: myocardial infraction; CABG: coronary artery bypass graft; PCI: percutaneous coronary 
intervention; ICD: implantable cardioverter defibrillator; CRT: cardiac resyncronisation therapy; ACE: angiotensin 
converting enzyme; ARB: angiotensin receptor blocker. 
 
DIG-PEF: Digitalis Intervention Group- Preserved Ejection Fraction; CHARM-Preserved: Candesartan in Heart failure 
Assessment of Reduction in Mortality and morbidity-Preserved; I-Preserve: Irbesartan in Heart Failure with Preserved 
Ejection Fraction Study. 
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Table 5-10. Baseline characteristics of patients without atrial fibrillation 
according to outcome of stroke (with ejection fraction ≥45% only). 
 
DIG-PEF 
(n=988) 
CHARM-Preserved 
(n=1781) 
I-Preserve 
(n=2895) 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Demographics, %       
Age, years 67 ±10 70 ±10   65 ±11 70 ±10 71 ±7 72 ±8 
Female  40 65 41 42 63 52 
LVEF ,% 55 ±8 58 ±8 56 ±9 55 ±7 60 ±9 59 ±9 
Caucasian 86 81 90 90 92 93 
NYHA       
I 20 13 - - - - 
II 58 65 64 49 18 14 
III 21 23 35 47 79 81 
IV 1 - 1 3 3 4 
Duration of heart 
failure, years 
- - 3 ±4 3 ±5 3 ±4 3 ±5 
Ischaemic aetiology 67 39 63 69 - - 
SBP, mmHg 137 ±21 150 ±24 137 ±19 141 ±20 137 ±15 139 ±13 
DBP, mmHg 77 ±11 76 ±13 78 ±11 78 ±10 79 ±9 80 ±8 
Heart rate, bpm 76 ±12 77 ±13 71 ±12 71 ±10 71 ±10 70 ±10 
Body mass index, 
kg/m2 
29 ±6  27 ±6 29 ±6 29 ±5 30 ±5 29 ±5 
Current smoker - - 13 14 18 22 
       
Laboratory tests       
Creatinine, µmol/L 111 ±34 115 ±42 96 ±35 104 ±41 86 ±27 94 ±31 
NT-proBNP, pg/ml 
(median) 
- - - - 
225  
(104-526) 
426  
(171-1122) 
       
Medical History, %       
Angina  30 32 67 75 46 39 
MI 50 39 48 56 25 29 
Revascularisation          
(PCI or CABG) 
- - 38 29 14 15 
Peripheral vascular 
disease 
- - - - - - 
Hypertension 59 68 66 75 90 92 
Previous Stroke  - - 7 29 8 17 
Diabetes 29 29 29 49 27 35 
Insulin treated 
diabetes 
- - 11 22 8 14 
       
Concomitant 
treatment, % 
      
Digoxin - - 15 22 5 14 
Diuretics               
(Thiazide or Loop) 
76 68 69 73 76 77 
ACE inhibitor 86 81 19 14 24 27 
ARB - - - - - - 
β-blocker - - 59 58 59 57 
Aldosterone 
antagonist 
8 7 0.1 - 18 23 
Pacemaker - - 4 10 3 5 
Device (ICD, CRT) - - 1 0 0.1 0 
Anti-arrhythmic - - 5 5 - - 
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DIG-PEF 
(n=988) 
CHARM-Preserved 
(n=1781) 
I-Preserve 
(n=2895) 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Without 
Stroke 
Stroke 
Antiplatelet - - 70 64 65 72 
Anticoagulant  - - 8 8 4 3 
Any antithrombotic 
(antiplatelet or 
anticoagulant) 
- - 76 69 68 75 
Nitrate 40 29 36 51 28 32 
Calcium channel 
blocker 
- - 33 27 42 41 
       
Treatment arm, % 50 39 51 46 50 47 
All continuous values are given in mean±standard deviation unless stated otherwise. Categorical values are presented in 
percentage.  
NYHA: New York Heart Association; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; 
AF: atrial fibrillation; MI: myocardial infraction; CABG: coronary artery bypass graft; PCI: percutaneous coronary 
intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation therapy; ACE: angiotensin 
converting enzyme; ARB: angiotensin receptor blocker. 
* Concomitant treatment of ACE inhibitor or ARB. 
 
DIG-PEF: Digitalis Intervention Group- Preserved Ejection Fraction; CHARM-Preserved: Candesartan in Heart failure 
Assessment of Reduction in Mortality and morbidity-Preserved; I-Preserve: Irbesartan in Heart Failure with Preserved 
Ejection Fraction Study. 
 
 
 
  
 134 
Table 5-11. Baseline characteristics of patients with atrial fibrillation according 
to stroke outcome, (with ejection fraction ≥45% only). 
 
CHARM-Preserved 
(n=792) 
I-Preserve 
(n=1233) 
Without Stroke Stroke Without Stroke Stroke 
Demographics, %     
Age, years 70 ±10 74 ±9  74 ±7 73 ±6 
Female  44 48 55 67 
LVEF ,% 57 ±9 58 ±8 58 ±9 56 ±8 
Caucasian 95 83 97 93 
NYHA     
I - - 0.1 - 
II 58 50 28 31 
III 40 48 69 63 
IV 2 3 3 6 
Duration of heart 
failure, years 
3 ±5 3 ±3 3 ±5 2 ±2 
Ischaemic aetiology 66 33 - - 
SBP, mmHg 135 ±18 143 ±18 135 ±16 137 ±17 
DBP, mmHg 77 ±11 78 ±12 78 ±9 81 ±9 
Heart rate, bpm 73 ±14 73 ±14 73 ±12 77 ±13 
Body mass index, 
kg/m2 
29 ±6 29 ±6 30 ±5 29 ±5 
Current smoker 12 10 18 8 
     
Laboratory tests     
Creatinine, µmol/L 105 ±36 105 ±38 94 ±30 95 ±31 
NT-proBNP, pg/ml 
(median) 
- - 
942 
(416-1663) 
1360  
(590-1937) 
     
Medical History, %     
Angina  41 40 36 48 
MI 24 28 19 21 
Revascularisation          
(PCI or CABG) 
20 23 11 6 
Peripheral vascular 
disease 
- - - - 
Hypertension 64 80 85 89 
Previous Stroke  10 20 12 18 
Diabetes 25 28 29 23 
Insulin treated 
diabetes 
8 13 9 1 
     
Concomitant treatment, 
% 
    
Digoxin 53 30 35 33 
Diuretics               
(Thiazide or Loop) 
88 93 88 95 
ACE inhibitor 16 28 28 29 
ARB - - - - 
β-blocker 46 50 59 54 
Aldosterone 
antagonist 
- - 27 31 
Pacemaker 14 8 13 7 
Device (ICD, CRT) 1 3 1 - 
Anti-arrhythmic 22 15 - - 
Antiplatelet 30 38 42 51 
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CHARM-Preserved 
(n=792) 
I-Preserve 
(n=1233) 
Without Stroke Stroke Without Stroke Stroke 
Anticoagulant  63 60 55 43 
Any antithrombotic 
(antiplatelet or 
anticoagulant) 
87 83 89 89 
Nitrate 24 35 23 26 
Calcium channel 
blocker 
30 43 34 38 
     
Treatment arm, % 49 53 50 50 
All continuous values are given in mean±standard deviation unless stated otherwise. Categorical values are presented in 
percentage.  
NYHA: New York Heart Association; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; 
AF: atrial fibrillation; MI: myocardial infraction; CABG: coronary artery bypass graft; PCI: percutaneous coronary 
intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation therapy; ACE: angiotensin 
converting enzyme; ARB: angiotensin receptor blocker. 
* Concomitant treatment of ACE inhibitor or ARB. 
 
CHARM-Preserved: Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Preserved;  
I-Preserve: Irbesartan in Heart Failure with Preserved Ejection Fraction Study. 
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The annual rates of stroke (adjusted for age and sex) within each trial, according to AF 
status, are shown in Table 5-12.  Neither patients with nor without AF have a significant 
downward trend for the rate of stroke across the trials. (Figure 5-5)  The 1-, 2-, 3- year 
cumulative incidence functions (CIF) of stroke for each trial, according to AF status, are 
shown in Table 5-12.  There was no obvious difference for the CIF of stroke among the 
trials.  
Figure 5-6 shows the effect of sequential introduction of treatment tested by the trials on 
stroke outcome.  Compared to patients without AF in the control arm of the earliest trial, 
DIG-PEF, the risk of stroke were 48% lower for their counterparts in the treatment arm of 
I-Preserve [HR 0.52 (95%CI: 0.27-1.00), p=0.051, after adjustment]. 
Table 5-12. Annual stroke rates and cumulative incidence of stroke at 
different time points for patients with and without atrial fibrillation. 
 DIG-PEF 
(n=988) 
CHARM-Preserved 
(n=2573) 
I-Preserve 
(n=4128) 
Patients without AF    
Number of patients without AF 988 1781 2895 
Number of stroke, n (%) 31 59 112 
Annual stroke rate*, 
1000 patient-years 
10.6 (6.8-14.3) 11.6 (8.6-14.6) 9.6 (7.9-11.4) 
    
Cumulative incidence of stroke†,  % 
(95% CI) 
   
1 year 1.01 (0.52-1.80) 1.01 (0.62-1.57) 0.97 (0.66-1.38) 
2 years 2.03 (1.28-3.06) 2.08 (1.49-2.82) 1.91 (1.45-2.45) 
3 years 2.66 (1.78-3.81) 3.17 (2.42-4.08) 2.64 (2.10-3.27) 
    
Patients with AF    
Number of patients without AF - 792 1233 
Number of stroke, n (%) - 40 84 
Annual stroke rate*, 
1000 patient-years 
- 18.5 (12.8-24.3) 17.8 (14.0-21.7) 
    
Cumulative incidence of stroke†, % 
(95% CI) 
   
1 year - 1.39 (0.74-2.40) 1.47 (0.90-2.26) 
2 years - 3.28 (2.20-4.70) 3.26 (2.37-4.36) 
3 years - 5.09 (3.68-6.81) 4.89 (3.78-6.20) 
AF indicates atrial fibrillation; n (%): number (percentage). *Annual rate of stroke adjusted for age and sex.  
† Cumulative incidence function of stroke occurrences were estimated accounting for competing risk of death. 
DIG-PEF: Digitalis Intervention Group- Preserved Ejection Fraction; CHARM-Preserved: Candesartan in Heart failure 
Assessment of Reduction in Mortality and morbidity-Preserved; I-Preserve: Irbesartan in Heart Failure with Preserved 
Ejection Fraction Study. 
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Figure 5-5. Trends for incidence rate of stroke for: (A) patients without atrial 
fibrillation; (B) patients with atrial fibrillation, across trials, with each 
treatment arm shown separately. 
C indicates control group; T: treatment group; DIG-PEF: Digitalis Intervention Group- Preserved Ejection Fraction; 
CHARM-Preserved: Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Preserved; I-
Preserve: Irbesartan in Heart Failure with Preserved Ejection Fraction Study. 
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Figure 5-6. Hazard ratios of stroke for: (A) patients without atrial fibrillation; (B) patients with atrial fibrillation, in each arm of the trials included. 
AF indicates atrial fibrillation. Annual rate of stroke was adjusted for age and sex. Hazard ratio of stroke was adjusted for age, sex, NYHA class, history of diabetes, previous stroke and ischaemic 
aetiology.  OAC: Oral anticoagulant at baseline. Ref: Reference. C: control; T: treatment; HR: hazard ratio; LCI: Lower confidence interval; UCI: Upper confidence interval. 
The reference group for patients without AF is the control group of DIF-PEF. The reference group for patients with AF is the control group of CHARM-PEF. 
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5.2.4. Discussion 
The rate of stroke in chronic ambulatory HF-PEF patients enrolled in three clinical trials 
spanning approximately a 20 year period, according to AF status, was static.  The overall 
rates of stroke in HF-PEF patients with and without AF are 1.6% and 1.0% per year, 
respectively.  The rate of stroke in patients with HF-PEF but without AF was comparable to 
the hypertension trials patients in the same age range (i.e. with a similar co-morbid 
phenotype to HF-PEF) who had a stroke risk of around 1% per year or less.305-309   
Although no pharmacological therapy has been shown to improve outcomes in patients 
with HF-PEF, 139-141 our study has suggested that patients with HF-PEF but without AF within 
the treatment arm of the contemporary I-Preserve trial may have a lower risk of stroke 
when compared to their counterparts in the control arm of the earliest trial, DIG-PEF, 
p=0.051.  Despite the nonsignificant difference, it is worth noting that the proportion of 
patients without AF who were anticoagulated, was very low in the I-Preserve.   
Our study has potential limitations.  We only considered patients included in the HF-PEF 
trials.  These selected subjects tend to be healthier than community dwelling HF-PEF 
patients.  Therefore, we may underestimate the rate of stroke in this population.  However, 
this is the first study to our knowledge that examined the rate of stroke in the three largest 
HF-PEF clinical trials, according to AF status, spanning a period of two decades.  We are also 
unable to examine reasons underlying clinical decisions to avoid anticoagulating patients 
with AF; the reasons may be entirely justified.  
The strengths of our study include the large sample size and the use of individual patient 
data recruited from rigorous clinical trials.  Previous studies that described the rate of 
stroke in heart failure populations mixed patients with reduced and preserved ejection 
 140 
fractions; or mixed patients with and without AF; or were based on a limited definition of 
AF, i.e. accepting a history of AF without ECG documentation.296, 297, 310 
In conclusion, the stroke incidence has not significantly declined over time in heart failure 
patients with preserved ejection fraction, enrolled to trials, irrespective of atrial fibrillation 
status at baseline.  The proportion of patients with atrial fibrillation that received oral 
anticoagulant treatment remains suboptimal across the trials.   
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Chapter 6  
Development and validation 
of predictive models for 
stroke in patients with heart 
failure and reduced ejection 
fraction but without atrial 
fibrillation 
6.1. Background 
Heart failure (HF) is thought to be a leading cause of cardio-embolic stroke.29  A meta-
analysis of historical HF trials (from 1980s to late 1990s) found that the annual stroke rate 
was between 1.3% to 2.4%.29, 142  However, whether heart failure per se, rather than atrial 
fibrillation (AF) associated with HF, accounts for this high risk is uncertain as most analyses 
of stroke in HF did not disaggregate patients with and without AF.  Furthermore, the total 
number of strokes in any individual study was usually small, in part due to the relatively 
modest size and short duration of many trials in heart failure.  As a consequence, the risk 
of stroke in patients with HF but without AF is poorly defined, particularly in a 
contemporary population.  
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HF, particularly HF with reduced ejection fraction (HF-REF), without AF may predispose to 
stroke through fulfilment of Virchow’s triad for thrombogenesis.152  First, patients with HF 
may have stasis of blood flow (‘blood flow abnormalities’) related to left ventricular systolic 
dysfunction and dyskinesis.145, 146  Second, patients with HF also have endocardial and 
endothelial dysfunction (‘vessel wall abnormalities’). 145, 146  Both of these problems may 
also lead to cerebral hypoperfusion and cerebral blood flow dysregulation, further 
increasing the risk of stroke.  Third, patients with HF have a hypercoagulable state 
(‘abnormal blood constituents’).145, 146  Importantly, with the availability of highly effective 
oral anticoagulant treatment, strokes potentially related to these factors may be 
preventable.  In the Warfarin/Aspirin Study in Heart Failure (WASH), there was no 
significant difference among the groups of patients receiving warfarin, aspirin and placebo, 
in the composite end point of death, stroke, or myocardial infarction, although this was a 
small trial.209  The larger Warfarin and Antiplatelet Therapy in Chronic Heart Failure trial 
(WATCH), which was terminated prematurely due to slow recruitment, suggested that 
there was a reduction in the rate of ischaemic stroke with warfarin as compared with 
aspirin.212  The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial (WARCEF), 
which was the most recent and by far the largest study, showed the potential 
thromboprophylaxis benefit of warfarin in WARCEF, although this was offset by an 
increased risk of major haemorrhage.211  This finding highlights the need understand the 
risk and predictors of stroke in a contemporary HF population. Identification of those at the 
highest risk of stroke coupled with the availability of newer oral anticoagulants which cause 
less bleeding might allow individualised and safer stroke treatment strategies in patients 
with HF without AF.  In other words, it may be possible, with effective risk stratification and 
safer anticoagulants, to identify a subset of HF patients without AF in whom the potential 
reduction in stroke outweighs the risk of major bleeding.     
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We therefore combined and analysed patient-level data from two large and contemporary 
HF trials, the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA, 
ClinicalTrials.gov NCT00336336)223 and the Gruppo Italiano per lo Studio della 
Sopravvivenza nell'Insufficienza cardiac- Heart Failure trial (GISSI-HF, ClinicalTrials.gov 
NCT00206310),224 to provide a comprehensive description of the current incidence of and 
risk factors for stroke in patients with HF.  We compared the rate of stroke in patients 
without AF, according to different risk categories, to the rate in those with AF.  
 
6.2. Methods 
6.2.1. Study populations 
In order to have a sufficiently large number of patients with HF and without AF, we pooled 
GISSI-HF and CORONA as both were recently conducted and neither showed an effect of 
study drug on the risk of the primary outcome or on stroke.  Each was a randomised, 
double-blind, placebo-controlled, multicentre trial which enrolled 4,574 and 5,011 
patients, respectively, with chronic HF.223, 224  Together, these trials included a broad 
spectrum of patients with HF.  CORONA enrolled patients aged ≥60 years with New York 
Heart Association (NYHA) functional class II–IV and HF with reduced ejection fraction (HF-
REF) of ischaemic aetiology.  Patients with NYHA class III-IV symptoms were eligible if their 
left ventricular ejection fraction (LVEF) was ≤40% (and class II patients if the LVEF was 
≤35%).  The primary outcome was the composite of cardiovascular death, myocardial 
infarction or stroke.  GISSI-HF enrolled patients with stable chronic HF (NYHA II–IV), 
irrespective of age, aetiology and LVEF i.e. both patients with HF-REF and HF with preserved 
ejection fraction (HF-PEF) were included. Patients with HF-PEF (LVEF >40%) had to have 
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experienced a HF hospitalisation in the year before enrolment.  The co-primary outcomes 
were death from any cause and the composite of death from any cause or cardiovascular 
hospitalisation.  In GISSI-HF patients were randomized to placebo or n-3 polyunsaturated 
fatty acids (PUFA); 4,574 were also randomly assigned to placebo or rosuvastatin 10 mg 
daily in a factorial design.  In CORONA, patients were randomly assigned to 10mg of 
rosuvastatin or matching placebo, once daily.  The first patient was randomized on 6 August 
2002 in GISSI-HF and 15 September 2003 in CORONA.  The median follow-up in GISSI-HF 
was 3.9 years and in CORONA it was 2.7 years.  Both trials were approved by the local ethics 
committees and conformed to the principles outlined in the Declaration of Helsinki.  In 
GISSI-HF, PUFA treatment led to a small but statistically significant reduction in both co-
primary endpoints but had no effect on the risk of stroke.  Rosuvastatin did not reduce the 
primary outcome (or the risk of stroke) in either trial.  The number of deaths from any cause 
in GISSI-HF and CORONA was 1,301 and 1,487, respectively. 
 
6.2.2. Stroke endpoint 
Incident strokes were centrally adjudicated by an independent endpoint committee in each 
trial and stroke was part of the primary or secondary composite cardiovascular outcomes 
in both trials.223, 224    
 
6.2.3. Incident AF 
AF was prospectively collected in GISSI-HF.  AF occurrence during the trial was defined as: 
the presence of AF on any of the ECGs performed at each follow-up visit, AF as a cause of 
worsening HF or hospital admission, and AF as an event occurring during a hospital 
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admission.  The occurrence of AF was not recorded prospectively in CORONA.  However, 
we retrospectively analysed adverse event reports for the occurrence of AF. 
 
6.2.4. N-terminal pro B-type natriuretic peptide 
In both studies N-terminal pro B-type natriuretic peptide (NT-proBNP) was measured in a 
subset of patients at a central laboratory using a commercially available assay (Roche 
Diagnostics, Basel, Switzerland). 
 
6.2.5. Statistical methods 
Patients with AF were defined as those with either AF confirmed on their baseline ECG or 
a history of AF.  The remaining patients were defined as those “without AF”.  Descriptive 
statistics were used to describe the pooled patient population from both trials and to 
compare these 2 sub-groups, using means (standard deviation [SD]) or medians (inter-
quartile range [IQR]) for continuous variables and count (percentage) for categorical 
variables.  
Incidence rate of stroke (per 1000 patient-years) were calculated during the trial follow-up 
period and were compared between the aforementioned patient sub-groups.  Cumulative 
incidence functions of stroke occurrences were estimated accounting for competing risk of 
death.290, 291  To satisfy the assumption of the independence of stroke events, recurrent 
stroke events in a patient after randomisation were not included in the analysis.  Uni- and 
multivariable predictors of risk for stroke were assessed using the Cox proportional hazards 
regression analysis. Continuous variables (e.g. body mass index and ejection fraction) were 
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evaluated by visual inspection of restricted cubic splines to identify potential non-linear 
effects.  For the multivariable analysis, we used previously established predictors of 
ischaemic stroke296, 297, 311-314 and added variables from our unadjusted univariable analyses 
that were significant at p<0.05.  The multivariable analysis was performed in two steps, 
only including patients without AF. We excluded patients with AF from the multivariable 
modelling because AF itself confers sufficient justification for oral anticoagulant treatment 
for stroke prevention.   
In step 1, a “best clinical model” was created from the pooled dataset of patients without 
AF using Cox modelling techniques.312  Eight variables that were found to be statistically 
significant from the unadjusted univariable analyses were included: age, body mass index 
(BMI), NYHA class, and history of coronary heart disease, peripheral artery disease, stroke, 
diabetes treated with insulin, and creatinine.  
In step 2, (loge) NT-proBNP was added to the independent variables identified in the step 1 
model, although this test was only available in a subset of patients. 
There were no data missing for the baseline variables used in the multivariable models.  We 
calculated the hazard ratio (HR) and corresponding 95 percent confidence intervals (95%CI) 
to express the hazard rate of stroke.  The statistical contribution of each variable to the 
predicted stroke was assessed by chi-square statistic.  The coefficients from statistically 
significant variables in the multivariable model were used to calculate an individual 
patient’s risk score for stroke.  A cumulative incidence function for stroke was estimated 
using competing risk technique290, 291 according to tertiles of risk score.  Where appropriate, 
the corresponding Kaplan-Meier curves for stroke occurrences were also plotted.  
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Model calibration and ability to separate populations of patients into risk groups were 
assessed by observing predicted vs. observed outcomes in tertiles, and by using the 
Hosmer-Lemeshow goodness-of-fit test.  The models’ discrimination abilities were 
evaluated by the overall C-index.240  All analyses were undertaken using SAS version 9.2 
(SAS Institute, Inc., Cary, NC, USA).  
 
6.3. Results 
A total of 9,585 patients were included in this analysis, of whom 3,531 had AF on their 
baseline ECG, or a history of AF, and 6,054 patients had no AF.   
NT-proBNP measurements were available in 4,381 patients (45.7%) overall (1,749 patients 
[49.5%] with AF and 2,632 patients [43.5%] without AF). 
 
6.3.1. Baseline characteristics 
The baseline characteristics of patients with and without AF are shown in Table 6-1.  The 
characteristics of patients without AF, according to subsequent stroke are shown in Table 
6-2. 
Patients with and without AF:   Patients without AF were slightly younger, had a slightly 
lower LVEF and had better NYHA functional class.  Patients without AF also had a higher 
mean eGFR and lower median NT-proBNP level than patients with AF.  There were several 
differences in medical history/co-morbidity, notably in history of myocardial infarction and 
hypertension with the former more common and the latter less frequent in patients 
without AF (compared to those with AF).  There were also notable differences in medical 
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therapy, particularly in use of antiplatelet therapy (68% of patients without AF vs. 36% in 
those with AF) and anticoagulant treatment (16% vs. 62%, respectively). 
Patients without AF- with and without stroke during follow-up:   Patients without AF who 
experienced stroke were older than those who did not, had worse NYHA class and higher 
creatinine levels.  Patients with stroke were more likely to have a history of prior stroke, 
myocardial infarction, peripheral arterial disease, hypertension and diabetes. 
The baseline characteristics of the 4,381 patients with a NT-proBNP measurement at 
baseline are shown in Tables 6-3 and 6-4. These did not differ importantly from the overall 
population. 
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Table 6-1. Baseline characteristics according to atrial fibrillation (AF) status at 
baseline. 
 
All patients 
(N= 9585) 
Without AF  
(n= 6054) 
AF  
(n= 3531) 
Demographics, n (%)    
Age (year) 70 ± 9 69 ± 10 73 ± 8  
<60 946 (10) 777 (13) 169 (5) 
60 - <65 1316 (14) 906 (15) 410 (12) 
65 - <75 3936 (41) 2539 (42) 1397 (40) 
≥75 3387 (35) 1832 (30) 1555 (44) 
Female sex 2212 (23) 1431 (24) 781 (22) 
NYHA class  
II 4717 (49) 3236 (53) 1481 (42) 
III 4680 (49) 2724 (45) 1956 (55) 
IV 188 (2) 94 (2) 94  (3) 
Duration of heart failure,  
   n (%) 
   
< 2 year 4122 (43) 2697 (45) 1425 (40) 
2-5 year 3218 (34) 2058 (34) 1160 (33) 
> 5 year 2241 (23) 1295 (24) 946 (27) 
LV Ejection Fraction, n (%) 32 ± 8  32 ± 7 33 ± 8 
>40% 461 (5) 216 (4) 245 (7) 
≤40%  4936 (52) 3138 (52) 1798 (51) 
≤30% 4188 (44) 2700 (45) 1488 (42) 
 
Baseline vital signs    
BMI, kg/m2  27 ± 5  27 ± 4  27 ± 5  
BP, mmHg    
Systolic 128 ± 17 128 ± 17 128 ± 17 
Diastolic 77 ± 9 77 ± 9 77 ± 9 
    Pulse pressure 51 ± 13  52 ± 13 51 ± 13 
Heart rate, beats/min 72 ± 12 71 ± 12 75 ± 14 
 
Laboratory measurements 
   
Total cholesterol, mmol/L 5.2 ± 1.1 5.3 ± 1.1 5.0 ± 1.1 
Serum creatinine, µmol/L    109 ± 30 107± 30 113 ± 30 
eGFR, ml/min/1.73m2 63 ± 19 65 ± 20 60 ± 18 
eGFR <60, n(%) 4451 (46) 2581 (43) 1870 (53) 
NT-proBNP, pmol/L  [median ( IQR)] 158 (21-295) 121 (9-233)  226 (63-289) 
 
Medical history, n (%) 
   
Myocardial infarction 4505 (47) 3003 (50) 1502 (43) 
Angina pectoris 4177 (44) 2521 (42) 1656 (47) 
CABG or PCI 2191 (23) 1472 (24) 719 (20) 
Hypertension 5659 (59) 3450 (57) 2209 (63) 
Diabetes mellitus 2673 (28) 1714 (28) 959 (27) 
Stroke 832 (9) 424 (7) 408 (12) 
Pacemaker 1124 (12) 595 (10) 529 (15) 
ICD or CRT 437 (5) 297 (5) 140 (4) 
Peripheral artery disease 981 (10) 578 (10) 403 (11) 
Current smoker 1172 (12) 864 (14) 308 (9) 
 
Medication, n (%) 
 
Diuretic (not aldosterone antagonist) 8534 (89) 5242 (87) 3292 (93) 
ACE inhibitor or ARB 8875 (93) 5646 (93) 3229 (92) 
Aldosterone antagonist 3800 (40) 2245 (37) 1555 (44) 
Beta-blocker 6619 (69) 4285 (71) 2334  (66) 
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All patients 
(N= 9585) 
Without AF  
(n= 6054) 
AF  
(n= 3531) 
Digitalis glycoside 3478 (36) 1595 (26) 1883 (53) 
Long-acting nitrate  3128 (33) 2058 (34) 1070 (30) 
Anti-arrhythmic drug  1537 (16) 736 (12) 801 (23) 
Antiplatelet therapy 5352 (56) 4094 (68) 1258 (36) 
Anticoagulant therapy  3146 (33) 963 (16) 2183 (62) 
Antiplatelet or anti-coagulant therapy  8230 (86) 4953 (82) 3277 (93) 
Antidiabetic drugs   
insulin 688 (7) 467 (8) 221 (6) 
oral hypoglycaemic 1553 (16) 997 (17) 556 (16) 
All continuous values are given in mean ± standard deviation unless stated otherwise. AF: atrial fibrillation;  n(%): number 
of observations (percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; 
PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation 
therapy; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker. 
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Table 6-2. Baseline characteristics of patients without atrial fibrillation 
according to stroke outcome. 
 
Patients without 
AF 
(N= 6054) 
Non-stroke 
(n=5848) 
Stroke  
(n= 206) 
Demographics, n (%)    
Age (year) 69 ± 10 69 ± 10 72 ± 9 
Age <60 777 (13) 760 (13) 17 (8) 
Age 60 - <65 906 (15) 880 (15) 26 (13) 
Age 65 - <75 2539 (42) 2466 (42) 73 (35) 
Age ≥75 1832 (30) 1742 (30) 90 (44) 
Female sex 1431 (24) 1388 (24) 43 (21) 
NYHA class  
II 3236 (53) 3148 (54) 88 (43) 
III 2724 (45) 2612 (45) 112 (54) 
IV 94 (2) 88 (2) 6 (3) 
Duration of heart failure (year)    
< 2 2697 (45) 2611 (45) 86 (42) 
2-5 2058 (34) 1987 (34) 71 (34) 
> 5 1295 (21) 1246 (21) 49 (24) 
LV Ejection Fraction, n %  32 ± 7  32 ± 7 31 ± 8 
>40% 216 (4) 207 (4) 9 (5) 
≤40 and >30% 3138 (52) 3040 (52) 98 (48) 
≤30% 2700 (45) 2601 (44) 99 (48) 
 
Baseline vital signs    
BMI, kg/m2 27 ± 4 27 ± 4 26 ± 4 
BP, mmHg    
Systolic 128 ± 17  128 ± 17 129 ± 17 
Diastolic 77 ± 9 77 ± 10 77 ± 9 
    Pulse pressure 52 ± 13 52 ± 13 51 ± 14 
Heart rate, beats/min 71 ± 12 71 ± 12 72 ± 11 
 
Laboratory measurements 
   
Total cholesterol, mmol/L 5.3 ± 1.1  5.3 ± 1.1 5.2 ± 1.0 
Serum creatinine, µmol/L    107 ± 30 107 ± 30 111 ± 30 
eGFR, ml/min/1.73m2 65 ± 20 65 ± 20  62 ± 19 
eGFR <60, n(%) 2581 (43) 2476 (42) 105 (51) 
NT-proBNP, pmol/L [median  
( IQR)] 
121 (9-233) 119 (8-230) 169 (42-297) 
 
Medical history, n (%) 
   
Myocardial infarction 3003 (50) 2892 (50) 111(54) 
Angina pectoris 2521 (42) 2421 (41) 100 (49) 
CABG or PCI 1472 (24) 1427 (24) 45 (22) 
Hypertension 3450 (57) 3326 (57) 124 (60) 
Diabetes mellitus 1714 (28) 1648 (28) 66 (32) 
Stroke 424 (7) 398 (7) 26 (13) 
Pacemaker 595 (10) 573 (10) 22 (11) 
ICD or CRT 297 (5) 289 (5) 8 (4) 
Peripheral artery disease 578 (10) 550 (9) 28 (14) 
Current smoker 864 (14) 833 (14) 31 (15) 
 
Medication, n (%) 
 
Diuretic (not aldosterone antagonist) 5242 (87) 5061 (87) 181 (88) 
ACE inhibitor or ARB 5646 (93) 5458 (93) 188 (91) 
Aldosterone antagonist 2245 (37) 2165 (27) 80 (39) 
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Patients without 
AF 
(N= 6054) 
Non-stroke 
(n=5848) 
Stroke  
(n= 206) 
Beta-blocker 4285 (71) 4142 (71) 143 (69) 
Digitalis glycoside 1595 (26) 1536 (26) 59 (28) 
Long-acting nitrate  2058 (34) 1971 (34) 87 (42) 
Anti-arrhythmic drug  736 (12) 720 (12) 16 (8) 
Antiplatelet therapy 4094 (68) 3947 (67) 147 (71) 
Anticoagulant therapy  963 (16) 930 (16) 33 (16) 
Antiplatelet or anti-coagulant therapy  4953 (82) 4776 (82) 177 (86) 
Antidiabetic drugs   
insulin 467 (8) 443 (8) 24 (12) 
oral hypoglycaemic 997 (16) 970 (17) 27 (13) 
All continuous values are given in mean ± standard deviation unless stated otherwise. AF: atrial fibrillation;  n(%): number 
of observations (percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; 
PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation 
therapy; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker. 
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Table 6-3. Baseline characteristics according to atrial fibrillation status at 
baseline for patients with available NT-proBNP measurement only.  
 
All patients 
(N= 4381) 
Without AF 
(n=2632) 
AF  
(n=1749) 
Demographics    
Age (year) 72± 8 71 ± 8 74 ± 7 
<60, n(%) 165 (4) 148 (6) 17 (1) 
60 - <65, n(%) 641 (15) 436 (17) 205 (12) 
65 - <75, n(%) 1867 (43) 1157 (44) 710 (41) 
≥75, n(%) 1708 (39) 891 (34) 817 (47) 
Female, n(%) 1048 (24) 665 (25) 383 (22) 
NYHA class, n (%)  
II 1849 (42) 1222 (46) 627 (36) 
III 2459 (56) 1370 (52) 1089 (62) 
IV 73 (2) 40 (2) 33 (2) 
Duration of heart failure (year),  
   n (%) 
   
< 2 1708 (39) 1064 (40) 644 (37) 
2-5 1563 (36) 956 (36) 607 (35) 
> 5 1110 (25) 612 (23) 498 (29) 
LV Ejection Fraction, %  31 ± 7 31 ± 7 32 ± 8 
>40, n(%) 97 (2) 50 (2) 47 (3) 
≤40 and >30, n(%) 2347 (54) 1401 (53) 946 (54) 
≤30, n(%) 1937 (44) 1181 (45) 756 (43) 
 
Baseline vital signs    
BMI, kg/m2 27 ± 5 27 ± 5 27 ± 5 
BP, mmHg    
Systolic 129 ± 17 129 ± 17 128± 17 
Diastolic 76 ± 9 76 ± 9 76 ± 9 
    Pulse pressure 52 ± 13 53 ± 13 52 ± 13 
Heart rate, beats/min 72 ± 12 70 ± 11 74 ± 13 
 
Laboratory measurements 
   
Total cholesterol, mmol/L 5.3 ± 1.1 5.4 ± 1.1 5.1 ± 1.1 
Serum creatinine, µmol/L    112 ± 29 111 ± 29 115 ± 28 
eGFR, ml/min/1.73m2 60 ± 17 61 ± 17 58 ± 15 
eGFR <60, n(%) 2302 (53) 1295 (49) 1007 (58) 
NT-proBNP, pmol/L [median  
( IQR)] 
158 (21-295) 121(9-233)  226 (63-390) 
 
Medical history, n (%) 
   
Myocardial infarction 2350 (54) 1503 (574) 847 (484) 
Angina pectoris 2727 (62) 1610 (61) 1117 (64) 
CABG or PCI 1059 (24) 664 (25) 395 (23) 
Hypertension 2759 (63) 1622 (62) 1137 (65) 
Diabetes mellitus 1258 (29) 766 (29) 492 (28) 
Stroke 489 (11) 251 (10) 238 (14) 
Pacemaker 497 (11) 244 (9) 253 (15) 
ICD or CRT 160 (4) 99 (4) 61 (4) 
Peripheral arterial disease 529 (12) 307 (12) 222 (13) 
Current smoker 476 (11) 335 (13) 141 (8) 
 
Medication, n (%) 
 
Diuretic (not aldosterone antagonist) 3900 (89) 2273 (86) 1627 (93) 
ACE inhibitor or ARB 4065 (93) 2459 (93) 1606 (92) 
Aldosterone antagonist 1785 (41) 994 (38) 791 (45) 
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All patients 
(N= 4381) 
Without AF 
(n=2632) 
AF  
(n=1749) 
Beta-blocker 3263 (75) 1981 (75) 1282 (73) 
Digitalis glycoside 1449 (33) 553 (21) 896 (51) 
Long-acting nitrate  1353 (31) 861 (33) 492 (28) 
Anti-arrhythmic drug  569 (13) 241 (9) 328 (19) 
Antiplatelet therapy 2578 (59) 1918 (73) 660 (38) 
Anticoagulant therapy  1497 (34) 431 (16) 1066 (61) 
Antiplatelet or anti-coagulant therapy  3895 (89) 2276 (87) 1619 (93) 
Antidiabetic drugs   
insulin 337 (8) 229 (9) 108 (6) 
oral hypoglycaemic 724 (17) 448 (17) 276 (16) 
 All values are given in mean ± standard deviation unless stated otherwise. AF:atrial fibrillation;  n(%): number of 
observations (percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; 
PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation 
therapy; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker. 
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Table 6-4. Baseline characteristics according to stroke outcome for patients 
without atrial fibrillation and available NT-proBNP measurement only. 
 
All patients 
(N=2632) 
Non-Stroke 
(n=2538) 
Stroke  
(n=94) 
Demographics    
Age (year) 71 ± 8 71 ± 8 71 ± 8 
<60, n(%) 148 (6) 143 (6) 5 (5) 
60 - <65, n(%) 436 (17) 421 (17) 15 (16) 
65 - <75, n(%) 1157 (44) 1120 (44) 37 (39) 
≥75, n(%) 891 (34) 854 (34) 37 (40) 
Female, n(%) 665 (25) 648 (26) 17 (18) 
NYHA class, n (%)  
II 1222 (46) 1182 (47) 40 (23) 
III 1370 (52) 1319 (52) 51 (54) 
IV 40 (2) 37 (2) 3 (3) 
   Duration of heart failure (year),  
   n (%) 
   
< 2 1064 (40) 1022 (40) 42 (45) 
2-5 956 (36) 928 (37) 28 (30) 
> 5 612 (24) 588 (23) 24 (26) 
LV Ejection Fraction, %  31 ± 7 31 ± 7 31 ± 8 
>40, n(%) 50 (2) 48 (2) 2 (2) 
≤40 and >30, n(%) 1401 (53) 1357 (53) 44 (47) 
≤30, n(%) 1181 (45) 1133 (45) 48 (51) 
 
Baseline vital signs    
BMI, kg/m2 27 ± 5 27 ± 5 27 ± 5 
BP, mmHg    
Systolic 129 ± 17 129 ± 17 129 ± 17 
Diastolic 76 ± 9 76 ± 9 78 ± 9 
    Pulse pressure 53 ± 13 53 ± 13 51 ± 13 
Heart rate, beats/min 70 ± 11 70 ± 11 73 ± 12 
 
Laboratory measurements 
   
Total cholesterol, mmol/L 5.4 ± 1.1 5.4 ± 1.1 5.2 ± 0.9 
Serum creatinine, µmol/L    111 ± 29 111 ± 29 113 ± 29 
eGFR, ml/min/1.73m2 61 ± 17 61 ± 17 61 ± 18 
eGFR <60, n(%) 1295 (49) 1245 (49) 50 (53) 
NT-proBNP, pmol/L [median (IQR)] 121 (9-233)  119 (8-230) 169 (41-297) 
 
Medical history, n (%) 
   
Myocardial infarction 1503 (57) 1448 (57) 55 (59) 
Angina pectoris 1610 (61) 1560 (610 50 (53) 
CABG or PCI 664 (25) 644 (25) 20 (21) 
Hypertension 1622 (62) 1566 (62) 56 (60) 
Diabetes mellitus 766 (29) 732 (29) 34 (36) 
Stroke 251 (10) 236 (9) 15 (16) 
Pacemaker 244 (9) 233 (9) 11 (12) 
ICD or CRT 99 (4) 95 (4) 4 (4) 
Peripheral arterial disease 307 (12) 295 (12) 12 (13) 
Current smoker 335 (13) 322 (13) 13 (14) 
 
Medication, n (%) 
 
Diuretic (not aldosterone antagonist) 2273 (86) 2191 (86) 82 (87) 
ACE inhibitor or ARB 2459 (93) 2372 (93) 87 (93) 
Aldosterone antagonist 994 (38) 955 (38) 39 (41) 
Beta-blocker 1981 (75) 1913 (75) 68 (72) 
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All patients 
(N=2632) 
Non-Stroke 
(n=2538) 
Stroke  
(n=94) 
Digitalis glycoside 553 (21) 534 (21) 19 (20) 
Long-acting nitrate  861 (33) 823 (32) 38 (40) 
Anti-arrhythmic drug  241 (9) 232 (9) 9 (10) 
Antiplatelet therapy 1918 (73) 1848 (73) 70 (74) 
Anticoagulant therapy  431 (16) 414 (16) 17 (18) 
Antiplatelet or anticoagulant therapy  2276 (86) 2192 (86) 84 (89) 
Antidiabetic drugs   
insulin 229 (9) 215 (8) 14 (15) 
oral hypoglycaemic 448 (17) 437 (17) 11 (12) 
All values are given in mean ± standard deviation unless stated otherwise. AF:atrial fibrillation;  n(%): number of 
observations (percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; 
PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator;CRT: cardiac resyncronisation 
therapy; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker. 
 
6.3.2. Rates of stroke 
Patients with AF:   The median follow-up duration in patients with AF was 2.97 (IQR: 2.22-
3.49) years and 165 of these 3,531 patients experienced a stroke (16.8 per 1000 patient-
years). The 1, 2, and 3 year cumulative incidence function (CIF) rates of stroke were 1.7 
(95%CI: 1.3-2.1), 2.8 (95%CI: 2.3-3.4), and 4.2 (95%CI: 3.6-4.9) %, respectively (Figure 6-1).  
The rate of patients treated with an anticoagulant was 14.0 per 1000 patient-years and; in 
those not treated it was 21.7 per 1000 patient-years.  In patients treated with an 
anticoagulant, the 1, 2, and 3 year CIF rates of stroke were 1.3 (95%CI: 0.9-1.8), 2.3 (95%CI: 
1.7-3.0), and 3.6 (95%CI: 2.9-4.5) %, respectively (Figure 6-2); the corresponding CIF rates 
for patients not treated with an anticoagulant were 2.3 (95%CI: 1.6-3.2), 3.7 (95%CI: 2.7-
4.8), and 5.2 (95%CI: 4.1-6.4) %, respectively (Figure 6-2). 
The median follow-up period in the 1,749 patients with AF and a NT-proBNP measurement 
at baseline was 2.61 (IQR: 2.17-3.04) years; 86 of these patients experienced a stroke (rate 
20.3 per 1000 patient-years). 
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Figure 6-1. Cumulative incidence function plot of stroke by atrial fibrillation 
(AF) status at baseline (with death as competing risk). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2. Cumulative incidence function plot of stroke for chronic heart 
failure patients with atrial fibrillation (AF), according to anticoagulant 
treatment at baseline (with death as competing risk).  
 
 158 
Patients without AF:   The median follow-up duration in patients without AF was 3.18 (IQR: 
2.45- 3.98) years and 206 of these 6,054 patients experienced a stroke (11.1 per 1000 
patient-years). The 1, 2, and 3 year CIF rates of stroke were 1.2 (95%CI: 0.9-1.5), 2.2 (95%CI: 
1.9- 2.6), and 3.1 (95%CI: 2.7-3.6) %, respectively (Figure 6-1).   
The median follow-up period in the 2,632 patients without AF but with a NT-proBNP 
measurement at baseline was 2.78 (IQR: 2.30-3.12) years; 94 of these patients experienced 
a stroke (rate 13.5 per 1000 patient-years). 
 
Incident AF and risk of stroke: In GISSI-HF, 3,138 patients did not have AF at baseline.  Of 
these, 85 patients (2.7%) experienced a stroke.  Of these 85 patients, 13 (15.3%) developed 
new AF before the occurrence of their stroke; the number of patients with a stroke without 
preceding AF was 72 (84.7%).  Nineteen patients (22.4%) with an incident stroke had new 
AF found before or after their stroke.    
In CORONA, 2,916 patients did not have AF at baseline.  Of these, 121 patients (4.1%) 
experienced a stroke.  Of these 121 patients, 9 (7.4%) developed new AF before the 
occurrence of their stroke; the number of patients with a stroke without preceding AF was 
112 (92.6%).  Fourteen patients (11.6%) with an incident stroke had new AF reported 
before or after their stroke. 
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6.3.3. Predictors of stroke in patients without AF – model without NT-
proBNP 
Figure 6-3 and Table 6-5 (unadjusted analysis) show the relationship between baseline 
variables and risk of stroke.  Table 6-6 shows the independent predictors of stroke (without 
inclusion of NT-proBNP).  The 5 variables which were significant in the multivariable model 
did not include blood pressure or ejection fraction.  The model in Table 6-6 can be used to 
calculate an individual’s risk of stroke as described the footnote of the table.  
 
Table 6-5. Exploratory unadjusted univariable analysis for outcome of stroke 
in patients without atrial fibrillation. 
Variables HR (95% CI) p-value 
Age (per 10 year increase) 1.48 (1.34-1.79) <0.001 
Female sex 0.84 (0.60-1.18) 0.313 
Heart rate (per 1bpm up to 70)* 1.03 (0.99-1.05) 0.056 
Systolic blood pressure (per 1mmHg increase) 1.00 (0.99-1.01) 0.962 
LVEF (per 5% increase up to 40%)† 0.87 (0.71-1.06) 0.172 
Creatinine (per 1 µmol/L increase up to 350)† 1.01 (1.00-1.01) 0.001 
BMI (per 5kg/m2 increase up to 30)† 0.73 (0.59-0.90) 0.003 
NYHA class (III & IV vs. I & II) 1.83 (1.39-2.41) <0.001 
HF duration (> 5 years vs. ≤ 5 years) 1.22 (0.88-1.68) 0.228 
Current smoker 1.04 (0.71-1.53) 0.828 
Coronary heart disease (angina, MI, revascularisation, CABG, 
IHD) 
1.65 (1.21-2.24) 0.001 
Peripheral artery disease 1.73 (1.16-2.59) 0.007 
Previous Stroke 2.19 (1.45-3.30) <0.001 
Hypertension 1.16 (0.88-1.54) 0.287 
Insulin treated diabetes 1.74 (1.14-2.66) 0.011 
Cholesterol 0.90 (0.79-1.02) 0.107 
NT-proBNP (log)‡ 1.29 (1.13-1.46) <0.001 
Significant level at conventional p<0.05 in bold. LVEF indicates left ventricular ejection fraction; BMI: body mass index; 
NYHA: New York Heart Association; MI: myocardial infarction; CABG: coronary arter bypas graft; IHD: ischaemic heart 
disease.  
* Heart rate was truncated to 70bpm to avoid co-linearity with possible atrial fibrillation. 
† The values were truncated to the level displayed due to individual variable’s non-linearity. 
‡  Univariable analysis for log NT-ProBNP was performed for patients with NT-ProBNP measurements only. 
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Figure 6-3. The relationship between baseline variables and risk of stroke in 
patients without atrial fibrillation. 
Variables are described in quintiles. AF indicates atrial fibrillation; BMI: body mass index; BP: blood 
pressure; LV: left ventricle; and NT-proBNP: N-terminal pro B-type natriuretic peptide. 
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Table 6-6. “Best clinical model” for stroke based on forward stepwise Cox 
proportional hazard regression. 
Variables Hazard 
ratio 
Lower 
95%CI 
Upper 
95%CI 
Χ2-
value 
Coefficients Standard 
error 
P-
value 
 Age (per 10 years 
increase) 
1.34 1.18 1.63 16.2 0.331 0.082 <0.001 
NYHA class (NYHA III and 
IV)  
1.60 1.21 2.12 10.8 0.472 0.143 0.001 
Diabetes treated with 
insulin  
1.87 1.22 2.88 8.1 0.626 0.220 0.004 
BMI (per 5kg/m2 increase 
up to 30) 
0.74 0.60 0.91 7.9 -0.301 0.107 0.005 
Previous Stroke 1.81 1.19 2.74 7.8 0.591 0.212 0.005 
There were no missing data for the variables included in the model above. Variables arranged by descending X2-value. 
See the supplement for explanation of how to use coefficients of the variables to calculate individual patient’s risk score 
of stroke. BMI: body mass index; NYHA: New York Heart Association. 
 
Examples of risk score calculation using the model presented in Table 6-6:  
This example illustrates the use Table 6-6 and associated Figures 6-4 and 6-5, to calculate the risk score of stroke in 
individual patients. 
For example, consider a patient aged 70 years in NYHA functional class II with a BMI of 25 kg/m2 and had a previous 
stroke. Using the model coefficients in Table 6-6, each multiplied by 10, this patient’s risk score for stroke is: (3.31 x 7) + 
[(-3.01) x 5] +  5.91 = 14.03. Note that age is in decades, hence 70 becomes 7; BMI is in steps of 5, BMI of 25 becomes 5.  
 
Figure 6-4 shows the distribution of the risk score for stroke.  Figure 6-5 shows the CIF plot 
for stroke with patients classified into 3 equal sized groups according to risk score.  The 
number of strokes in tertiles 1, 2 and 3 were 36, 66 and 104 respectively.  The 1, 2 and 3 
year CIF rates of stroke in the two higher risk tertiles were; tertile 2: 1.1 (95%CI: 0.7-1.7), 
2.0 (95%CI: 1.4- 2.7), and 2.9 (95%CI: 2.2-3.7) %, respectively, and tertile 3: 1.8 (95%CI: 1.3-
2.4), 3.5 (95%CI: 2.8-4.4), and 5.0 (95%CI: 4.1-6.1) %, respectively.  The 1, 2 and 3 year 
Kaplan-Meier rates of stroke in the two higher risk tertiles were;  tertile 2: 1.2 (95%CI: 0.8-
1.8), 2.1 (95%CI: 1.6- 2.9), and 3.2 (95%CI: 2.4-4.1) %, respectively, and tertile 3: 1.9 (95%CI: 
1.4-2.6), 4.1 (95%CI: 3.2-5.1), and 5.9 (95%CI: 4.8-7.2) %, respectively (Figure 6-6).  Patients 
in risk-tertile 3 had an overall stroke rate of 19.8 per 1000 patient-years.  
Figure 6-7 shows the model’s goodness-of-fit by comparing observed and expected 
probabilities of stroke at 3 years with the patients divided into tertiles.  The calibration was 
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also assessed using the Hosmer-Lemeshow test, which was p=0.122.  Model discrimination 
was evaluated using the overall C-index, which was 0.75 (95%CI: 0.62-0.86). 
 
Figure 6-4. Distribution of the risk score for stroke- best clinical model (i.e. 
model without NT-proBNP). 
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Figure 6-5. Cumulative incidence function plot for stroke by tertiles of their 
risk scores in patients without atrial fibrillation- best clinical model (i.e. model 
without NT-proBNP [with death as competing risk]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-6. Kaplan-Meier plot for stroke by tertiles of their scores in  
patients without atrial fibrillation- best clinical model (i.e model without NT-
proBNP). 
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Figure 6-7. Comparison of observed and expected strokes rates after 3 years 
for patients categorised by tertiles of risk scores derived from the best clinical 
model (i.e. without NT-proBNP).  
Observed indicates as read from each Kaplan-Meier tertile group at 3 years; expected, as estimated from Cox model in 
each tertile. 
 
 
6.3.4. Predictors of stroke in patients without AF - model including NT-
proBNP 
When NT-proBNP was added to the 5 predictive variables described above, only 2 of the 
previous variables, along with log NT-proBNP, remained independent predictors – diabetes 
treated with insulin and history of stroke (Table 6-7).  The model in Table 6-7 can be used 
to calculate an individual’s risk of stroke as described in the footnote for the table.  
Figure 6-8 shows the distribution of the risk score for stroke. Figure 6-9 shows CIF plots for 
stroke with patients classified into 3 equal sized groups according to risk score.  The number 
of strokes in tertiles 1, 2 and 3 were 16, 34 and 44, respectively.  The 1, 2 and 3 year CIF 
rates of stroke in the two higher risk tertiles were; tertile 2: 1.4 (95%CI 0.7-2.3), 2.5 (95%CI: 
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1.6-3.7), and 3.8 (95%CI: 2.6-5.4) %, respectively; and tertile 3: 1.9 (95%CI: 1.2-3.0), 3.3 
(95%CI: 2.3-4.6), and 5.9 (95%CI: 4.2-7.9) %, respectively.  Patients in risk-tertile 3 had an 
overall stroke rate of 22.9 per 1000 patient-years.   Figure 6-10 shows the model’s goodness 
of fit, as described above.  Calibration was good (p=0.644 for the Hosmer-Lemeshow test).  
The overall C-index for the model including NT-proBNP was 0.80 (95%CI: 0.61-0.94) which 
was not significantly different from the overall C-index for the model without NT-proBNP 
(p=0.185).  
 
Table 6-7. “Final model” for stroke based on forward stepwise Cox 
proportional hazard regression, adding NT-proBNP to independent predictors 
identified in Table 6-6 (n=2,632). 
Variables Hazard 
ratio 
Lower 
95%CI 
Upper 
95%CI 
Χ2-
value 
Coefficients Standard 
error 
P-
value 
Log NT-proBNP 1.32 1.11 1.57 10.4 0.280 0.087 0.001 
Diabetes treated with insulin 2.09 1.19 3.70 6.5 0.739 0.290 0.011 
Previous Stroke 1.92 1.10 3.35 5.3 0.653 0.283 0.021 
There were no missing data for the variables included in the model above. The model as applied to subset of patients 
with NT-proBNP measurement at baseline only. Variables arranged by descending X2-value.  
 
For patient with available NT pro-BNP measurement, risk score for stroke can be estimated using coefficients in Table 6-
7 and Figure 6-9, using similar steps described the footnote for Table 6-6. 
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Figure 6-8. Distribution of the risk score for stroke derived from model 
including NT-proBNP. 
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Figure 6-9. Cumulative incidence function plot for stroke by tertiles of their 
risk scores in patients without atrial fibrillation- model including NT-proBNP 
(with death as competing risk). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-10. Comparison of observed and expected strokes rates after 3 years 
for patients categorised by tertiles of risk scores derived from model including 
NT-proBNP.  
Observed indicates as read from each Kaplan-Meier tertile group at 3 years; expected, as 
estimated from Cox model in each tertile. 
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6.3.5. Validation of risk model 
We tested the predictive model in the Candesartan in Heart Failure: Reduction in Mortality 
and morbidity (CHARM) HF-REF trials.110, 222  These trials included 1,227 patients with and 
3,349 patients without AF.  The median follow-up was 40 months.  There were 59 strokes 
in the patients with AF and 107 strokes in those without AF, giving stroke rates in patients 
with and without AF 18.3 and 11.4 per 1000 patients-years, respectively.  We tested the 
model without NT-proBNP as natriuretic peptides were not measured in CHARM.  
Using the same analytical approach (Table 6-8, Figures 6-11 and 6-12), the 1, 2 and 3 year 
CIF rates of stroke in the two higher risk tertiles were; tertile 2: 1.4 (95%CI: 0.8-2.2),  1.8 
(95%CI: 1.1-2.7) and 2.7 (95%CI: 1.9-3.8) %, respectively; and tertile 3: 1.5 (95%CI: 0.9-2.4), 
3.1 (95%CI: 2.2-4.2) and 4.3 (95%CI: 3.2-5.6)%, respectively.  Patients in risk-tertile 3 of the 
validation model derived from CHARM HF-REF trials had an overall stroke rate of 17.9 per 
1000 patient-years.  The overall C-index for the model was 0.71 (95%CI: 0.52-0.87).  
 
Table 6-8. Validation of “best clinical model” using CHARM-REF for patients 
without atrial fibrillation (n=3,349). 
Variables Hazard 
ratio 
Lower 
95%CI 
Upper 
95%CI 
Χ2-
value 
P-value Coefficients derived 
from CORONA-GISSI 
Age (per 10 year increase) 1.63 1.34 1.97 24.2 <0.001 0.331 
Previous Stroke 2.02 1.18 3.45 6.7 0.010 0.591 
Insulin treated diabetes 1.59 0.89 2.86 2.4 0.121 0.626 
BMI (per 5kg/m2 up to 30) 0.86 0.66 1.16 1.0 0.321 -0.301 
NYHA (III and IV) 1.04 0.70 1.56 <0.1 0.840 0.472 
See footnote of Table 6-6 for explanation on how to use the coefficients to predict individual patient’s risk of stroke. AF 
indicates atrial fibrillation. AF defined as medical history of AF or baseline ECG that confirmed AF; BMI: body mass index; 
NYHA: New York Heart Association.  
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Figure 6-11. Validation using CHARM HF-REF, for patients without atrial 
fibrillation: Distribution of the risk score for stroke- best clinical model (i.e. 
model without NT-proBNP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-12. Validation using CHARM HF-REF, for patients without atrial 
fibrillation: Cumulative incidence function plot for stroke by tertiles of their 
risk scores based on ‘best clinical model’, accounting death as competing risk. 
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6.4. Discussion 
We confirmed that heart failure patients with AF are at high risk of stroke, with an average 
incidence rate of 1.6% per year, despite anticoagulant treatment in 62% of the patients.   
Patients without AF, overall, had a lower, but still substantial, risk of 1.2% per year.  
However, a small number of demographic and clinical variables identified a subset of these 
patients without AF who were at greater risk.  Specifically, patients in the upper tertile of 
the risk score had a rate of stroke that approximated to the risk of patients with AF and not 
treated with an anticoagulant in the two trials analysed (2.0% per year versus 2.2% per 
year, respectively).   
The risk of stroke in our patients without AF was similar to the risk of stroke in WARCEF 
patients treated with aspirin which was approximately 1.4% per year,211  especially taking 
account of the fact that 16% of our patients were treated with an oral anticoagulant (and 
82% with an anticoagulant or antiplatelet agent) at baseline.  A lower thrombo-embolism 
rate of 1.0% per year was reported by the SCD-HeFT investigators in systolic heart failure 
patients without AF (56 of the 71 events were a stroke).297  This lower rate of events in SCD-
HeFT might be explained by the higher use of antithrombotic therapy at baseline (warfarin 
in 28% and aspirin in 59%) in that study.  In our patients with AF, the risk of stroke or 
systemic embolism was less that in AF patients with heart failure treated with warfarin in 
RELY-AF199 (1.9% per year) and ROCKET-AF200 (2.1%), as well as patients with left ventricular 
systolic dysfunction in ARISTOTLE201 (1.8%).  This is likely explained by the requirement for 
patients in these trials to have additional risk factors for stroke.  These previous reports 
suggest that our findings are at least generalisable to other patients with heart failure in 
clinical trials.  
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Interestingly, left ventricular ejection fraction was not predictive of stroke in our study, 
despite some, but not all, prior studies suggesting otherwise.193, 315  These prior studies did 
not, however, differentiate between patients with and without AF.  Furthermore, in our 
study, neither systolic blood pressure nor history of hypertension, were predictive of 
stroke.  Although this is at variance with studies in other patient populations, it is consistent 
with the “reverse epidemiology” of heart failure and the recognised association between 
higher blood pressure and better outcomes in this condition.316-318  A similar reverse 
epidemiologic relationship was noted between both body mass index and LDL cholesterol 
and stroke.317, 318 
NT-proBNP was measured in approximately half of our patients.  NT-proBNP was an 
independent predictor of stroke when added to the variables described above.  Indeed, the 
resultant model contained only 2 other predictive variables.  However, the addition of NT-
proBNP did not improve the model c-statistic significantly.  Although the value of NT-
proBNP as a predictor of adverse outcomes in heart failure, to our knowledge, this is the 
first demonstration that NT-proBNP is a predictor of stroke in patients without AF.  This 
finding adds to recent observations that NT-proBNP is an independent predictor of stroke 
risk in patients with AF.319-321 
A particular strength of this study is the validation of our predictive model in another 
dataset.  Consequently, our findings have clear clinical implications.  With a small number 
of routinely collected clinical variables it is possible to identify patients with heart failure 
but without AF who are at sufficiently high risk of stroke potentially to justify 
anticoagulation. Clearly, there is as yet no trial evidence to justify such treatment but our 
findings suggest a means of identifying patients for such a trial.  It may even be that 
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measurement of plasma NT-proBNP concentration on its own may be sufficient to risk 
stratify patients with respect to stroke and this possibility should be investigated further. 
The focus of our analysis was on patients without AF as there are already well established 
risk scores for stroke in patients with AF (e.g. CHADS2,187 CHA2DS2-VASc186).  Moreover, 
guidelines recommend an oral anticoagulant for most patients with both AF and heart 
failure47, 48, 71, 166-168 – these patients are usually elderly, most have a history of 
hypertension, and many have vascular disease and diabetes i.e. the vast majority have a 
CHA2DS2-VASc score of at least 2.  Interestingly, the predictors of stoke in patients with 
heart failure, not in AF, are somewhat different than the remainder of CHA2DS2-VASc i.e. 
age, diabetes, stroke/ TIA/ thrombo-embolism, vascular disease and female sex.  Although 
age, diabetes and prior stroke were also in our model, hypertension and vascular disease 
were not.  In addition, NYHA class III/IV and decreasing BMI were also predictive.  We don’t 
think these differences occurred by chance as we found them in two independent cohorts.  
Moreover, our model for this different set of variables had a high overall c-index for 
prediction of stroke (and one that was higher than usually found for CHADS2 or CHA2DS2-
VASc).186, 188  We think it is important to identify the most accurate predictors of stroke in 
patients with heart failure as we really should be thinking about testing the potential value 
of targeted anticoagulant therapy in patients at the highest risk of stroke. 
Limitations- The number of strokes overall was modest but greater than in any prior study. 
Each of the two trials included had specific selection criteria and, hence, our findings may 
not be generalisable to all patients with heart failure, particularly patients with HF-PEF who 
were largely excluded from this analysis.  Although our data suggest that only the minority 
of strokes are related to incident AF, detection of new onset AF was suboptimal.  New onset 
AF was collected systematically in GISSI-HF but not in CORONA.  However, even in GISSI-
 173 
HF, paroxysms of AF may not have been detected as ambulatory monitoring was not 
performed.  As it is well known that subclinical AF is common in heart failure and it is 
possible (or even likely) that many more strokes might be related to unrecognised/ 
undetected AF.  However, waiting for the development of clinically recognized AF before 
employing anticoagulant therapy may not the optimum preventative strategy.  An 
alternative approach might be to screen for subclinical AF but how to best do this is 
uncertain: Should this be done with ambulatory monitoring or an implanted device? If the 
former, how often would this screening have to be repeated?  How much would either 
strategy cost?  Moreover, as described above, there are other reasons why patients with 
heart failure are at risk of thromboembolic and other types of ischaemic stroke.  We believe 
that our data support the possibility of a broader preventive role for anticoagulant therapy 
in heart failure patients in sinus rhythm, especially as new agents with a lower risk of 
bleeding are available.  Of course this hypothesis needs to be tested prospectively in a 
randomised trial.  NT-proBNP was only available in about half of the patients and was 
unavailable in our validation cohort.  
In conclusion, we found that a high-risk subset of a third of HF patients without AF have a 
risk of stroke that is at least as great as in HF patients with AF.  This high-risk subset can be 
identified using simple clinical variables.  These risks of stroke in these patients might be 
reduced by treatment with an oral anticoagulant.  This hypothesis needs to be tested in a 
clinical trial. 
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Chapter 7  
Development and validation 
of predictive model for 
stroke in patients with heart 
failure and preserved 
ejection fraction but without 
atrial fibrillation 
7.1. Background 
Up to half of patients with heart failure have a preserved ejection fraction (HF-PEF).93, 123, 
124  These patients differ from heart failure patients with reduced ejection fraction (HF-REF) 
in several respects - they tend to be older, commonly women and are more likely to have 
a history of hypertension and atrial fibrillation (AF); they are less likely to have coronary 
artery disease.  Although mortality rates may not be as high as in patients with HF-REF, the 
prognosis of HF-PEF patients is considerably worse than that of patients with hypertension, 
angina pectoris, atrial fibrillation or diabetes in the same age range and gender 
distribution.132  The single most common cause of hospital admission in these patients is 
worsening heart failure and this, along with death, has been the focus of therapeutic 
interventions in HF-PEF.132  However, given the demographic profile and co-morbidity 
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cluster characterising these patients, stroke may also be a clinically important outcome in 
HF-PEF.  Little is known about the incidence of stroke in HF-PEF, particularly in the absence 
of AF.  
To investigate this further, we therefore combined and analysed patient-level data from 
two large HF-PEF trials, the Candesartan in Heart failure Assessment of Reduction in 
Mortality and Morbidity- Preserved trial (CHARM-Preserved, ClinicalTrials.gov 
NCT00634712)141 and the Irbesartan in Heart Failure with Preserved Systolic Function trial 
(I-Preserve, NCT00095238),139 to provide a robust estimate of the current incidence of 
stroke in patients with HF-PEF, with and without AF.  We also tested a simple clinical model, 
developed in Chapter 6 for the HF-REF population,292 for predicting the risk of stroke in 
patients without AF in this pooled dataset.  Easy identification of those at highest risk of 
stroke coupled with the availability of new oral anticoagulants with a low risk of bleeding 
might allow for a stroke prevention strategy which has an acceptable benefit/ risk balance 
in patients with HF without AF. 
 
7.2. Methods 
7.2.1. Study populations 
In order to have a sufficiently large number of HF-PEF patients without AF for analysis, we 
pooled data from the CHARM-Preserved (NCT00634712) and I-Preserve (NCT00095238) 
trials.  Each was a randomised, double-blind, placebo-controlled, multicentre trial and was 
approved by the appropriate institutional review boards.  CHARM-Preserved and I-Preserve 
enrolled 3,023 and 4,128 patients, respectively.139, 141  Together, these trials included a 
broad spectrum of patients with chronic HF-PEF.   
 176 
CHARM-Preserved enrolled patients aged ≥18 years in New York Heart Association (NYHA) 
functional class II to IV with a left ventricular ejection fraction (LVEF) >40% (although for 
the purposes of this study we included only patients with a LVEF ≥45%).  I-Preserve enrolled 
patients aged ≥60 years in NYHA functional class II to IV with a LVEF ≥45% and corroborating 
ECG, echocardiographic or radiologic evidence.  In addition, patients had to have been 
hospitalised for heart failure in the preceding 6 months or, if not, had to be in NYHA 
functional class III or IV.  N-terminal pro B-type natriuretic peptide (NT-proBNP) was 
measured at baseline in I-Preserve but not in CHARM-Preserved.  In CHARM-Preserved, 
patients were randomly assigned to candesartan (target dose of 32mg once daily) or 
matching placebo.141  In I-Preserve, patients were randomised to irbesartan (target dose 
300mg once daily) or matching placebo.139  The primary outcome in CHARM-Preserved was 
the composite of cardiovascular death or HF hospitalisation141, 322 and in I-Preserve it was 
the composite of all-cause mortality or cardiovascular hospitalisation.139, 323  The median 
follow-up in CHARM-Preserved was 3.1 years and in I-Preserve it was 4.1 years.  Study 
treatment did not reduce the risk of the primary outcome or the risk of stroke in either 
trial.139, 141 
 
 
7.2.2. Incident stroke 
Incident strokes were centrally adjudicated by an independent endpoint committee in each 
trial using similar definitions and stroke was part of the primary or secondary composite 
cardiovascular outcomes in both trials.139, 141, 322, 323  Stroke in both trials was defined as a 
persistent (≥24 hours) disturbance of focal neurological function resulting in symptoms 
thought to be due to cerebral infarction, evidence of haemorrhage or for which there is no 
certain aetiology.139, 141, 322, 323 
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7.2.3. Incident AF 
The occurrence of AF was retrospectively collected in CHARM-Preserved during the trial 
close-out using a specifically designed case-report form.  Incident AF was recorded 
prospectively in I-Preserve, using a specific case-report form.  
 
7.2.4. Statistical methods 
We included only patients with a LVEF of ≥45% (all 4128 patients in I-Preserve and 2573 of 
the 3023 in CHARM-Preserved).  Patients with AF were defined as those with either AF 
confirmed on their baseline ECG or with a history of AF.  The remaining patients were 
defined as those “without AF”.  Descriptive statistics were used to describe the pooled 
patient population from both trials and to compare these two sub-groups, using means 
(standard deviation [SD]) or medians (inter-quartile range [IQR]) for continuous variables 
and count (percentage) for categorical variables.  
The incidence rate of stroke (per 1000 patient-years) was calculated over the trial follow-
up period and was compared between the AF and no AF sub-groups.  Cumulative incidence 
functions of stroke occurrences were estimated accounting for competing risk of death.290, 
291.  To satisfy the assumption of the independence of stroke events, recurrent stroke 
events in a patient after randomisation were not included in the analysis.   
Continuous variables (e.g. body mass index, ejection fraction and creatinine level) were 
assessed by visual inspection of restricted cubic splines to identify potential non-linear 
effects.  Uni- and multivariable predictors of the risk for stroke were evaluated using Cox 
proportional hazards regression analysis in patients without AF.  We excluded patients with 
AF from the multivariable modelling because AF itself confers sufficient justification for oral 
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anticoagulant treatment for stroke prevention.  Two separate multivariable analyses for 
stroke were created.  First, a “HF-PEF stroke model” was created using established 
predictors of ischaemic stroke296, 297, 311-313, 324 with the addition of variables that were 
significant (p<0.05) in univariable analysis of our dataset.  The final list of variables included 
was: age, sex, LVEF, NYHA class III/IV, body mass index (BMI), creatinine level, systolic blood 
pressure, history of stroke, hypertension and diabetes treated with insulin.  Second, we 
applied a recently published multivariable predictive model for stroke in patients with HF-
REF (“HF-REF stroke model”) in our HF-PEF cohort.292   The five variables included in this 
model were: age, body mass index (BMI), NYHA class, history of stroke and diabetes treated 
with insulin.  There were no data missing for the baseline variables used by either model.  
We calculated the hazard ratio (HR) and corresponding 95 percent confidence intervals 
(95%CI) to express the hazard rate of stroke.  The statistical contribution of each variable 
to the predicted risk of stroke was assessed by the chi-square statistic.  In order to be 
consistent with the previous chapter, Chapter 6,292 we compared each model’s 
discrimination ability using estimates of overall C-index for the Cox regression models 
according to method of Pencina and D’Agostino,240 as outlined by Liu et al.241  We pre-
determined that we would proceed using only the HF-REF stroke model if the overall C-
indices for the two models were not meaningfully different.  
The coefficients from statistically significant variables in the final multivariable model were 
used to calculate an individual patient’s risk score for stroke.  The cumulative incidence 
function for stroke was estimated using competing risk techniques290, 291 according to 
tertiles of risk score.  Where appropriate, the corresponding Kaplan-Meier curves for 
occurrence of stroke were also plotted.  
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Final model calibration and the ability to separate patients into risk groups were assessed 
by observing predicted compared with observed outcomes in tertiles, and by using the 
Hosmer-Lemeshow goodness-of-fit test.  The model’s discrimination abilities were 
evaluated by the overall C-index.240, 241  
Finally, we validated the preferred risk model in a third HF-PEF trial: the Treatment of 
Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) 
[NCT00094302].140  TOPCAT included patients aged ≥50 years with at least one symptom 
and sign of heart failure, a LVEF ≥45% and either a hospitalisation with heart failure in the 
preceding 12 months or an elevated NT-proBNP or BNP.  
All analyses were undertaken using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA). 
 
7.3. Results 
Of the 6,701 patients with a LVEF ≥45%, 2,025 (30%) had a history of AF or had AF on their 
baseline ECG; and 4,676 patients (70%) had no AF.  
 
7.3.1. Baseline characteristics 
The baseline characteristics of patients with and without AF are shown in Table 7-1.  The 
baseline characteristics of patients without AF, according whether or not they experienced 
a subsequent stroke, are shown in Table 7-2. 
 
Patients with and without AF:   Patients without AF were younger and were more likely to 
have a history of coronary artery disease and hypertension, compared to patients with AF.    
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Patients without AF also had a slightly higher systolic blood pressure but had a lower mean 
serum creatinine and much lower median NT-proBNP level than patients with AF.  There 
were also notable differences in medical therapy, particularly in use of antiplatelet therapy 
(69% of patients without AF versus 39% of those with AF) and anticoagulant treatment (6% 
versus 57%, respectively), but also in relation to diuretics, mineralocorticoid receptor 
antagonists, antiarrhythmic agents and digoxin. 
 
Patients without AF- with and without incident stroke during follow-up:  Among patients 
without AF, those who experienced a stroke (compared with those who didn’t), were older, 
more likely to have a history of diabetes, hypertension and stroke and had worse NYHA 
functional class.  Patients experiencing stroke also had a higher systolic blood pressure, 
creatinine and NT-proBNP level.  Compared with those not experiencing stroke, those who 
did were less likely to be treated with lipid lowering therapy but more likely to be taking 
nitrates, anti-platelet therapy and insulin.  Very few patients in either group were treated 
with an oral anticoagulant (263 in total, 6%).  LVEF did not differ between patients with 
versus without stroke. 
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Table 7-1. Baseline characteristics according to atrial fibrillation (AF) status at 
baseline. 
 
All patients 
(N= 6701) 
Without AF  
(n= 4676) 
AF  
(n= 2025) 
Demographics, n (%)    
Age, year 70 ±9 69 ±9 72 ±8  
<65 1728 (26) 1400 (30) 328 (16) 
65 - <75 2858 (43) 2032 (44) 826 (41) 
≥75 2115 (32) 1244 (27) 871 (43) 
Race    
Caucasians 6212 (93) 4273 (91) 1939 (96) 
Afro-American/ Afro-Caribbean 190 (3) 155 (3) 35 (2) 
Other 299 (5) 248 (5) 51 (3) 
Female sex 3576 (53) 2542 (54) 1034 (51) 
NYHA class  
II 2461 (37) 1657 (35) 804 (40) 
III 4085 (61) 2918 (62) 1167 (58) 
IV 155 (2) 101 (2) 54 (3) 
Duration of heart failure, year       
< 2 year 3989 (60) 2778 (59) 1211 (60) 
2-5 year 1557 (23) 1110 (24) 447 (22) 
> 5 year 1116 (17) 764 (16) 353 (17) 
LV Ejection Fraction, % 58 ± 9 58 ± 9 58 ± 9 
 
Baseline vital signs    
BMI, kg/m2 30 ±6 30 ±6 29 ±6 
BP, mmHg    
Systolic 136 ±17 137 ±16 135±17 
Diastolic 78 ±10 79 ±10 78 ±10 
    Pulse pressure 58 ±14 58 ±14 58 ±14 
Heart rate, beats/min 71 ±11 71 ±11 73 ±12 
 
Laboratory measurements 
   
Serum creatinine, µmol/L    90 ±30 88 ±29 96 ±31 
Haemoglobin, g/ dL 14 ±2 14 ±2 14 ±2 
NT-proBNP*, pg/mL [median (IQR)] 339(134-964) 230(104-537) 951(428-1698) 
 
Medical history, n (%) 
   
Coronary heart disease 3898 (58) 2960 (63) 938 (46) 
Myocardial infarction 2025 (58) 1599 (34) 426 (21) 
Angina pectoris 3298 (49) 2517 (54) 781 (39) 
CABG or PCI 1377 (21) 1078 (23) 299 (15) 
Hypertension 5342 (80) 3779 (81) 1563 (77) 
Diabetes mellitus 1865 (28) 1313 (28) 552 (27) 
Stroke 621 (9) 379 (8) 242 (12) 
ICD  29 (0.4) 11 (0.2) 18 (1) 
Current smoker 3707 (55) 2597 (56) 1110 (55) 
 
Medication, n (%) 
 
Diuretic (loop or thiazide) 5160 (77) 3392 (73) 1768 (87) 
 Loop diuretic 3739 (56) 2278 (49) 1461 (72) 
Thiazide diuretic 1912 (29) 1481 (32) 431 (21) 
ACE inhibitor  1495 (22) 1020 (22) 475 (24) 
Aldosterone antagonist 1285 (19) 788 (17) 497 (25) 
Beta-blocker 3845 (57) 2761 (59) 1084 (54) 
Digitalis glycoside 1250 (19) 405 (9) 845 (42) 
Calcium channel blocker 2474 (37) 1809 (39) 665 (33) 
 182 
 
All patients 
(N= 6701) 
Without AF  
(n= 4676) 
AF  
(n= 2025) 
Anti-arrhythmic drug  615 (9) 179 (4) 436 (22) 
Long-acting nitrate  1948 (29) 1476 (32) 472 (23) 
Lipid lowering therapy 2342 (35) 1786 (38) 556 (28) 
Antiplatelet therapy 3985 (60) 3204 (69) 781 (39) 
Anticoagulant therapy  1405 (21) 263 (6) 1162 (57) 
Any antithrombotic (antiplatelet or anti-
coagulant therapy)  
5209 (78) 3408 (73) 1801 (89) 
Antidiabetic therapy (any) 1531 (23) 1096 (23) 435 (22) 
Insulin therapy 600 (9) 438 (9) 162 (8) 
    
Placebo arm in the original trial 3343 (50) 2322 (50) 1021 (50) 
All continuous values are given in mean ± standard deviation unless stated otherwise. AF: atrial fibrillation;  n(%): number 
of observations (percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; 
PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator; ACE: angiotensin converting 
enzyme. 
*Available in 3479 patients.  
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Table 7-2. Baseline characteristics according to stroke outcome in patients 
without atrial fibrillation (AF). 
 
Patients without AF 
(N=4676) 
Non-stroke 
(n=4505) 
Stroke  
(n=171) 
Demographics, n (%)    
Age, year 69 ±9 69 ±9  71 ±8 
<65 1400 (30) 1366 (30) 34 (20) 
65 - <75 2032 (43) 1956 (43) 76 (44) 
≥75 1244 (27) 1183 (26) 61 (36) 
Race    
Caucasians 4273 (91) 4116 (91) 157 (92) 
Afro-American/ Afro-Caribbean 155 (3) 148 (30 4 (7) 
Other 248 (5) 241 (5) 7(4) 
Female sex 2542 (54) 2459 (55) 83 (49) 
NYHA class  
II 1657 (35) 1612 (36) 42 (26) 
III 2918 (62) 2799 (62) 119 (70) 
IV 101 (2) 94 (2) 7 (4) 
Duration of heart failure, year       
<2 year 2778 (59) 2673 (59) 105 (61) 
2-5 year 1110 (24) 1076 (24) 34 (20) 
>5 year 764 (16) 734 (16) 30 (18) 
LV Ejection Fraction, % 58 ±9 58 ±9 57 ±8 
 
Baseline vital signs    
BMI, kg/m2 30 ±6 30 ±6 29 ±5 
BP, mmHg    
Systolic 137 ±16 137 ±16 140 ±15 
Diastolic 79 ±10 79 ±10 79 ±9 
    Pulse pressure 58 ±14 58 ±14 61 ±14 
Heart rate, beats/min 71 ±11 71 ±11 71 ±10 
 
Laboratory measurements 
   
Serum creatinine, µmol/L    88 ±29 88 ±29 96 ±33 
Haemoglobin, g/ dL 14 ±2 14 ±2 14 ±1 
NT-proBNP*, pg/mL  
(median ±IQR) 
230 (104-537) 225 (104-525) 426(170-1121) 
 
Medical history, n (%) 
   
Coronary heart disease 2960 (63) 2855 (63) 105 (61) 
Myocardial infarction 1599 (34) 1534 (34) 65 (38) 
Angina pectoris 2517 (54) 2429 (54) 88 (51) 
CABG or PCI 1078 (23) 1044 (23) 34 (20) 
Hypertension 3779 (81) 3632 (81) 147 (86) 
Diabetes mellitus 1313 (28) 1245 (28) 68 (40) 
Stroke 379 (8) 343 (8) 36 (21) 
ICD  11 (0.2) 11 (0.2) 0 (0) 
Current smoker 2597 (56) 2502 (56) 95 (56) 
 
Medication, n (%) 
 
Diuretic (loop or thiazide) 3392 (73) 3266 (73) 126 (74) 
 Loop diuretic 2278 (49) 2195 (49) 83 (49) 
Thiazide diuretic 1481 (32) 1430 (32) 51 (30) 
ACE inhibitor  1020 (22) 982 (22) 38 (22) 
Aldosterone antagonist 788 (17) 753 (17) 35 (20) 
Beta-blocker 2761 (59) 2663 (59) 98 (57) 
Digitalis glycoside 405 (9) 391 (9) 14 (8) 
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Patients without AF 
(N=4676) 
Non-stroke 
(n=4505) 
Stroke  
(n=171) 
Calcium channel blocker 1809 (39) 1747 (39) 62 (36) 
Anti-arrhythmic drug  179 (4) 173 (4) 6 (4) 
Long-acting nitrate  1476 (32) 1410 (31) 66 (39) 
Lipid lowering therapy 1786 (38) 1734 (38) 52 (30) 
Antiplatelet therapy 3204 (69) 3080 (68) 124 (73) 
Anticoagulant therapy  263 (6) 255 (6) 8 (5) 
Any antihthrombotic (antiplatelet or anti-
coagulant therapy  
3408 (73) 3278 (73) 130 (76) 
Antidiabetic therapy 1096 (23) 1040 (23) 56 (33) 
Insulin therapy 438 (9) 409 (9) 29 (17) 
    
Placebo arm in the original trial 2322 (50) 2231 (50) 91 (53) 
All continuous values are given in mean ± standard deviation unless stated otherwise. AF: atrial fibrillation;  n(%): number 
of observations (percentage of observations within the group); BMI: body mass index; CABG: coronary artery bypass graft; 
PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator; ACE: angiotensin converting 
enzyme. 
* Available in 2452 patients. 
 
 
 
 
 
7.3.2. Rates of stroke 
Patients with AF:   The median follow-up duration in patients with AF was 3.4 (IQR: 2.8-4.4) 
years and 125 of these 2,025 patients (6.2%) experienced a stroke (18.0 per 1000 patient-
years).  The 1, 2, and 3 year cumulative incidence function (CIF) rates of stroke were 1.4 
(95%CI: 1.0-2.0), 3.3 (95%CI: 2.6-4.1), and 5.0 (95%CI: 4.1-6.0) %, respectively. (Figure 7-1)  
The stroke rate in patients treated with an anticoagulant was 15.1 per 1000 patient-years 
and; in those not treated with an anticoagulant it was 21.9 per 1000 patient-years.  In 
patients treated with an anticoagulant, the 1, 2, and 3 year CIF rates of stroke were 1.1 
(95%CI: 0.6-1.9), 2.7 (95%CI: 1.9-3.7), and 4.1 (95%CI: 3.1-5.4) %, respectively (Figure 7-2); 
the corresponding CIF rates for patients not treated with an anticoagulant were 1.9 (95%CI: 
1.1-2.9), 4.1 (95%CI: 2.9-5.5), and 6.1 (95%CI: 4.6-7.8) %, respectively. (Figure 7-2)  
 
Patients without AF:   The median follow-up time in patients without AF was 3.5 (IQR: 3.0-
4.6) years and 171 of these 4,676 patients (3.7%) experienced a stroke (10.0 per 1000 
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patient-years). The 1, 2, and 3 year CIF rates of stroke were 1.0 (95%CI: 0.8-1.3), 2.0 (95%CI: 
1.6-2.4), and 2.8 (95%CI: 2.4-3.3) %, respectively. (Figure 7-1)  
 
Incident AF and risk of stroke: In CHARM-Preserved, 1,781 patients did not have AF at 
baseline. Out of 1,781, 59 patients (3.3%) experienced a stroke. Of these 59 patients, 10 
(17%) developed new AF before the occurrence of their stroke; the number of patients with 
a stroke without preceding AF was 49 (83%).  Development of AF was not reported in any 
patient following a stroke.  
In I-Preserve, 2,895 patients did not have AF at baseline. Out of 2,895, 112 patients (4%) 
experienced a stroke. Of these 112 patients, 18 (16%) developed new AF before the 
occurrence of their stroke; the number of patients with a stroke without preceding AF was 
94 (84%).  
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Figure 7-1. Cumulative incidence function plot for stroke in patients with heart 
failure and preserved ejection fraction (HF-PEF) [pooled data from CHARM-
REF and I-Preserve], according to atrial fibrillation (AF) status at baseline (with 
death as competing risk). 
 
 
 
Figure 7-2. Cumulative incidence function plot for stroke in HF-PEF patients 
with atrial fibrillation, according to anticoagulant treatment at baseline 
(considering death as a competing risk). 
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7.3.3. Predictors of stroke in HF-PEF patients without AF  
Figure 7-3 and Table 7-3 show the relationship between baseline variables and risk of stroke 
(univariable analysis).  Table 7-4 shows an adjusted analysis using the four independent 
predictors identified in a multivariable stroke model developed in HF-PEF cohort (previous 
stroke, age, diabetes treated with insulin and male sex).  These overlapped with the five 
independent predictors in the HF-REF stroke model (previous stroke, age, diabetes treated 
with insulin, BMI and NYHA class), as shown in Table 7-5.  The overall C-index for the HF-
PEF model was 0.71 (95%CI: 0.57-0.84) compared with 0.73 (0.59-0.85) using the HF-REF 
model (p for difference=0.415).  Thus, we proceeded using the previously validated HF-REF 
model.  This model can be used to calculate an individual’s risk of stroke as described in the 
footnote for Table 7-5.  
 
Table 7-3. Exploratory unadjusted univariable analysis for outcome of stroke 
in patients without atrial fibrillation. 
Variables HR (95% CI) p-value 
Age (per 10 year increase) 1.48 (1.22-1.79) <0.001 
Female sex 0.72 (0.53-0.97) 0.029 
Heart rate (per 1bpm up to 70)* 1.00 (0.98-1.03) 0.881 
Systolic blood pressure (per 1mmHg increase) 1.01 (1.00-1.02) 0.030 
LVEF (per 5% increase) 0.91 (0.84-0.99) 0.033 
Creatinine (per 10 µmol/L increase up to 350)† 1.09 (1.05-1.15) <0.001 
BMI (per 5kg/m2 increase) 0.89 (0.76-1.03) 0.100 
NYHA class (III & IV vs. I & II) 1.38 (0.98-1.94) 0.067 
HF duration (≥2 years vs. <2 years) 0.91 (0.67-1.25) 0.565 
Current smoker 0.80 (0.59-1.08) 0.147 
Coronary heart disease (angina, MI, revascularisation, CABG, 
IHD) 
1.01 (0.74-1.37) 0.962 
Previous Stroke 3.23 (2.24-4.67) <0.001 
Hypertension 1.30 (0.85-2.01) 0.229 
Insulin treated diabetes 2.25 (1.51-3.36) <0.001 
NT-proBNP, pg/mL (log)‡ 1.48 (1.27-1.73) <0.001 
Significant level at conventional p<0.05 in bold. LVEF indicates left ventricular ejection fraction; BMI: body mass index; 
NYHA: New York Heart Association; MI: myocardial infarction; CABG: coronary artery bypas graft; IHD: ischaemic heart 
disease.  
* Heart rate was truncated to 70bpm to avoid co-linearity with possible atrial fibrillation. 
† The values were truncated to the level displayed due to individual variable’s non-linearity. 
‡  Univariable analysis for log NT-ProBNP was performed for patients with NT-ProBNP measurement only, (n=2,452). 
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Figure 7-3. The relationship between baseline variables and risk of stroke in 
HF-PEF patients without atrial fibrillation. 
Variables are divided by quintiles. BMI indicates body mass index; BP: blood pressure; LV: left ventricular; NT-proBNP: 
N-terminal pro-B-type natrieretic peptide. 
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Table 7-4. “HF-PEF model for stroke” derived from HF-PEF cohort, without 
atrial fibrillation. 
Variables Hazard 
ratio 
Lower 
95%CI 
Upper 
95%CI 
Χ2-value 
(Χ2=82.8) 
Coefficients 
Previous Stroke 2.92 2.02 4.23 32.4 1.071 
Age (per 10 year increase) 1.63 1.34 1.97 21.6 0.450 
Diabetes treated with insulin 2.52 1.68 3.78 19.9 0.923 
Sex (Male)  1.60 1.17 2.16 8.9 0.465 
 
 
Table 7-5. List of variables from the “HF-REF model for stroke” in patients 
without atrial fibrillation. 
Variables Coefficients from HF-REF stroke model* 
Previous Stroke  0.591 
Diabetes treated with insulin  0.626 
Age (per 10 years increase) 0.331 
BMI (per 5kg/m2 increase up to 30) -0.301 
NYHA class (NYHA III and IV) 0.472 
*HF-PEF stroke model is as described in Chapter 6.  
BMI: body mass index; NYHA: New York Heart Association. 
 
Examples of risk score calculation using the model presented in Table 7-5:  
This example illustrates the use Table 7-5 and associated Figures 7.4, 7-5 and 7-6, to calculate the risk score of stroke in 
individual patients. 
For example, consider a patient aged 70 years in NYHA functional class II with a BMI of 25 kg/m2 and had a previous 
stroke. Using the model coefficients in Table 7-5, each multiplied by 10, this patient’s risk score for stroke is: (3.31 x 7) + 
[(-3.01) x 5] +  5.91 = 14.03. Note that age is in decades, hence 70 becomes 7; BMI is in steps of 5, BMI of 25 becomes 5.  
 
 
Figure 7-4 shows the distribution of the risk score for stroke and illustrates the risk of stroke 
for a given score. A score of approximately 12 predicts a risk of stroke similar to that which 
was seen among patients with AF in the current cohort.  Figure 7-5 shows CIF plot for stroke 
with patients classified into 3 equal sized groups according to risk score.  The numbers of 
strokes in tertiles 1, 2 and 3 were 37, 45 and 89 respectively.  The 1, 2 and 3 year CIF rates 
of stroke in the two higher risk tertiles were; tertile 2: 1.1 (95%CI: 0.6-1.7), 1.6 (95%CI: 1.0-
2.3), and 2.3 (95%CI: 1.6-3.2) %, respectively, and tertile 3: 1.4 (95%CI: 0.9-2.1), 3.0 (95%CI: 
2.3-4.0), and 4.5 (95%CI: 3.6-5.6) %, respectively.  
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The 1, 2 and 3 year Kaplan-Meier rates of stroke in the two higher risk tertiles were; tertile 
2: 1.1 (95%CI: 0.7-1.7), 1.6 (95%CI: 1.1- 2.4), and 2.4 (95%CI: 1.7-3.3) %, respectively, and 
tertile 3: 1.4 (95%CI: 1.0-2.2), 3.2 (95%CI: 2.4-4.2), and 4.9 (95%CI: 3.9-6.2) %, respectively. 
(Figure 7-6)  There is little difference between the CIF and Kaplan-Meier curves.  Patients 
in risk-tertile 3 had an overall stroke rate of 16.0 per 100 patient-years.  
 
 
Figure 7-4. Distribution of risk score for stroke and its relation to predicted 
risk of stroke within the follow-up period. 
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Figure 7-5. Cumulative incidence function plot for stroke occurrence according 
to tertile of risk score in patients without atrial fibrillation (with death as 
competing risk). 
 
 
Figure 7-6. Kaplan-Meier plot for stroke according to tertile of risk score in 
patients without atrial fibrillation. 
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Figure 7-7 shows the model’s goodness-of-fit by comparing observed and expected 
probabilities of stroke at 3 years with the patients divided into tertiles.  The calibration was 
also assessed using the Hosmer-Lemeshow test, which was p=0.761. 
 
 
Figure 7-7. Comparison of observed and expected stroke rates after 3 years 
for patients categorised by tertiles of risk score derived from the HF-REF 
stroke model.  
Observed indicates as read from each Kaplan-Meier tertile group at 3 years; expected, as estimated from Cox model in 
each tertile. 
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7.3.4. Validation of stroke risk model 
We tested the predictive model in TOPCAT, which included 1,240 patients with and 2,205 
patients without AF.  The mean follow-up was 3.5 years.  There were 65 strokes in the 
patients with AF and 52 strokes in those without AF, giving stroke rates in patients with and 
without AF 16.4 and 7.1 per 100 patients-years, respectively.  
Using the same analytical approach (Table 7-6, Figures 7-8 and 7-9), the 1, 2 and 3 year CIF 
rates of stroke in patients without AF, in the two higher risk tertiles were; tertile 2: 1.3 
(95%CI: 0.6-2.4),  1.3 (95%CI: 0.6-2.3) and 1.7 (95%CI: 0.9-2.9) %, respectively; and tertile 
3: 1.5 (95%CI: 0.8-2.7), 1.7 (95%CI: 0.9-2.9) and 2.6 (95%CI: 1.6-4.1)%, respectively.  
Patients in risk-tertile 3 of the validation model derived from TOPCAT cohort had an overall 
stroke rate of 10.6 per 100 patient-years.  The overall C-index for the model was 0.86 
(95%CI: 0.62-0.99).  
 
 
Table 7-6. Validation of stroke model using TOPCAT for patients without atrial 
fibrillation (n=2,205). 
Variables Hazard 
ratio 
Lower 
95%CI 
Upper 
95%CI 
P-value Coefficients derived 
from HF-REF stroke 
model 
Previous Stroke 2.49 1.12 5.53 0.026 0.591 
Diabetes treated with 
insulin 
1.90 1.04 3.45 0.036 0.626 
BMI (per 5kg/m2 increase 
up to 30) 
0.84 0.49 1.45 0.529 -0.301 
Age (per 10 year increase) 1.09 0.81 1.46 0.582 0.331 
NYHA class (NYHA III and IV) 1.02 0.55 1.86 0.959 0.472 
See footnote of Table 7-5 for explanation of how to use to predict individual patient’s risk of stroke. BMI: 
body mass index; NYHA: New York Heart Association.  
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Figure 7-8. Validation using TOPCAT for patients without atrial fibrillation: 
Distribution of the risk score for stroke. 
 
 
 
 
Figure 7-9. Cumulative incidence function plot for stroke by tertile of their risk 
scores in patients without atrial fibrillation (using TOPCAT)- accounting death 
as competing risk. 
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7.4. Discussion 
In this analysis, HF-PEF patients with AF were at a high risk of stroke, with an average 
incidence rate of 1.8% per year which is similar to the rate for HF-REF patients with AF (1.6% 
per year), as reported in Chapter 6.  
HF-PEF patients without AF in the present study had a lower risk of stroke compared to 
those with AF.  However, the overall rate of stroke in HF-PEF patients without AF (1.0% per 
year) was similar to the rate we recently reported in heart failure patients with a reduced 
ejection fraction without AF (1.2% per year).  Moreover, as in HF-REF, a small number of 
demographic and clinical variables identified a subset of HF-PEF patients without AF who 
were at greater risk of stroke than the remainder.  Specifically, in our pooled analysis, 
patients in the upper third of the risk score had a rate of stroke (1.6% per year) which was 
higher than in HF-PEF patients with AF receiving an anticoagulant (1.5% per year), although 
not as high as in similar patients not treated with an anticoagulant (2.2% per year).   
We have been unable to find other reports of the risk of stroke in HF-PEF patients without 
AF although patients in the same age range in clinical trials for hypertension (i.e. with a 
similar co-morbid phenotype to HF-PEF) have a stroke risk of around 1% per year or less.305-
309  In HF-PEF patients with AF randomised to warfarin in ARISTOTLE201 the rate of stroke 
was 1.4% per year which was similar to the rate in anticoagulant-treated AF patients in our 
study (1.5% per year).  In AF patients with HF and a LVEF >40% in RELY-AF199 the rate of 
stroke or systemic embolism was 2.07% per year in the warfarin group; in ROCKET-AF200 
the rate of the same outcome in similarly defined patients was 2.06% per year.  The higher 
event rates in the latter two trials are due to broader composite outcome (which included 
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non-cerebral systemic embolism) and the requirement for patients in these trials to have 
additional risk factors for stroke.  
The similar risk of stroke in patients with HF-PEF and HF-REF, without AF, is also of interest.  
We previously reported that LVEF was not predictive of stroke in HF-REF patients without 
AF.  Neither was LVEF an independent predictor of stroke risk in the present study although 
we examined only patients with a LVEF ≥45%.  This finding is consistent with observations 
in three recent trials comparing non-vitamin K antagonist oral anticoagulants (NOACs) to 
warfarin in patients with AF.  In those trials, the risk of stroke and systemic embolism was 
similar, irrespective of LVEF category, in patients with AF and concomitant HF.  A similar 
conclusion was reached by the Atrial Fibrillation Clopidogrel Trial with Irbesartan for 
Prevention of Vascular Events (ACTIVE) in AF patients not treated with an oral anticoagulant 
where the risk of stroke was similar in patients with concomitant HF-REF or HF-PEF.325 
As in HF-REF, we found that neither systolic blood pressure nor history of hypertension, 
were independent predictors of stroke.  Although this contrasts with the findings in other 
patient cohorts, it is consistent with the “reverse epidemiology” of heart failure and the 
known association between higher blood pressure and better outcomes in this 
condition.316-318  Likewise, we saw an association between lower body mass index and 
higher risk of stroke, another feature of the “reverse epidemiology” in heart failure.316-318 
A particular strength of this study is the validation of our predictive model in another 
dataset (TOPCAT).  Consequently, our findings have clear clinical implications.  With a small 
number of routinely collected clinical variables it is possible to identify patients with HF-
PEF, but without AF, who may be at sufficiently high risk of stroke potentially to justify 
anticoagulation.  Clearly, there is yet no trial evidence to justify such treatment but our 
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findings suggest a means of identifying patients for such a trial.  Consistent with this 
hypothesis, prior trials in patients with heart failure and reduced ejection fraction, 
collectively suggest that anticoagulation can reduce the risk of stroke in patients in sinus 
rhythm.  However, in the largest of these, the Warfarin Versus Aspirin in Reduced Cardiac 
Ejection Fraction trial (WARCEF), while warfarin was effective in reducing ischaemic stroke 
this benefit was offset by major bleeding.  With non-vitamin K oral anticoagulants, the risk-
to-benefit balance might be more favourable, especially as the target INR in WARCEF was 
2.75 (range 2.0 to 3.5).209-212 
Limitations- Each of the two trials included had specific inclusion and exclusion criteria and, 
hence, our findings may not be generalisable to all patients with HF-PEF.  Notably, few 
patients were in NYHA class IV, and worse functional class was a predictor of higher risk of 
stroke.  Hence, the risk of stroke may be higher in “real world” patients than in the cohort 
studied.  Although our data suggest that only the minority of strokes are related to incident 
AF, systematic detection of new onset AF was insensitive e.g. ambulatory monitoring was 
not performed.  It is widely recognised that silent AF is frequent in heart failure and 
undetected AF may have accounted for more strokes than realised.274, 275  However, waiting 
for the development of clinically recognised AF before employing anticoagulant therapy 
may not be the ideal preventive strategy, and the best and most cost-effective way to 
screen for silent AF in HF-PEF is unknown.  In addition, these patients may have other 
reasons to develop thromboembolic and other types of ischaemic stroke e.g. endothelial 
dysfunction and blood stasis.  It may be too simplistic to assume that an anticoagulant can 
substantially reduce the risk of stroke in those with HF-PEF at highest risk. 
CHARM-Preserved and I-Preserve were randomised controlled trials in heart failure rather 
than stroke trials. While the definition of stroke in the two trials may not be identical to 
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that used in contemporary stroke trials, it was applied consistently by adjudicators blinded 
to treatment allocation and thus gave an unbiased estimate of treatment effect.  
Unfortunately, classification of stroke subtype was not carried out in either trial.  When the 
trials were conducted, neuroimaging was not standard in patients with suspected stroke in 
many, if not most countries, involved.  Therefore, we are unable to distinguish between 
ischaemic and haemorrhagic strokes.  
In conclusion, we found that a relatively high-risk subset of a third of HF-PEF patients 
without AF have a risk of stroke similar to that in HF-PEF patients with AF.  This higher-risk 
subset can be identified using five simple clinical variables.  The risk of stroke is similar in 
HF-PEF and HF-REF patients without AF and is predicted by the same variables.  The risk of 
stroke in these patients might be reduced by treatment with an oral anticoagulant but this 
hypothesis needs to be tested in a clinical trial.  The rate of stroke in the highest risk tertile 
was not quite as high as in patients with AF not treated with an anticoagulant so it is 
uncertain what the benefit/ risk ratio of such treatment might be. 
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Chapter 8  
The outcome of patients 
with chronic heart failure 
who had acute ischaemic 
stroke and were treated with 
systemic thrombolysis 
8.1. Background 
Stroke is one of the leading causes of mortality and disability.6  One of the few available 
medical therapies for acute ischaemic stroke is systemic thrombolysis with recombinant 
tissue plasminogen activator (rtPA), within 3 or 4.5 hours of symptoms onset.166, 167, 173   
However, only a third of patients treated with thrombolysis achieve evident benefit.171  
Thrombolysis treatment also carries a small risk of intracerebral haemorrhage.  This raises 
the question of whether certain baseline characteristics might identify patients in whom 
thrombolysis does not lead to a clinically-important net benefit.  Age, diabetes, atrial 
fibrillation (AF) and prior stroke have previously been investigated and do not seem to 
influence the response to treatment.174, 176, 177, 326  Other co-morbidities such as chronic 
heart failure (CHF) might, however, be important in this respect. 
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CHF ranks second as a cause of cardio-embolic stroke after AF.29  Recent studies suggest 
that CHF may contribute to the pathophysiology of ischaemic stroke through various 
mechanisms: CHF causes cerebral hypoperfusion and dysregulation of cerebral blood flow; 
contributes to a pro-thrombotic state; and predisposes to cardio-embolism mainly, but not 
exclusively, through AF.142, 327 
Therefore, there are theoretical reasons why CHF might reduce the benefit of systemic 
thrombolysis in acute ischaemic stroke.  First, patients with CHF may have longstanding 
thrombus in a dilated left ventricle generating emboli which, after reaching intracerebral 
vessels, are unlikely to dissolve to recanalise the vessel with thrombolysis.  Second, 
systemic thrombolysis may partially dissolve and thus destabilise thrombus in the left 
ventricle, potentially releasing a shower of micro-emboli and increasing the risk of early 
recurrent ischaemic stroke.  Third, some strokes in patients with CHF may be directly 
related to pump-failure causing hypoperfusion and giving rise to watershed infarct.155  
Fourth, there are potential pharmacokinetic changes due to delayed circulation time and 
probably increased volume of distribution for the thrombolytic agent that may render 
thrombolysis treatment less effective in CHF patients who are experiencing acute ischaemic 
stroke.  
Therefore we have examined whether CHF modifies the response to thrombolytic therapy 
in patients with acute ischaemic stroke.  We hypothesised that the improvement in the 
modified Rankin Scale (mRS) in patients receiving systemic thrombolysis would be 
diminished in those with CHF compared to patients without CHF.  The mRS is a commonly 
used scale to assess global outcome after stroke, and the most widely used clinical outcome 
measure in stroke trials.228  The scale ranges from 0-6, running from full function without 
stroke symptoms to death.228 
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8.2. Methods 
8.2.1. Data source  
We conducted a non-randomised cohort analysis using data obtained from the Virtual 
International Stroke Trials Archive (VISTA, http://www.vistacollaboration.org/).218  VISTA is 
a collaborative stroke trials registry that collates and provides access to completed trials’ 
data (from year 1998), anonymised in relation to patients and trials’ identity, for novel 
exploratory analyses.  All trials lodged in VISTA already have local institutional review board 
approved procedure in accordance with the Declaration of Helsinki.  All stroke patients 
were treated as per institutional practice and stroke guidelines acceptable at the point of 
trial conduct.  The cohort data that were released to us did not contain trials that 
investigated thrombolysis therapy in hyper-acute stroke.  However, the data contained 
trials in which thrombolysis was commonly used as standard therapy.  Conduct and 
reporting of the analysis is in accordance with the STROBE guidelines for cohort studies.258 
 
8.2.2. Participants and variables 
We selected patients who had been randomised to receive placebo or any drug now known 
to possess no confirmed action on stroke outcome.  We excluded patients who lacked the 
relevant baseline or outcome information: baseline National Institutes of Health stroke 
scale (NIHSS), age, medical history, concomitant medication, occurrence of adverse and 
serious adverse events and mRS at day 90.  Death was recorded as mRS grade 6.  AF was 
defined as history of AF or evidence of AF on baseline ECG.  The presence of CHF was based 
on the ‘history of CHF’ that was recorded at baseline for acute stroke trials; data were not 
available on ejection fraction or aetiology.    
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8.2.3. Definition of outcome events 
Symptomatic recurrent stroke was defined as any stroke with neurological deterioration, 
as indicated by NIHSS that was higher by ≥4 points than the value at baseline, or any stroke 
leading to death within 7 days of acute stroke.  Similarly, symptomatic intracerebral 
haemorrhage was defined as any intracerebral haemorrhage with neurological 
deterioration, with worsening NIHSS ≥4 points from baseline, or any intracerebral 
haemorrhage leading to death, within 7 days of acute stroke.  
 
8.2.4. Statistical methods 
Descriptive statistics were used to compare those with and without CHF, differentiating 
those who received systemic thrombolysis from those who did not.  We described mean 
(standard deviation [SD]) or median (inter-quartile range [IQR]) for continuous variables 
and count (percentage) for categorical variables.  Unadjusted comparisons of CHF presence 
and thrombolysis treatment groups were conducted using the 2-sample t test, Mann-
Whitney U test, 2 proportions test, or χ2 test depending on the distribution and nature of 
the data. 
Our primary outcome measure was the distribution of the mRS at day 90 using the full scale 
(i.e. ordinal shift).176  To allow comparison with previous trials, we reported dichotomised 
outcomes at day 90 (recurrent stroke, symptomatic intracerebral haemorrhage, mortality 
and good outcome categories).  Good outcome categories at day 90 included mRS 0-1, mRS 
0-2 and NIHSS 0-1.  Reported odds ratios (ORs) express the odds of achieving a specific 
outcome in association with thrombolysis treatment or CHF status, stratified by AF 
respectively.  ORs and 95% confidence intervals (95%CIs) of ordinal outcome measures 
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were obtained using ordinal logistic regression and the associated p-values calculated using 
the Cochran-Mantel-Haenszel test.  Dichotomised outcome measures were investigated 
using binary logistic regression.  Adjustments were made primarily for age and baseline 
NIHSS.259  We also made adjustment for other clinically-important variables and variables 
that were found to be significantly different in the unadjusted univariable analysis 
(backward elimination approach with conventional p-value <0.05).  Input covariates were: 
age, baseline NIHSS, baseline glucose level, cigarette smoking, history of coronary heart 
disease, diabetes, hypertension, TIA and previous stroke, stratified by AF respectively.   
Evidence of any interaction between the presence of CHF and systemic thrombolysis; and 
among the presence of CHF, age and systemic thrombolysis was investigated.  The 
relationships showing the association of CHF, and the association of thrombolysis 
treatment (for patients with CHF only), with full scale mRS at day 90 against age, were 
plotted to explore the interaction across the age range.  All analyses were undertaken using 
SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA) and R version 2.10.0.328 
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8.3. Results 
8.3.1. Baseline characteristics 
We obtained data for 5,677 acute ischaemic stroke patients, of whom 2,366 (41.7%) 
received systemic thrombolysis treatment within the therapeutic window. (Figure 8-1)  A 
total of 503 (8.9%) patients had known history of CHF on admission of whom 209 (41.6%) 
received thrombolysis.  Two hundred and seventy (53.7%) of the CHF patients had 
concomitant AF.  Patients with CHF tended to be older than those without and had more 
severe neurological impairment (i.e. more severe baseline NIHSS).  Other baseline 
demographics such as sex, blood pressure, history of ischaemic heart disease, diabetes, 
hypertension and previous stroke were not significantly different between CHF patients 
who were treated versus not-treated with thrombolysis.  Irrespective of thrombolysis 
treatment and previous anticoagulation, the mean INR at baseline was sub-therapeutic 
(<2).  Detailed baseline characteristics are given in Table 8-1 and Table 8-2.  
 
Figure 8-1. Flow diagram describing selection of data from VISTA for the 
analysis reported.  
 
CHF indicates chronic heart failure. 
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Table 8-1. Baseline characteristics of patients with chronic heart failure. 
Variable; n/ N(%) Thrombolysis Treatment P-value 
Treated Untreated 
Male 104/209 (49.8%) 141/294 (48.0%) 0.690 
Age, years; mean (SD), N 72.9 (12.2), 209 73.6 (11.7), 294 0.527 
Baseline NIHSS; median (IQR), N 15 (11-19), 209 14 (10-18), 294 0.079 
SBP (mmHg); mean (SD), N 148.4 (26.8), 206 150.1 (27.0), 290 0.497 
DBP (mmHg);  mean (SD), N 78.7 (18.0), 206 78.9 (17.0), 290 0.907 
Heart rate (beats/ min); mean (SD), N 83 (21), 205 81 (18), 291 0.364 
BMI; mean (SD), N 27.4 (6.1), 199 27.2 (5.1), 276 0.812 
Glucose (mmol/L); mean (SD), N 7.7 (3.3), 178 8.0 (3.0), 255 0.349 
Platelets; mean (SD), N  223.7 (83.2), 169 234.5 (86.4), 242 0.205 
INR at baseline; mean (SD), N 1.38 (0.47), 149 1.30 (0.55), 211 0.153 
Non-smoker 117/208 (56.3%) 168/294 (42.9%) 0.003 
Myocardial Infarction 68/209 (32.5%) 72/294 (24.5%) 0.047 
Ischaemic heart disease 101/209 (48.3%) 160/294 (54.4%) 0.178 
Atrial fibrillation 112/209 (53.6%) 158/294 (53.7%) 0.973 
Hypertension 167/209 (79.9%) 248/294 (84.4%) 0.196 
Diabetes 61/209 (29.2%) 83/294 (28.2%) 0.815 
Transient ischaemic attack 16/197 (8.1%) 28/272 (10.3%) 0.426 
Previous stroke 51/209 (24.4%) 74/294 (25.2%) 0.844 
Digoxin prescription 77/209 (36.8%) 98/294 (33.3%) 0.416 
CHF: chronic heart failure; Categorical variables are given in n/N (%) format: number of observations/ total 
no. of cases with available information (percentage); SD: standard deviation; NIHSS: National Institutes of 
Health stroke scale; IQR: inter-quartile range. SBP: Systolic blood pressure; DBP: Diastolic blood pressure; 
BMI: Body mass index. Significant values (P<0.05) given in bold. 
 
Table 8-2. Baseline characteristics of patients without chronic heart failure. 
Variable; n/ N(%) Thrombolysis Treatment P-value 
Treated Untreated 
Male 1237/2157 (57.3%) 1620/3017 (53.7%) 0.009 
Age, years; mean (SD), N 67.6 (12.9), 2157 69.3 (12.3), 3017 <0.001 
Baseline NIHSS; median (IQR), N 14 (10-18), 2157 11 (7-15), 3017 <0.001 
SBP (mmHg); mean (SD), N 153.8 (24.1), 2127 156.4 (26.9), 2980 <0.001 
DBP (mmHg);  mean (SD), N 81.7 (15.9), 2126 84.7 (16.2), 2980 <0.001 
Heart rate (beats/ min); mean (SD), N 78 (17), 2119 78(16), 2973 0.689 
BMI; mean (SD), N  27.0 (4.8), 2019 26.9 (4.7), 2932 0.374 
Glucose (mmol/L); mean (SD), N 7.3 (2.7), 1859 7.8 (3.2), 2624 <0.001 
Platelets; mean (SD), N  233.1 (72.5), 1688 237.8 (80.1), 2497 0.053 
INR at baseline; mean (SD), N 1.28 (0.85), 1348 1.24 (1.02), 2190 0.271 
Non-smoker 881/2153 (41.0%) 1633/3014 (54.2%) <0.001 
Myocardial Infarction 269/2157 (12.5%) 331/3017 (11.0%) 0.097 
Ischaemic heart disease 510/2157 (23.6%) 945/3017 (31.3%) <0.001 
Atrial fibrillation 458/2157 (21.2%) 741/3017 (24.6%) 0.005 
Hypertension 1492/2157 (69.2%) 2270/3017 (75.2%) <0.001 
Diabetes 399/2157 (18.5%) 756/3017 (25.1%) <0.001 
Transient ischaemic attack 162/2065 (7.8%) 249/2864 (8.7%) 0.287 
Previous stroke 265/1892 (12.3%) 661/3014 (21.9%) <0.001 
Digoxin prescription 202/2157 (9.4%) 396/3017 (13.1%) <0.001 
CHF: chronic heart failure; Categorical variables are given in n/N (%) format: number of observations/ total 
no. of cases with available information (percentage); SD: standard deviation; NIHSS: National Institutes of 
Health stroke scale; IQR: inter-quartile range. SBP: Systolic blood pressure; DBP: Diastolic blood pressure; 
BMI: Body mass index. Significant values (P<0.05) given in bold. 
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8.3.2. Outcome 
Regardless of CHF status, ordinal analysis of the mRS at day 90 showed more favourable 
overall outcome among patients who received thrombolysis than comparators, after 
adjustment for age and baseline NIHSS; OR: 1.44 (95%CI: 1.04-2.01, p=0.029) for CHF 
patients vs. OR: 1.50 (95%CI: 1.36-1.66, p<0.001) for those without CHF. (Figure 8-2) 
Adjustment for other clinically-important variables (as mentioned in the Methods section, 
section 8.2.4) and variables that differed at baseline, resulted in loss of statistical 
significance for the favourable treatment effect among patients with CHF [OR: 1.35 (95%CI: 
0.92-1.98) p=0.121] but left it broadly unchanged for non-CHF patients [OR: 1.35 (95CI%: 
1.21-1.52) p<0.001]. 
CHF was associated with worse overall outcome on mRS at day 90 after adjustment for age 
and baseline NIHSS [OR: 0.73 (95%CI: 0.62-0.87) p<0.001].  Adjustment for all other 
variables (as mentioned in the Methods section) did not change significance of poor 
outcome [OR: 0.76 (95%CI: 0.63-0.93) p=0.007).  Similar associations and patterns were 
also observed for CHF within individual thrombolysis treatment groups. (Table 8-3)  
Similar trends that failed to reach statistical significance were observed when outcome was 
dichotomised as recurrent stroke and symptomatic intracerebral haemorrhage when 
comparing stroke patients with and without CHF.  Likewise, there was no difference on the 
dichotomised outcome when evaluating CHF patients who received thrombolysis 
treatment versus those who did not. (Table 8-4)  However, stroke patients with CHF 
appeared to have a higher risk of mortality by day 90 than those without CHF, irrespective 
of thrombolysis treatment received, OR: 1.61 (95%CI: 1.23-2.11, p=0.001). (Table 8-4)  
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Figure 8-2. Modified Rankin scale outcome at day 90 with thrombolysis 
treatment in patients with chronic heart failure, CHF (top) and those without 
(bottom).  
Values provided in each box denote the percentage of patients. CHF: chronic heart failure;   
alteplase: thrombolytic agent. 
 
 
 
 
 
Table 8-3. Ordinal modified Rankin scale outcome analysis for the influence of 
chronic heart failure according to treatment group. 
 Variable adjustment Odds ratio [OR] (95%CI) P-value 
Treatment group 
(Patient who received thrombolysis 
group) 
 
Age and baseline NIHSS 0.73 (0.56-0.94) 0.017 
 
As listed in footnote* 
 
0.78 (0.57-1.06) 
 
0.120 
Control group 
(Patient who did not received 
thrombolysis treatment group) 
 
Age and baseline NIHSS 0.74 (0.59-0.92) 0.008 
 
As listed in footnote* 
 
0.59 (0.59-0.98) 
 
0.037 
*Adjustment: age, baseline NIHSS, glucose level at baseline, smoking history, history of coronary heart disease, 
hypertension, diabetes, TIA and previous stroke (stratified by atrial fibrillation). 
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Table 8-4. Clinical outcomes at 90 days (adjusted for age and baseline NIHSS). 
Outcome Control Thrombolysis OR (95%CI) c P b All 
Symptomatic recurrent stroke by 7 days; n/N (%) 
CHF 16/ 294 (5.4%) 9/209 (4.3%) 0.97 (0.30-3.14) 0.959 25/503 (5.0%) 
No CHF 102/3017 (3.4%) 70/2157 (3.3%)   172/5174 (3.3%) 
OR (95%CI) c 0.76 (0.35-1.64) 0.95 (0.37-2.42)   0.82 (0.46-1.49) 
P a 0.484 0.916   0.516 
All 118/3311 (3.6%) 79/2366 (3.3%)   197/ 5677 (3.5%) 
 
Symptomatic intracerebral haemorrhage by 7 days; n/N (%) 
CHF 2/294 (0.7%) 5/209 (2.4%) 2.88 (0.44-18.78) 0.269 7/503 (1.4%) 
No CHF 20/3017 (0.7%) 44/2157 (2.0%)   64/5174 (1.2%) 
OR (95%CI) c 0.85 (0.18-4.02) 1.16 (0.37-3.66)   1.03 (0.42-2.56) 
P a 0.840 0.800   0.948 
All 22/3311 (0.7%) 49/2366 (2.1%)   74/5677 (1.3%) 
 
Mortality; n/N(%) 
CHF 94/294 (32.0%) 57/209 (27.3%) 0.73 (0.43-1.23) 0.241 151/503 (30.0%) 
No CHF 487/3017 (16.1%) 317/2157 (14.7%)   804/5174 (15.5%) 
OR (95%CI) c 1.64 (1.16-2.32) 1.50 (0.96-2.36)   1.61 (1.23-2.11) 
P a 0.005 0.076   0.001 
All 581/3311 (17.6%) 374/2366 (15.8%)   955/5677 (16.8%) 
 
n/N: number of observations/ total no. of cases with available information. 
a P-values downward show the difference between CHF status split by thrombolysis treatment group.  
b P-values across show the difference between control and thrombolysis treatment groups split by CHF status. Significant 
values (P<0.05) given in bold.  
c ORs are the odd ratios of achieving specific outcome when comparing groups across horizontally or when comparing 
groups vertically, adjusted for age and baseline NIHSS.  
 
 
 
Exploratory analysis for good outcomes categories at Day 90 (mRS 0-1, mRS 0-2 and NIHSS 
0-1) did not show statistically significant results (Table 8-5). 
There was no interaction observed between thrombolysis treatment and age on outcome 
among patients with CHF (p=0.815, Figure 8-3A).  There was a limited interaction between 
CHF and age, where the presence of CHF was associated with poorer outcome for patients 
aged approximately >65 years, after adjustment for thrombolysis treatment and baseline 
NIHSS (p=0.022, Figure 8-3B).    
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Table 8-5. Exploratory analysis for good clinical outcome at 90 days (adjusted 
for age and baseline NIHSS). 
Outcome Control Thrombolysis OR (95%CI) c P b All 
mRS 0-1; n/N (%) 
CHF 59/290 (20.3%) 43/204 (21.1%) 1.21 (0.67-2.20) 0.521 102/494 (20.7%) 
No CHF 885/3000 (29.5%) 634/2132 (29.7%)   1519/5132 (29.6%) 
OR (95%CI) c 1.00 (0.71-1.40) 0.91 (0.48-1.76)   1.00 (0.78-1.29) 
P a 0.9991 0.7860   0.9991 
All 944/3290 (28.7%) 677/2336 (29.0%)   1621/5626 (28.8%) 
 
mRS 0-2; n/N (%) 
CHF 83/290 (28.6%) 63/204 (30.9%) 1.42 (0.82-2.45) 0.207 146/494 (30.0%) 
No CHF 1261/3000 
(42.0%) 
951/2132 (44.6%)   2212/5132 (43.1%) 
OR (95%CI) c 1.00 (0.74-1.35) 1.00 (0.70-1.44)   1.00 (0.80-1.26) 
P a 0.999 0.898   0.991 
All 1344/3290 
(40.9%) 
1014/2336 
(43.4%) 
  2358/5626 (41.9%) 
 
NIHSS 0-1; n/N (%) 
CHF 57/282 (20.2%) 45/196 (23.0%) 1.61 (0.89-2.88) 0.113 102/478 (21.3%) 
No CHF 847/2934 (28.9%) 645/2065 (31.2%)   1492/4999 (29.9%) 
OR (95%CI) c 0.88 (0.61-1.27) 0.79 (0.51-1.24)   0.99 (0.77-1.30) 
P a 0.491 0.307   0.995 
All 904/3216 (28.1%) 690/2261 (30.5%)   1594/5477 (29.1%) 
 
n/N: number of observations/ total no. of cases with available information; NIHSS: National Institutes of Health stroke 
scale; mRS: modified Rankin scale. Significant values (P<0.05) given in bold. 
a P-values downward show the difference between CHF status split by thrombolysis treatment group.  
b P-values across show the difference between control and thrombolysis treatment groups split by CHF status. Significant 
values (P<0.05) given in bold.  
c ORs are the odd ratios of achieving specific outcome when comparing groups across horizontally or when comparing 
groups vertically, adjusted for age and baseline NIHSS.  
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Figure 8-3. Odds of favourable outcome across the spectrum of mRS at day 90 for each year 
of age: A) Outcomes in CHF patients differentiating thrombolysis treated versus those 
untreated (i.e. interaction between thrombolysis treatment and age among CHF patients) 
after adjustment for baseline NIHSS; B) Outcomes in all patients contrasting patients with 
CHF versus those without (i.e. interaction between CHF and age) after adjustment for 
baseline NIHSS and thrombolysis treatment. 
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8.4. Discussion 
Acute ischaemic stroke patients with chronic heart failure (CHF) have worse outcomes than 
those without CHF, irrespective of thrombolysis treatment.  However, we have shown that 
acute stroke patients treated with systemic thrombolysis have overall more favourable 
outcomes across the mRS spectrum, regardless of CHF status, than those untreated 
(adjusted for age and baseline NIHSS).  No interaction between CHF and systemic 
thrombolysis treatment on outcome was identified.  These findings were supported by a 
range of dichotomised secondary outcome measures described.      
CHF patients in our study were older and had more neurological impairment at baseline as 
compared to those without CHF.  Stroke patients with AF share similar characteristics,177, 
326 with stroke patients with CHF in our cohort.  CHF was associated with worse stroke 
outcomes, even after adjustment for age and baseline NIHSS, in contrast to AF, which has 
no independent relationship to stroke outcome.177  It is also likely that presence of CHF 
presumably meant a pre-morbid functional status of mRS >1 (surrogate for multiple co-
morbidities).  The syndrome of heart failure itself probably contributes to or worsens the 
associated underlying diseases such as hypertension, coronary artery disease, and diabetes 
mellitus.329  Our findings are in line with the prognostic data from the SITS-MOST registry 
that found CHF to be an independent predictor of 90-day mortality.330 
We also found that the rates of recurrent stroke and symptomatic intracerebral 
haemorrhage were similar between stroke patients with and without CHF.  We only 
reported recurrent stroke/ symptomatic intracerebral haemorrhage that occurred up to 7 
days post-initial stroke, as the main focus of the study was the influence of thrombolysis 
treatment following hyper-acute stroke in CHF patients.  Recurrent stroke and symptomatic 
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intracerebral haemorrhage were derived from Serious Adverse Events (SAE) rather than 
systematic brain imaging and thereby only cover those recurrent strokes and symptomatic 
intracerebral haemorrhages that were clinically-important.   
Our study has limitations.  Although our analysis was performed using data derived from 
rigorous clinical trials, the non-randomised nature of registry data inevitably incorporates 
selection bias.  We based the label of ‘CHF’ from ‘history of CHF’ reported in the trials.  
Thus, the robustness of the diagnosis needs to be interpreted with caution.  The small 
number of CHF patients may have also contributed to the loss of power in the exploratory 
analysis for dichotomised outcomes.  As variables were defined and obtained variously in 
different trials, this could result in random error within variables.  Specific definitions for 
each variable cannot be accessed from the pooled databases used in VISTA, as data were 
anonymised for trial source.  The absence of pre-stroke functional status (i.e. pre-stroke 
mRS) data have precluded pre- and post-stroke functional comparison.  Although patients 
included in the acute stroke trials usually have ‘good’ pre-stroke mRS (as often ‘good’ pre-
stroke mRS is a prerequisite entry criteria for acute stroke trials), CHF patients may still 
have some degree of functional limitation that are not captured using the mRS.  
Our analysis might have been strengthened if data on ejection fractions, New York Heart 
Association (NYHA) functional class and biomarkers such as N-terminal-pro-brain 
natriuretic peptide (NT-proBNP) were available.  Nonetheless, the proportion of patients 
with CHF was consistent with the proportion of digoxin use at baseline (Tables 8-1 and 8-
2).  Digoxin use has been applied as a proxy for CHF diagnosis as it has specificity of 
approximately 99% and sensitivity of approximately 28% for diagnosis of CHF.331, 332 
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In conclusion, patients with CHF have worse stroke outcomes than those without CHF.  
However, CHF does not modify the benefit of thrombolysis in acute ischaemic stroke.  Our 
analysis, therefore, should reassure clinicians considering systemic thrombolysis treatment 
in hyper-acute ischaemic stroke patients with CHF.  There is no justified reason for 
excluding patients solely due to CHF status.   
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Chapter 9  
Discussion and conclusions 
In this thesis, I describe a set of studies that consider various topics relating to risk and 
management of cardio-embolic stroke.  This is a broad theme and I concentrated on two 
interconnected examples:   the primary dysrhythmic condition, atrial fibrillation (AF), and 
the primary functional condition, heart failure.  Despite knowing a vast amount about both 
conditions, there are many aspects of these in relation to stroke that have limited reliable 
evidence, and clinical management is conducted in a relative vacuum.  I hoped that by 
exploring historical data sets that are readily available, I could inform management 
decisions in some everyday clinical challenges.  The nature of the data available to me has 
inevitably determined or restricted the range and depth of studies that I could undertake.  
However, there is still a clear theme, and several valuable lessons to derive from the 
analyses.   
In Chapter 3, I highlighted one of the common uncertainties confronted by clinicians in 
managing AF-related stroke.  In AF-related strokes, there is considerable concern regarding 
early recurrent stroke and the risk of haemorrhagic complications.  Although there is no 
clear benefit from acute anticoagulant therapy in the hyper-acute stage after stroke,246, 247 
the therapeutic value of later or prolonged oral anticoagulant treatment in patients with 
AF is indisputable.196, 244, 245  Additionally, the International Stroke Trial (IST) and the 
Chinese Antiplatelet Stroke Trial (CAST) showed that early initiation of antiplatelet therapy 
can potentially improve outcome.254, 255  It is also argued that the magnitude of risk for 
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recurrent stroke in patients with AF reflects the cumulative risk in terms of heart function, 
atrial or ventricular thrombo-embolism, associated hypercoagulability and general burden 
of cardiovascular risk factors.47, 48, 54, 77     
The risk of recurrent stroke in patients with AF is approximately 5% during the first 2 weeks 
of stroke.333  The risk of recurrence attenuates over time although it still remains higher 
than in the general population.333  On the other hand, the absolute risk of intracerebral 
haemorrhage may be high following recent brain infarction.43, 44  The risk of intracerebral 
haemorrhage is even higher following IV thrombolysis treatment, with an increase in the 
absolute risk of 6%.334  This brings the real concern regarding the latency after stroke at 
which the net effect of antithrombotic treatment switches from neutral (or harm) to 
beneficial.  Starting oral anticoagulant therapy in the form of the traditional vitamin K 
antagonist, VKA, (i.e. warfarin) may be safe as warfarin requires a few days to achieve its 
therapeutic level and may even exert a transient prothrombotic influence.  The delayed 
anticoagulant effect may buy some time for the brain tissue to be less vulnerable to 
haemorrhage.  Meanwhile, immediate initiation of an antiplatelet agent contributes a 20% 
relative risk reduction in early recurrent stroke as reported by clinical trials.254, 255   
Therefore, at least theoretically, it would make sense that combined antithrombotic 
therapy introduced sequentially (i.e. antiplatelet treatment then oral anticoagulant 
treatment [commonly warfarin]) at the acute stage after stroke could have benefit and 
possibly justify the potential risk of haemorrhage.  However, extra caution is required for 
the non-vitamin K oral anticoagulants (NOACs) due to their immediate anticoagulation 
effect.  
The clinical relevance of the above findings may be improved by factoring in recognition 
that some individuals are more likely to have haemorrhagic transformation of their infarcts, 
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with clinical deterioration.  Contributory factors may include a large infarct size, elderly 
patients with possible amyloid disease, and excessively elevated blood pressure.  An 
approach for such higher-risk patients is perhaps to repeat the non-contrast CT brain scan 
roughly 48-72 hours from the stroke to evaluate the infarct size or identify evidence of any 
haemorrhagic complication.  
With accumulating evidence that supports the use of oral anticoagulant treatment for 
stroke prevention in patients with AF, Chapter 4 brings a ‘closer to home’ perspective on 
oral anticoagulant prescription in Glasgow’s community-dwelling stroke survivors with AF. 
The cross-sectional analysis of a city-wide primary care database found that oral 
anticoagulant treatment is significantly underused in this high risk population, and those at 
the highest risk were less likely to be treated than patients at lower risk.  The low rate of 
prescription of oral anticoagulants among stroke survivors with AF who are from areas of 
socioeconomic deprivation is of particular concern.  These findings should reinforce the 
need for health service planners to improve cardiovascular risk management in the 
affected areas.  The data used in this chapter describe prescribing patterns that existed 
before the NOACs became widely available.  Thus, it provides an ideal baseline to assess 
the impact of NOAC availability on the overall prescribing of anticoagulant agents in this 
high risk group of patients.  Although outwith the scope of this thesis, I am planning to 
revisit the issue by performing a time-trend analyses of anticoagulant treatment to 
investigate the impact of the NOAC availability on the stroke incidence, using latest 
available data from the primary care database.  I have submitted a project proposal to the 
Glasgow’s primary care database administrator, to check the data availability and 
feasibility.   
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In Chapter 5, I investigated the incidence of stroke within the available heart failure trials 
spanning a 30 year period, according to AF status at baseline.  Despite the stepwise 
introduction of disease-modifying drugs for heart failure with reduced ejection fraction (HF-
REF), I found that stroke incidence has not significantly declined over time in patients 
enrolled to the trials.  Although there was a notable increase in the extent of oral 
anticoagulant use among patients with AF, the proportions receiving treatment remained 
suboptimal across the period covered by the trials.  Interestingly, lower risks of stroke were 
observed in patients without AF from groups with greater exposure to oral anticoagulants.  
This appears consistent with the thrombo-prophylaxis benefit suggested in the Warfarin 
versus Aspirin in Reduced Cardiac Ejection Fraction trial (WARCEF).211  However, WARCEF 
also highlighted that the thrombo-prophylaxis benefit have been offset by an increased risk 
of major bleeding.211  Given the improved risk-benefit profile of the NOACs, identification 
of modern patients at the highest risk of stroke may allow individualised and safer stroke 
prevention strategies in patients with heart failure but without AF. 
Chapters 6 and 7 shed light on the frequency of stroke in contemporary ambulatory 
patients with heart failure but without AF, while highlighting the potential for using 
predicted stroke risk to refine patient selection. Although both chapters deal with heart 
failure, I begin with patients who have reduced ejection fraction (HF-REF) in chapter 6 and 
move to those with preserved ejection fraction (HF-PEF) in chapter 7.  In both chapters, the 
common risk model for stroke was derived from five clinical predictors, including age, New 
York Heart Association (NYHA) functional class, diabetes treated with insulin, body mass 
index and a history of previous stroke.  It is easy to propose new models to predict risk.  I 
validated the models that I examined within independent cohorts in each chapter.  Patients 
who had heart failure and sinus rhythm and who were classified in the highest tertile of the 
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risk score, demonstrated a risk of stroke that approximated to patients with heart failure 
and AF.  Patients with HF-REF but without AF in the upper third of the risk score had a 
stroke rate of 2.0% per year.  Patients with HF-PEF but without AF in the upper tertile of 
the risk score has a stroke rate of 1.6% per year.  These risks exceed the risk of stroke in 
patients with AF who have a CHA2DS2-VASc score of 1 (i.e. stroke risk of 1.3% per year).47  
According to the European Society of Cardiology guidelines, patients with AF who have a 
CHA2DS2-VASc score of ≥1 should receive effective stroke thrombo-prophylaxis, either VKA 
e.g. warfarin (with ≥70% time in therapeutic range) or one of the NOACs.71  The annual 
incidence of fatality caused by VKA administration has been estimated to be 1%.335  
However, this estimate is based on old data, and, although difficult to prove, the overall 
improvement in anticoagulation control in the past 20-25 years means that a more realistic 
figure is about 0.2%.335  The positive net clinical benefit of the NOACs for stroke prevention 
is more apparent, with lower risk of haemorrhage, compared to VKA agent.  Therefore, the 
high risk of stroke in the subgroup of patients with heart failure but without AF, may be 
reduced by a safer oral anticoagulant treatment. 
Nonetheless, some caution must be taken to generalise the results given the retrospective 
nature of the studies in Chapters 6 and 7.  Haemorrhage risk was not part of the risk model 
for stroke, undermining consideration of net clinical benefits for the decisions regarding 
anticoagulation treatment.  The next logical step would be to plan an adequately powered 
randomised, double-blind, controlled trial to investigate the benefit of a NOAC versus 
aspirin in patients with heart failure but without AF.  The risk score prediction proposed 
could guide the recruitment of potential trial participants.  The risk model would be 
applicable to the eligible patients with heart failure but without AF.  Patients with a risk 
score beyond a certain threshold could be randomised to receive either aspirin or a NOAC.  
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What threshold score one might use in a future trial is likely a matter of debate – it seems 
that a score that gives a risk similar to that in patients with AF (i.e. a level of risk that we 
currently treat) is not an unreasonable starting point.  That equates to a score of 
approximately 12.  
Using the risk score prediction to guide trial recruitment will focus the trial on patients at 
the higher risk of stroke who are most likely to benefit from oral anticoagulant treatment 
e.g. patients with older age, chronic diabetes or history of previous stroke.  Previously, the 
neutral WARCEF trial recruited relatively young patients with heart failure (mean age 61 
years) who had severe ejection fraction reductions (mean left ventricular ejection fraction 
of 25%). Only 43% of the recruited patients in WARCEF had evidence of ischaemic heart 
disease (i.e. surrogate for cardiovascular burden).211  I would propose instead that any 
future evaluation of anticoagulants in patients with heart failure but without AF should be 
based on risk-stratification, irrespective of left ventricular ejection fraction.  However, the 
proposed risk-stratification approach may affect the recruitment rate.  It took 6 years to 
complete the open-design WARCEF trial.211     
Given the competing risks of death and heart failure hospitalisations observed in WARCEF, 
the choice of outcomes in such a trial requires careful consideration.  As a major stroke is 
perceived by more than half of those at risk of as being worse than death,8 it is reasonable 
to emphasise a robust stroke outcome in the trial design, i.e. an up-to-date definition of 
stroke event, preferably with neuroimaging evidence.  The primary outcome would be the 
composite of all cause death, myocardial infarction and stroke.  The secondary efficacy 
outcomes could include composite of cardiovascular mortality and heart failure 
hospitalisations; and the separate outcomes of cardiovascular mortality and 
hospitalisations due to worsening of heart failure or cardiovascular-related events. The 
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safety evaluations of the trial should include bleeding events.  Major bleeding events may 
be defined according to the International Society on Thrombosis and Haemostasis 
criteria:336 clinically overt bleeding that requires a transfusion of ≥2 units packed red blood 
cells or whole blood, or associated with fatality or critical state.  Non-major bleeding events 
may be defined as overt bleeding not meeting the criteria for major bleeding.  The trial 
could, for example, have 90% power to detect a 20% relative risk reduction in the 
composite of primary outcomes, at approximately 5%, 2-sided statistical significance level, 
in the intention-to-treat population. The calculation was based on crude annual event rates 
that were conservatively estimated for each component of the composite primary 
endpoints (death, MI and stroke).  The estimated annual adjusted rate of the composite 
primary outcomes for patients randomised to aspirin is approximately 15% over 5 years 
follow-up.  From this calculation, a sample size of 4,564 patients (2,282 patients in each 
placebo and treatment arms) is required.  However, a larger sample size of approximately 
5,500 patients is realistically required to factor in any treatment withdrawals or loss to 
follow-ups for 10% of the recruited patients; and expected crossover of study medication 
(i.e. aspirin to NOAC) following detection of AF for another 10% of patients.  Indeed, such 
trial will require a substantial support from clinicians and the industry.  
The stroke risk score prediction model for patients with heart failure but without AF 
presented in Chapters 6 and 7, consists of two continuous (advancing age and decreasing 
BMI), and three categorical variables (NYHA class III/ IV, insulin treated diabetes and 
previous history of stroke).  The risk score needs at least a pocket calculator to compute. 
Although outwith the scope of this thesis, I am currently working to simplify the reported 
risk-score into an integer based score for easy use at the bedside.  Work is also underway 
to validate the stroke model that includes a biomarker, NT-proBNP, using data from the 
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latest ‘Prospective comparison of angiotensin receptor neprilysin inhibitor (ARNI) with 
angiotensin converting enzyme inhibitor to Determine Impact on Global Mortality and 
morbidity in Heart Failure trial’ (PARADIGM-HF).119    
Sadly, our best efforts at prevention sometimes fail, either because patients are not offered 
appropriate treatment (as described in Chapter 4) or because treatment is not anyway 
completely effective.  We must still consider how to treat patients with acute stroke who 
have heart failure (or AF).  In Chapter 8, I have shown that patients with chronic heart 
failure have worse stroke outcome that those without the condition.  However, chronic 
heart failure does not modify the benefit of IV thrombolysis in acute stroke.  This ought to 
reassure clinicians considering IV thrombolysis treatment in hyper-acute ischaemic stroke 
patients with chronic heart failure.  There is no justification to exclude patients from the 
treatment solely due to heart failure status.  
In conclusion, the work that I present in this thesis both summarises and extends our 
knowledge of the complex relationship between stroke and the heart, focusing on atrial 
fibrillation and heart failure.  Some clinically relevant questions have been answered, albeit 
with retrospective analyses and through preliminary conclusions. Equally many questions 
have been raised.  I hope that my work may assist clinicians who are dealing with stroke in 
patients with atrial fibrillation or heart failure.  Since these conditions are common and 
each carry a poor prognosis, even small advances in treatment may have a useful societal 
impact.     
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